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Abstract 
MALT lymphoma is specifically associated with t(11; 18)(q2l; q2l), t(1; 14)(p22; q32) and 
t(14; 18)(q32; q2l). t(11; 18)(q2l; q2l) fuses the N-terminal of the API2 gene to the C- 
terminal of the MALT1 gene and generates a functional AP12-MALTI fusion product. 
t(1; 14)(p22; q32) and t(14; 18)(q32; q2l) bring the BCLIO and MALT1 gene respectively to 
the IgH locus and deregulate their expression. The oncogenic activity of the three 
independent chromosomal translocations is linked by the physiological role of BCLIO and 
MALTI. in antigen receptor mediated NFKB activation. In this thesis, 
immunohistochemical and molecular genetic methods have been developed and used to 
investigate the frequency of these translocations in MALT lymphomas of various sites and 
their role in the pathogenesis, diagnosis, prognosis and treatment of this malignancy. 
t(l 1; 1 8)(q2 I; q2 1) was detected by RT-PCR of the AP12-MALT I fusion transcript and was 
found most frequently in MALT lymphomas from the lung (38%) and stomach (24%), 
moderately in those from the ocular adnexae (16%), but rarely in those from the salivary 
gland (M), thyroid, skin, and other rare sites. The translocation was not seen in the 
preceding diseases associated with the development of MALT lymphoma including H. 
pylori associated gastritis, lymphoepithelial sialadenitis and Hashimoto's thyroiditis, nor in 
other subtypes of non-Hodgkin's lymphomas. In gastric MALT lymphoma, 
t(11; 18)(q2l; q2l) was significantly associated with advanced cases and was a reliable 
marker for those not responding to H. pylori eradication including cases at stage IE. 
t(1; 14)(p22; q32) positive MALT lymphoma was characterised by strong BCLIO nuclear 
expression in contrast to the cytoplasmic expression of the protein in normal B-cells. 
Moderate BCLIO nuclear expression was seen in t(1; 14)(p22; q32) negative MALT 
lymphomas including all those with t(11; 18)(q2l; q2l) and up to 20% of cases without 
t(11; 18)(q2l; q2l). Based on BCLIO immunohistochemstry followed by interphase FISH, 
t(1; 14)(p22; q32) was found in MALT lymphomas from the lung (12%) and stomach (5%), 
but not in those from the ocular adnexae, salivary gland, thyroid and skin. In gastric MALT 
lymphoma, t(1; 14)(p22; q32) positive cases did not respond to H. pylori eradication. 
iv 
t(14; 18)(q32; q2l) positive MALT lymphoma was characterised by strong homogeneous 
cytoplasmic expression of both MALTI. and BCLIO. In MALT lymphomas without 
t(14; 18)(q32; q2l) including those with t(1; 14)(p22; q32) or t(11; 18)(q2l; q2l), MALTI 
expression was generally weak or negative. Based on MALTI and BCLIO 
immunohistochernistry followed by interphase FISH, t(14; 18)(q32; q2l) was found in 
MALT lymphomas of the lung (6%), ocular adnexae (7%) and liver (17%) but not in those 
from the stomach, salivary gland, thyroid and skin. 
t(11; 18)(q21; q2l), t(1; 14)(p22; q32) and t(14; 18)(q32; q21) were variably involved in MALT 
lymphoma of different sites. Detection of these translocations has significant implications 
in diagnosis and prognosis of MALT lymphoma. 
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Chapter 1. General introduction 
Lymphomas are neoplastic proliferations of B or T lymphocytes or their precursors, 
which account for 3-5% of all malignancies diagnosed'. Approximately 60% of 
lymphomas are Non-HodgIdn's lymphomas (NHLs), while the remaining 40% are 
Hodgkin's lymphomas (HLs). Unlike HLs that rarely arise outside lymph nodes, about 
60% of NHLs arise in the lymph nodes and the remaining 40% arise from extranodal 
sites'. The most common site of'extranodal lymphoma is the gastrointestinal tract 
followed by the skin, orbit, lung, thyroid, and salivary gland. These extranodal 
lymphomas, although broadly similar, behave somewhat differently from nodal 
lymphomas. 
1.1 Histology of lymph nodes and mucosa-associated lymphoid tissue (MALT) 
1.1.1 Lymph nodes 
The anatomical distribution and structure of lymph nodes are adapted to deal with 
antigens carried to the node in the afferent lymphatics that drain sites at various 
distances from the node. The lymph nodes are situated at intervals along the lymphatics 
throughout the body, with well-recognised concentrations at certain sites, such as axilla, 
cervical region, groin, etc. Their position is in accordance with their function as a major 
part of the body's defence. In other words, lyrnph nodes are strategically placed to 
perform the function of immune surveillance. 
-I- 
There are three different cell groups in the lymph node. These are the B cells, T cells 
and accessory cells. Most of the lymph node B cells are present in the cortex, where 
they are concentrated in follicles. In unstimulated or resting lymph nodes, the follicles, 
known as primary follicles, are inconspicuous and consist of aggregates of small 
lymphocytes without a centre. In reactive nodes, however, the follicles, known as 
secondary follicles, have prominent structure consisting of a follicle centre and a zone of 
small lymphocytes, known as the mantle zone, partially surrounding the follicle centre. 
The follicle centre is populated principally with two types of B cells, the centroblast and 
centrocyte, and also contains macrophages and follicular dendritic cells (FDC). The 
lymphoid tissue between the B cell follicles and impinging on the medulla is known as 
the paracortex and it is here that the T cells are foundý. 
1.1.2 MALT 
MALT represents a specialised part of the mucosal immune system, functioning as the 
primary immune defence against foreign antigens introduced through the mucosal 
surfaces of the body3. 
Besides lamina propria lymphocytes and the intra-epithelial lymphocytes, the most 
prominent structural component of MALT is the organised nodular lymphoid tissue that 
occurs in the terminal ileum as Peyer's patcheS4. Peyer's patches are characterised by the 
lymphoid follicle, which is composed of a follicle centre, a thin mantle zone and a 
marginal zone (Figure 1.1)1'5. The marginal zone represents one of the distinct 
compartments of the B cell area in lymphoid tissues. It is especially well developed in 
the white pulp of the spleen and in Peyer's patches of the gut, but not in lyrnph nodes, 
with the exception of the ones in the mesenterium67. The marginal zone comprises a 
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particular subset of lymphoid cells, which are characterised by abundant clear cytoplasm 
and a pale, irregular, centrally located nucleuS8 . Due to the resemblance to 
follicle 
centre cells, marginal zone B cells have been indicated as 'centrocyte-like (CCL) cells'. 
On the luminal side of the follicle, the marginal zone merges into a mixed cell infiltrate 
that covers the dome of the Peyer's patches. In the Peyer's patches, the mixed cell 
infiltrate of the dome region is composed of plasma cells, dendritic cells, macrophages, 
small lymphocytes and CCL cells. The CCL cells infiltrate the overlying epithelium. 
Animal models suggest that the function of Peyer's patches is associated with the 
1,5,9,10 
generation of humoral immune response in the gut 
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Figure 1.1. MALT, Peyer's patches and MALT lymphorna A: Peyer's Patch, a germinal 
centre (GC) is surrounded by an inner follicular mantle (FM), and an outer marginal zone (NIZ). 
IEBC indicates intraepithelial B cells. B: MALT lymphorna, histological features are strikingly 
similar to those of the Peyer's patch, comprising a reactive B cell follicle surrounded by 
neoplastic marginal zone B cells that invade gastric gland epithelium to form lymphoepithelial 
lesions (LELs). 
Unlike peripheral lymph nodes that are structurally and functionally adapted to respond 
to antigen transported through afferent lymphatics, MALT has evolved to protect the 
mucosa from antigen in direct contact with the epithelial surface within the lumen. 
Antigens taken up by specialised mucosal epithelial cells are transported to the mucosal 
organised lymphoid tissues where naYve B cells are stimulated to undergo germinal 
centre reaction and become memory B cells or plasma cells (detailed in the next 
section) I, i. These anti gen-experienc ed B cells are programmed preferentially for 
mucosal immune defense. They may leave mucosa. and enter circulation via the 
mesenteric lymph nodes and thoracic duct, then home back to the mucosa. 
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1.2 B cell development 
Nonnal B cell differentiation begins with precursor B lymphoblasts (blast cells that are 
the precursors of the entire B cell lineage) that undergo immunoglobulin (Ig) variable 
region Q), diversity region (D) and joining region (1) (VDJ) gene rearrangement and 
differentiate into mature surface Ig (sIg) positive (IgM+ IgD+) nSfve B cells that are 
often CD5+11. NaYve B cells are small resting lymphocytes that circulate in the blood 
and also occupy primary lymphoid follicles and follicular mantle zones 11,12 . On 
encountering antigen, naYve B cells migrate into the centre of a primary follicle and 
transform into blasts (centroblasts) and actively proliferate, forming a germinal 
centre 13,14 . The proliferating centroblasts occupy the dark zone and undergo somatic 
hypermutations in their rearranged Ig gene. This results in marked intraclonal diversity 
in a population of cells derived from only a few precursors, a characteristic feature of 
germinal centre B cells. The B cell progeny bearing mutated Ig gene move to the light 
zone, where they interact with antigen presented by FDC through their surface Ig. Those 
expressing surface Ig with high affinity to antigen are rescued by expression of BCL2 
and selected to undergo Ig class switch from IgM to IgG or IgA. They exit the germinal 
centre as antibody secreting plasma cells or memory B cells, while those expressing 
surface Ig without high affinity to antigen die in situ by apoptosis. These apoptotic cells 
are cleared by macrophages, histologically characterised by tingible body macrophages. 
The B cell maturation during the germinal centre reaction is a highly regulated complex 
process that is T cell dependent. Deregulation of the molecules that control the germinal 
centre reaction, such as BCL2, BCL6, plays an important role in lymphomagenesis. 
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1.3 MALT lymphoma 
1.3.1 The MALT lymphorna concept 
The concept that MALT lymphoma represents a distinct entity was proposed by Isaacson 
and Wright in 1983 15 based on clinico-pathological studies of low grade B cell 
lymphoma of the stomach and immunoproliferative small intestinal disease (IPSID). 
Clinically, both low grade B cell lymphoma of the stomach and IPSID are remarkably 
indolent and respond favorably to treatment. Histologically, these lymphomas 
recapitulate the morphology of Peyer's patches rather than lymph node 16 . Subsequently, 
the MALT lymphorna concept extends to include low grade B cell lymphomas derived 
from the lung 17 , salivary gland", thyroid'9, ocular adnexae 
20,21 
, and skin as they share 
similar clinical and histological features. Interestingly, these mucosal organs are 
normally devoid of any organised lymphoid tissue. However MALT can be acquired as 
a result of chronic inflammatory or autoimmune disorder. It is believed that MALT 
lymphoma originates from the acquired MALT'. 
The MALT lymphoma concept proposed entirely on the base of clinico-pathological 
observations is firmly supported by subsequent immunophenotypic and molecular 
studies. MALT lymphoma as a specific pathological entity was first included in the 
22 REAL classification in 1994 . In 2001, it is classified as extranodal marginal zone B 
cell lymphorna of MALT in the WHO Classification of Neoplastic Diseases of the 
Hematopoietic and Lymphoid Tissues 23 . 
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1.3.2 MALT lYmphoma and its preceding diseases 
MALT lymphoma is the third most common NHLs, comprising about 40% of those 
arising from the extranodal sites 24 . The stomach 
is the most common site of MALT 
lymphoma, accounting for 30-50% of cases. Other common sites include lung (14%), 
salivary gland and thyroid (14%), ocular adnexae (12%), and skin (11%)25. 
MALT lymphoma is usually preceded by chronic inflammation or autoimmune disorder, 
. 26 such as Helicobactor pylori (H. pylori) associated chronic gastritis , Hashimoto's 
thyroiditis'9, Sj6gren's syndrome / myoepithelial. sialadenitis (MESA)18, follicular 
bronchiolitis 27 . In addition, cutaneous marginal zone B cell lymphoma is linked to 
28,29 Borrelia burgdoferiinfection , while IPSID and ocular adnexal MALT lymphoma has 
been recently shown to bo associated with Campylobacter jejuni 30 and Chlamydia 
psittaci infection in some cases 
31 
. 
Gastric MALT lymphoma occurs usually over the age of 50, with a peak in the 7th 
decade, although an increasing number of cases are being reported in patients at an 
earlier age. The male-to-female ratio is approximately 1.5: 1. The clinical presentation 
is usually more suggestive of a chronic inflammatory process than a lymphoma and 
naturally varies with the site of the disease. The symptoms of gastric MALT lymphoma 
are usually those of chronic gastritis. Endoscopic findings are also usually not specific, 
and are those of gastritis and / or peptic ulcer. 
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1.3.3 Histopathology 
All MALT lymphomas from different sites are similar, recapitulating the morphological 
features of the Peyer's patches of the terminal ileum. The histopathological features can 
be summarised as follows (Figure 1-1). 
1. The MALT lymphoma cells are characterised by small to medium-sized, slightly 
irregular nuclei with moderately dispersed chromatin and inconspicuous nucleoli, 
resembling those of centrocytes, thus frequently referred as CCL cells. However, they 
are morphologically and immunophenotypically almost identical to the marginal zone B 
cells (Figure 1.1 and Table 1.1), from which MALT lymphoma is thought to arise 16 . 
2. CCL lymphoma cells infiltrate around reactive B cell follicles, external to a 
preserved follicular mantle, in a marginal zone distribution, and spread diffusely into the 
surrounding mucosa. They invade and destroy the epithelial lining of local glands, ducts 
or crypts, resulting in the so-called lymphoepithelial lesions (LELs), a characteristic 
feature of MALT lymphoma. LELs are aggregates of three or more neoplastic cells with 
distortion or destruction of the epithelium, often accompanied by eosinophilic 
32 degeneration of epithelial cells 
3. Plasma cell differentiation is present in approximately 30% of MALT lymphomas 
and tends to be maximal beneath the surface epithelium' 25 . At the one extreme, there 
may be moderate numbers of plasma cells and demonstration of Ig light chain restriction 
by immuohistochemistry is necessary to detennine whether they are a part of the 
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neoplastic clone. At the other extreme, plasma cell differentiation may be a striking 
feature, as seen in IPSID. 
4. Residual reactive B cell follicles are a constant finding. They may either be 
naked or surrounded by a complete or partial lymphocytic corona, whereby the 
neoplastic proliferation forms a marginal zone pattern. Reactive germinal centres may 
be invaded or overrun by the neoplastic proliferation, known as 'follicular 
colonization'33,34. Residual gem-iinal centres may become difficult to recognise and this 
can lead to a close resemblance to follicular lymphoma. There are three types of 
follicular colonization. Type I: reactive follicles are over-run and virtually replaced by 
CCL cells, resulting in confluent but poorly defined follicles in which fragmented 
residues of follicle centre cells (FCC) and small, darkly stained mantle zone cells are 
dispersed. Type II: follicle centres are selectively wholly or partialy replaced by CCL 
cells, resulting in expansion of the follicle centres massively, and loss of the 
characteristic zonal pattern of reactive follicle centres. Type III: the intrafollicular CCL 
cells show plasma cell differentiation. 
5. Transformed centroblast- or immunoblast-like cells may be present in variable 
numbers in MALT lymphoma but when sheets of transformed cells are present the 
tumour should be diagnosed as diffuse large B cell lymphoma (DLBCL) and the 
presence of accompanying MALT lymphoma should be noted (section 1.4.3.5. of 
Chapter 1). 
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Figure 1.2. Morphology of marginal zone B cells and MALT lymphoma A&B: MALT 
lymphoma cells closely resemble marginal zone B cells. C: High magnification of a 
lymphoepithelial lesion showing infiltration and destruction of gastric gland epithelium by 
centrocyte-like cells. D: Gastric MALT lymphoma showing marked plasma cell differentiation. 
The plasma cells are distended with eosinophilic Ig. 
1.3.3.1 Immunophenotypic features 
The immunophenotype of MALT lymphoma is almost identical to that of normal 
marginal zone B cells' 6. Tumour cells typically express IgM, and less often IgA or IgG. 
The turnour cells of MALT lymphorna are CD20+, CD19+, CD79a+, CD5-, CD23-, 
CDIO-, cyclin Dl-, CD43+/-, CDllc+/-. BCL2 is positive in most cases. IgD 
expression may be variable 35 (Table 1.1). There is no specific marker for MALT 
lymphoma at present. A recent study showed that IRTAI (immunoglobulin superfamily 
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receptor translocation-associated 1) was selectively and consistently expressed by B- 
cells beneath and within the dome epithelium of the Peyer patches and turnour cells 
involved in LELs in MALT lymphoma 36 . However, whether IRTAI. can serve as a 
diagnostic marker for MALT lymphoma remains unknown. 
Table 1.1. Comparison of immunophenotypic and genotypic features of MALT 
lymphoma and normal marginal zone B cell 
Immunophenotype 
CD5 CDIO CD23 CD43 Cyclin DI IgD IgM 
MALT Lymphoma + 
Marginal Zone B Cells + 
1.3.3.2 Genotypic features 
Molecular investigations of MALT lymphoma have demonstrated that the lymphoma 
cells have clonally rearranged Ig heavy and light chain genes 37 . Their rearranged Ig 
genes s ow igh levels of somatic mutations with features of antigen selection: high 
replacement mutation versus silent mutation in complementarity determining region 
(CDR) regions, consistent with their memory B cell phenotype. 
1.3.3.3 Normal cell counterpart of MALT lymphoma 
Several strands of evidence strongly indicate that NMLT lymphoma originates from the 
marginal zone B cells of the acquired MALT. First, MALT lymphoma cells have a 
similar morphology to marginal zone B cells 1,16. The lymphoma cells are distributed in 
marginal pattern. When they spread, they also preferentially occupy the marginal zone 
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of lymph node and spleen. Second, MALT lymphoma cells are immunophenotypically 
similar to marginal zone B cells (section 1.4.3.1). Finally, the rearranged Ig gene of 
MALT lymphoma shows similar frequencies and features of somatic mutations to those 
38-40 
of the marginal zone B cells of the Peyer's patches and acquired MALT 
1.3.3.4 Multifocality and dissemination pattern 
Histological examinations of surgical specimens of gastric MALT lymphoma showed 
multifocal microlymphomas with identical Ig light chain restriction scattered throughout 
the gastric mucosa4l. A subsequent study by sequence analysis of the rearranged Ig 
heavy chain gene (IGH) confirmed the identity of different microlymphornatous 
lesionS42 . Further study by microdissection and clone-specific PCR demonstrated the 
presence of turnour cells in reactive lymphoid tissues without any histological evidence 
of the lymphoma43. A wide dissemination within gastric mucosa has also been well 
documented by Fend et a144 and Hoshida et a145. 
MALT lymphomas generally remain localised for prolonged periods. However, regional 
lymph nodes may be involved by MALT lymphornal. MALT lymphoma cells show a 
tendency to involve marginal zone when they disseminate to lymph nodes. Gastric 
MALT lymphoma has been shown preferentially to disseminate to the marginal zone of 
46 the spleen 
When remote spread occurs, gastric MALT lymphoma preferentially migrates to other 
mucosal sites such as the small intestine and salivary gland"-4'. MALT lymphoma 
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rarely involves peripheral lymph nodes, but disseminates to the bone marrow in 5-10% 
of cases 
49 
. 
The propensity of gastric MALT lymphoma, to disseminate to other parts of the 
gastrointestinal mucosa and splenic marginal zone is thought partially to reflect the 
homing properties of the turnour cells. Dogan et al5O reported a case of gastric MALT 
lymphoma with secondary intestinal involvement and found that the mucosal homing 
receptor a407 integrin was strongly expressed by the intestinal tumour but not by the 
gastric lesion. However, a high level of a4,67 expression could be induced in gastric 
lymphoma cells following activation by a H. pylori generated T cell response. This 
suggests that a4fl7+ tumour cells could be similarly generated in gastric lymphoma, in 
vivo and thus become 'programmed' to home to an appropriate microenvironment where 
the mucosal addressin cell adhesion molecule (MAdCAM-1), the ligand for a4fl7, is 
expressed. 
1.3.3.5 High grade transformation 
Transfonned centroblasts or immunoblast-like cells are frequently seen in MALT 
lymphoma. These large cells may be scatter or form clusters or sheets, presenting as a 
DLBCL. The observation of the coexistence of low and high grade components in the 
same primary gastric lymphoma led to the assumption that high grade tumour evolves 
directly from low grade disease. However, the low and high grade lesions may not be 
, 52 always clonally related5l . Chan et al examined a series of gastric MALT lymphomas 
and showed identical Ig light chain restriction in both low and high grade tumour 
53 
components of the same case . Peng et al and others further provided the genetic link 
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between low and high grade tumour components by microdissection and molecular 
analysis of the rearranged Ig geneS53-55. It is believed that in cases with coexistence of 
MALT lymphoma and DLBCL, the DLBCL is most likely transformed from the low 
grade disease. However, in cases where only DLBCL is seen, it is a debate whether 
DLBCL originates from a MALT lymphoma or develops de novo. Given the fact that 
DLBCL frequently overruns the MALT lymphorna, it is believed that at least a 
proportion of DLBCL in the mocosal sites are transformed from an undetected MALT 
lymphoma. 
De Jong et al 56 suggested dividing gastric MALT lymphoma into four categories. 
Category A refers to classical low grade MALT lymphoma in which transformed blasts 
comprise no more than 5% of cells and do not occur in clusters of more than ten cells. 
In category B, transformed cells may account for 10-20% of cells and occur in clusters 
of up to 20 cells. Category C is characterised by unequivocal high grade transformation 
with sheets of transformed cells that may leave only small foci of low grade lymphoma. 
In category D, no MALT lymphoma component is detectable and it is probably better 
classified as DLBCL. The classification of gastric MALT lymphoma is clinically 
relevant. Approximately, 90% of tumours of category A have a 10-year survival. The 
prognosis is slightly but significantly poorer in category B cases with a 10-year survival 
of approximately 78%. The survival for high grade cases is significantly worse but, 
interestingly, there was no difference in the clinical outcome between categories C and 
D where the 10-year survival for both was approximately 45%. Similarly, in a large 
series reported by Cogliatti et al, there was no significant difference in the survival 
between transfonned MALT and de novo DLBC07. 
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1.3.3.6 Differential diagnosis 
The differential diagnosis of MALT lymphoma includes H. pylori associated gastritis 
and other small B cell lymphomas such as follicular lymphoma, mantle cell lymphoma 
and lymphoplasmacytic lymphoma. 
In severe H. pylori-associated chronic gastritis, sometimes known as follicular gastritis, 
the appearance can closely simulate lymphoma, making histological diagnosis difficult, 
especially based on small biopsies. Wotherspoon and Isaacson introduced a histological 
scoring system to help the differential diagnosis 26 . Follicular lymphoma, mantle cell 
lymphoma and small lymphocytic lymphoma very rarely occur as primary tumour of the 
stomach. Nonetheless, secondary gastric involvement by these lymphomas is relatively 
common. Distinction from these small B cell lymphomas is based on a combination of 
the characteristic morphologic, immunophenotypic and genotypic features as outlined in 
Table 1.2. 
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1.4 The pathogenesis of MALT lymphoma 
The development of MALT lymphoma is a multistage process. This is best understood 
in gastric MALT lymphoma since it is the most common and has been extensively 
studied among MALT lymphoma of different sites. The development of gastric MALT 
lymphoma involves not only acquisition of genetic abnormalities but also 
immunological stimulations mediated by H. pylori infection. 
1.4.1 H. pylori infection and its role in development of gastric MALT lymphoma 
H. pylori is an unipolar, multiflagellate spiral shaped, microaerophilic, Gram negative 
bacterium that lives in the luminal surface of the stomacO59. The bacterium is 
implicated in several gastrointestinal diseases, such as peptic ulcer, gastric 
adenocarcinoma and MALT lymphoma6o. 
In 1988, it was recognised that chronic H. pylori infection induced lymphoid infiltrate in 
the gastric mucosa6l 62 , which gradually formed the acquired MALT. In 1991, 
Wotherspoon et al. studied a large series of gastric MALT lymphoma and demonstrated 
H. pylori infection in the vast majority of caseS26 . This is confirmed by subsequent 
studies and ffirther underlined by an epiderniological study in northeastern Italy, where a 
markedly high incidence of gastric MALT lymphoma is accompanied by a high 
prevalence of H. pylori infection63. Furthermore, in a case control study, Parsonnet et al. 
showed a significant association between previous H. pylori infection and the 
development of gastric MALT lymphoma ý4. In addition to H. pylori, H. heilmannii 
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infection is also found to be associated with the development of gastric MALT 
I)-mphoma albeit its infection is infirqucntý5. 
The prccisc rolc of H. M-lori in the dcvclopment of gastric MALT lymphoma is not 
totally clear. Nonetheless, there is compelling evidence indicating that both the host 
responses to H. pylori infection and bacterial status play a critical role in the 
pathogenesis of gastric MALT lymphoma. 
1.4.2 Immunological stimulation 
Several histological features of MALT lymphoma, which include the presence of 
plasma-ccli diffcrcntiation, blasts, follicular colonization and its association with activc 
tumour ccil proliferationW4 , suggest that MALT lymphoma cells prcscrvc 
B ccll 
propcilics and that their growth may be partially driven by antigcnic stimulation via 
surface receptors. Recent studies indicate that both direct and indirect antigen 
stimulation mcchanisms arc involvcd. 
1.4.2.1 Direct antigen stimulation 
MALT Iymphoma cclls invariably cxprcss surfacc Ig. Using anti-idiotype antibody to 
mimick antigen stimulation, Husscll et al showed that MALT lymphoma cells actively 
proliferated in vitro", suggesting that tumour cells may receive antigcnic stimulations 
through surface antigen receptor. This notion is reinforced by subsequent studies of 
somatic mutation of the rearranged Ig gene. Most of MALT lymphomas show high 
levels of somatic mutation in the Ig gcnc, with features of antigen sclcction3s. In 
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addition, the majority of cases show evidence of intraclonal sequence variations, i. e. 
8,48,67 
ongoing mutation. 3 
Since somatic mutation occurs in the rearranged Ig gene only during the germinal centre 
reaction, and depends on antigen and T cells, the finding of ongoing Ig somatic mutation 
in MALT lyinphoma suggests that turnour-cell growth is partially driven by direct 
antigen stimulation. There are some preliminary data suggesting that the rate of ongoing 
mutations gradually declines during the evolution from an early to a late phase of low 
grade tumour and that the activity finally disappears in the high grade lesions 68 ' 69 . Thus, 
it is likely that the role of direct antigen stimulation in the pathogenesis of this tumour 
progressively decreases during turnour evolution. 
The antigens rccognised by the surface Ig of MALT lymphoma. cells are not fully 
characterised. The data collected so far suggest that the turnour-derived Ig does not 
recognise H. pylori but react with various autoantigenS70. Antibodies to gastric epithelial 
cells are commonly present in serum samples from patients with H. pylori gastritiS71 . An 
anti-idiotype antibody to Ig of a gastric MALT lymphoma cross-reacts with reactive B 
cells in H. pylori-associated gastritis 72 . These findings suggest that gastric MALT 
lymphorna cells are transformed from autoreactive B cells, which are induced by H. 
pylori infection. In line with these findings, the VH germline used by MALT lymphoma 
38,48 
cells is frequent those employed by auto-antibodies 
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1.4.2.2 Indirect antigen stimulation 
The close association of H. pylori infection with gastric MALT lymphoma development 
prompted research into the immunological responses of the tumour cells to H. pylori. 
By co-culturing tumour cells with 13 clinical strains of heat-killed H. pylori, Hussell et 
al demonstrated that H. pylori induced tumour cells to proliferateý3. This effect was 
associated with expression of interleukin-2 (IL-2) receptors and secretion of Ig by 
tumour cells. The effect was strain-specific but not due to specificity of lymphoma cells 
for H. pylori antigens. Removal of tumour-infiltrating T cells before the experiment 
abolished all the effects of H. pylori on tumour cells. Furthennore, the stimulating effect 
of H. pylori on turnour B cells could be completely blocked by an antibody to CD40L 73 . 
Thus, H. pylori stimulated lymphoma B cells through tumour-infiltrating T cells, 
involving CD40 and CD40L costimulatory molecules. 
The active role of turnour-infiltrating T cells in the growth of turnour B cells is supported 
by a study of T cell clones isolated from gastric MALT lymphoma. T cell clones 
responding to H. pylori stimulation were CD4-positive helper cells rather than CD8- 
positive cytotoxic cells74 . These specific T cell clones activated tumour B cells 
in a dose 
dependent manner 
74 
. 
The critical role of H. pylori mediated immunological stimulation in the growth of 
gastric MALT lymphoma cells is further supported by the demonstration of complete 
tumour regression following H. pylori eradication. It is believed that eradication of H. 
pylori leads to disappearance of H. pylori specific tumour infiltrating T cells, 
consequently removing the critical growth support to the turnour B cells. 
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Unlike low grade tumour cells, transformed MALT lymphoma. cells appeared to be 
unresponsive to H. pylori mediated T cell stimulation in vitro". However, this 
obsen-ation is only based on study of a single case. More recent studies showed that 
some of transformed gastric MALT lymphomas were also responsive to H. pylori 
eradication 75-80 , suggesting that H. pylori mediated immune response may also play a 
role in the gro%,. Ih of transformed IýLALT lymphornas. 
1.43 11. pylori virulent factors and host responses to II. pylori infection in 
dcvclopment or gastricMALT lymphoma 
1.4.3.111. pylod virulent factors 
Tbc incidcncc of 11. pylori associatcd chronic gastritis is high, occurring in 50% - 90% 
of population depending on geographic variationss"82. Analysis of surgical specimens of 
gastric MALT lymphoma showcd H. pylori associatcd chronic gastritis in 92% - 
98.3'Yo26'23.11. p)-lori virulent factors am highly associated with peptic ulcer and gastric 
cancer compared %ith gastritiss4.95. 
ncrc arc a numbcr of 11. pylori virulcnt factors that are associatcd with cnhanccd 
pathogenicity or the bacterium. They include the H. pylori cytotoxin and Cag 
pathogenicity island (PAI) such as cytotoxin-associated gene A (CagA), Cag& 
vacuolating cytotoxin A (%-acA), induced by contact with epithelium A fteA), blood 
group antigen binding adhcsin A (babA), out inflammatory protein A (oipA), and 
hypothetical protein Q (hqpQ)86. 
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These virulent factors have been extensively studied in peptic ulcers and gastric cancer. 
Cag PAI has been sho%Nm to be significantly associated with peptic ulcers and gastric 
cancer as compared with H. pylori associated chronic gastritis. However, it is unclear 
whether these virulent factors are associated with gastric MALT lymphoma. Several 
controversial results have been published. De Jong ct al examined the primary H. pylori 
cultures using a PCR assay for the Cag. 4 gene and showed that gastric MALT lymphoma 
was not associated with the CagA positive strain 87 . while Eck ct al observed a significant 
asscwiation using a semlogical test8s. In a subsequent study, Pcng ct al examined the 
gastric biopsics; using a PCR assay for the CagA gcne and demonstratcd that the CagA 
positivc strain of H. pylori was significantly associatcd with DLBCL but not MALT 
lymphomas of the stomach, as comparcd, %%ith H. pylori gastriti? 9. A recent study by 
Lchours ct al invcstigatcd scvcn 11. pylori virulcnce factors including CagA, CagE, vac, 4, 
iccA, babA and hopQ and two adhesins (sabA and hopZ) in 43 H. pylori strains isolatcd 
from patients %ith gastric IýLALT lymphoma and 39 strains from age-matched patients 
with gastritis alone. Tbcy found that only in patients infected with strains harbouring the 
WAI allclc, sab. 4 functional status, and hopZ "ofr' status, the odds of dcvcloping a 
NIALT lyrnphoma wcrc 10 timcs highcr. Howcvcr, this triplc association was only sccn 
in 23% of gasuic MALT lymphomas. The results remain to be validated in future 
studies. It also remains to be investigated whether there are other H. pylori virulence 
factors, which may bc associatcd nith MALT 1), mphoma dcvclopment. 
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1.4.3.2 Host factors 
H. p)-lori infection not only induces immune responses that stimulate the growth of 
infiltrating B and T cells, but also causes inflammatory responses that generate reactive 
oxygen species (ROS)9ý ROS can cause a range of genetic damages, in particularly 
double strand break-, which may lead to acquisition of genetic abnormalities critical to 
development of MALT lymphoma. Ile severity of DNA damage depends not only on 
the virulent factors of H. pylori but also the individual's ability to respond to H. pylori 
infcction and dctoxify ROS. 
The immune response rcsulting from H. p)-tori infcction is primarily via Thl, a 
proinflarnmatory response, mediated by a cascade of cytokincs including interlcukin 18 
(IL-18), IL-2, IL-1, tumour nccrosis factor-a and intcrfcron--y. Thcse cytok-ines rcgulate 
thcir o%%m lcvcls of cxprcssion by autocrinc cffccts, but thcy also influcncc downstrcwn 
cytokinc cxprcssion, thcrcby amplifying the inflammatory rcsponsc. IL-I is onc of the 
principal proinflammatory c)Iok-incs that mediate the Thl immune response following IL 
pylori infcction, with IL-19 production bcing up-rcgulated in the prcscnce of H. 
pylori 91 0 92 . IL-10 is also one of the most powerful inhibitors of gastric acid secretion, the 
hpochlorhydria associatcd with high-produccr variants of IL-1 governing the extent of 
11. pylori infcction and distribution of gastritis. As a conscqucncc, polymorphic variants 
in IL-1 may affect not only the primary inflammatory response but also the level of 
rcsponsc following amplification. 
The data from two groups have sho%vn an increased risk of gastric carcinoma associated 
with inheritance of the IL-IB-31 (CC)IIL-1 RN 212 gcnotyp 03*95. The findings suggest 
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that the IL-IB-31 C allele in the context of H. pylori infection is associated with a 
proinflammatory phenotype and therefore an increased risk of DNA damage and 
ultimately contributing to gastric carcinoma developmen ? 3-95 .A recent study has 
demonstrated a significant association bet-. vccn gastric MALT lymphoma and 
inheritance of the IL-I RN 212 genotype96, consistent with that previously finding in 
gastric carcinoma. However, they found no associated risk with IL-IB-31 genotype. 
The study also showed that the glutathionc S-transfcrasc (GST) TI null gcnotypc was 
associatcd uith risk of gastric MALT lymphoma. GST TI has a strong antioxidant 
function in ncutralising frcc radicals. These data support the hypothesis that the risk of 
dcvcloping gastric MALT lymphoma is influenccd by interindividual variation in 
inflammatory rcsponsc and antioxidativc capacity. However, the study failed to include 
11. pylori associatcd gastritis as a control group and the significance of the finding 
rcmains to bc invcstigatcd. 
1.5 Gcnetic abnormalities 
As discusscd above, IL pylori inrcction induces acquisition of MALT in the gastric 
mucosa, a prcrcquisitc for MALT lymphoma development, and its mediated 
immunological stimulation plays a direct role in the evolution of the transformed clone. 
On the othcr hand, 11 pylori infection also promotes the acquisition of genetic 
abnormalities and malignant transformation of rcactivc B cclls. H. pylori infcction 
tnggcrs inflammatory rcsponscs by attracting and activating ncutrophils, which relcase 
ROS90. ROS is k-no%%m to cause a range of genetic damage, particularly double strand 
brcak, thus may havc a rolc in the acquisition of gcnctic abnormalitics during MALT 
lymphorna dcvclopmcnt. Thcrc arc a numbcr of gcnctic abnonnalitics idcntiried in 
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INIALT Iymphoma, including chromosomal translocations, specifically associated with 
s lymphorna entity. 
1.5.1 t(11; 18)(q2l; q2l)IAP12-, IL4LT] 
The t(11; 18)(q2l; q2l) is the most frequent chromosomal translocation in IýLAIT 
lymphomas"'100. Remarkably, the t(11; 18)(q2l; q2l) is usually the sole chromosomal 
aberration. In contrast, t(11; 18)(q2l; q2l) negative turnours show a wide range of 
abnormalities including trisomics 3,12,18. In 1999, Dierlamm ct allo', subsequently 
Akagi ct al'02 and Morgan et al 103 showed that t(11; 18)(q2l; q2l) causes a reciprocal 
fusion between AP12, a k-no%%m gene at II q2 I and AULTI, a novel gcne at 18q2 1. As the 
AP12-MALTI fusion transcripts, but not the MALTI-AP12 fusion transcripts, wcrc 
constantly cxprcsscd, the AP12-AIALTI fusion was thought to bc most likcly oncogcnic. 
Following idcntirication of the gcncs involvcd in t(11; 18)(q2l; q2l), RT-PCR and 
inicrphasc FISH wcrc developed for detection of the translocation'04-105. These methods 
allow scrccning of large series of lymphoma cases. So far, studies from independent 
rmcarch groups showcd that t(11; 18)(q2l; q2l) occurrcd at variabic frcqucncics in 
NIALT Iymphomas of various sites but not in closely related nodal or spicnic marginal 
zone B ccll IYMphomas nor in other NHLs'04,106"11. Nevertheless, it remains to be 
investigated: 1) whcthcr the translocation occurs in the prc-malignant diseases associated 
with MALT lyrnphoma; 2) what the true incidence of the translocation in MALT 
lymphoma of diffcrcnt sitcs, particular those from sites other than stomach and lung is; 
3) what the role of t(11; 18)(q2l; q2l) in multistage development of gastric MALT 
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mphoma. in particular with reference to staging and treatment responses to H 
cradication is. 
1.5.1.1 The I P12 and If -1 L TI genes: structure and function 
Tlic API-'. together %%ith APII. %%as onginally identified as proteins recruited to the 
-n as c- turliour necrosis, lactor receptor 11 (TNFRID complex The API2 gene, kno%% 
L4P2,1IL4P-1. M111C. belongs to a family of genes that encode inhibitors of apoptosis 
prowins (IAPs). which arc charactensed by a domain of about 7710 anilno acids temied 
BIR (baculoviral TAP rcpcat). It contains three BIR domains in its amino-ternimus, a 
middle CARD icaspasc rccmitnient donlain) foliowed by a carbox N'- term, nal zinc 
binding RING finger domain (Figure 1.3)"'-ý' The BIR domains are Important for 
inhibition of caspascs and suppression of apoptosis' 1` while the CARD has been shown 
to mediate protein-protcin intcractionsll-. The RING finger motif is involved in 
autoubiquitination and degradation of the AP12 protein and has been shown to 
ncgatl%-cl%. regulate the function of the protein'"" 
A 93% 1% 
AP 12 
0f Is ols 
A%' A%. ' A% I A% 
MALTI DD '194. lot C2Sp3sQ4lk* 
AA 
1.3: Schcmatic presentation of AP12 and WALTI gene structure and prinicr 
po%ition%. Krio%%n Ilicakpoints arc indicated hý ai-rm%hcatis, and nucleic acids arc TILlIlIbCrCd 
a,: ý: ording to cDNA wquence of the AP12 (GenBank. N\1_001 165) and MALTI genes 
(., \I. 130356). The frequency of individual known breakpoints . vas given"' 
Arrows indicate the position of primers used. f-S and f-AS, sense and anti-sense pnimer for PCR 
from frozen tissues. p-S and p-AS. sense and anti-scnse primer for PCR from para ffi n -embedded 
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tissues; BUZ, baculo%irus IAP repeat; CARD, caspasc recruitment domain; DD, death domain; 
Ig-1, lg4tkc C2 domain'04*110. 
Wild t)pe AP12 is capable of inhibiting the biological activities of caspases 3,7 and 9 in 
in Oro studies, and is thus believed to be an apoptosis inhibitor 114 . However, full length 
AP12 did not protcct cclls from apoptosis induccd by Bax ovcr-cxpression and TNFa 
trcatmcnt'20. Deletion of the C-tcrminal RWG domain of API2 restores its antiapoptotic 
potcntiall". Enginccrcd mutant LAPs that contain only BIR domains can bind and 
121 
inhibit caspascs, cmphasising the importance of the BIR motifs in inhibiting apoptosis . 
AP12 mRNA is highly expressed in lymphoid tissues (spleen and thymus)'22, indicating 
that it has a rolc in B and T ccll function. 
The AIALTI gene, rcccntly classcd as a paracaspasc, comprises an N-tcrminal death 
domain (DD), followed by two Ig-likc C2 domains and a caspasc-likc domain (Figure 
13)123. AIALTI does not have classic activities of caspascs' 23 . 
MALT] knock out micc 
studies showed that MALTI spccifically links the antigen receptor signaling to NFxB 
activation pathway, and acts at the downstream of BCL10124 However, MALTI alone 
123.125 docs not activatc NFxB in in ritro assays 
1.5.1.2 Characteristics or theAP12-314-ILTI fusion 
Ile brcak-points of t(I 1; 18)(q2l; q2l) arc characteristic and most of the breakpoints for 
both thcAP12 and AfALTI gcncs occur in introns, appear to be in a random fashion'07' 126 . 
In the AP12 gcnc, all the brcak-points occur do%%mstrcam, of the third BIR domain but 
upstream of the C-tcrminal RING, with 93% just before the CARD (Figure 1.1)104,106-110. 
In contrasý the brcakToints in the AIALTI gcnc arc more variable, occurring in four 
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different introns upstream of the caspase-like domain (Figure 1.1)10'-""0. Thus, the 
resulting AP12-AL4LTI fusion transcripts always comprise the N-terminal API2 with 
three intact BIR domains and C-terminal AULT] region containing an intact caspase-like 
C2 domain. Importantly, all AP12-AL4LTJ fusion transcripts are in fi-ame, despite that 
some of brcak-points at the genomic level are in exons and potentially cause fi-ame 
shift126 . indicating selection pressure for a functional fusion protein during 
1), rnphomagenesis. 
The spccific: selection of certain functional domains of the AP12 and MALTI genes to 
form a fusion product strongly suggests the importance and synergy of these domains in 
oncogcnic activities. The BIR domain of AP12 has been shown to confcr anti-apoptotic: 
activity""'O. However, the anti-apoptotic: activity of the AP12 BIR domain was much 
weaker than that of the XIAP and has been shown to be suppressed by its C-tcrminal 
RING fingcr domain 120. As a result, wild t)pe AP12 did not protect cells from apoptosis 
upon stimulation by death signals 120 . The negative cffect of the RING fingcr on BIR 
function may be associatcd with its activity of promoting auto-ubiquitination and 
degradation 118.120. Rcplaccmcnt of the C-tcrminal AP12 with the C-tcrminal of MALTI 
by the fusion product would rclcasc the intrinsic anti-apoptotic activity of the BIR 
domain and therefore make the new molecule anti-apoptotic. The incoming C-tcrminal 
MALTI may furthcr cnhancc the anti-apoptotic activity of the BIR domain. It has bccn 
rcccntly shown that the AP12-MALTI fusion product, but not AP12 or MALTI alonc 
was capablc of activating NFxB'23"25"27. AP12-MALT1 fusion product with two Ig-likc 
C2 domain is morc potcnt in NFxB activation than thosc without Ig-likc C2 domain. 
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The BIR domain is capable of mediating oligomcrisation of BIR-containing protein 128 . 
It has been proposed that the AP12-MALTI fusion protein might be oligomerised 
through the BIR-BIR interaction, and through C-tcrminal MALTI the fusion product can 
constitutivcly activatc NFjcB (Figurc 1.1) 127 . Intcrcstingly, the API2 genc promotcr 
is 
knoum to be NFicB responsive, so that expression of the API2-, AL4LT] transcript is likely 
to be transactivated by NFO. This could set a positive feedback loop resulting in 
unrclcntcd NFxB activation. NFKB is a transcriptional factor and can transactivate gcnes, 
such as thosc cncoding c)lokincs and gro%%th factors, which are important for ccllular 
activation, proliferation and survival. Thus, it is likely that the AP12-NlALTI fusion 
product mcdiatcs its oncogenic activity through NFO activation. It has bccn rcccntly 
sho%%m that the AP12-MALTI fusion products inhibit DNA damages induced p53 
mcdiatcd apoptosis in an NFKB depcndant manncr 129 . 
In addition to its ability to activatc NFKB, the AP12-MALTI, fusion product has bccn 
shown to significantly suppress both UV- and ctoposide-induccd apoptosis in in vitro 130 . 
The anti-apoptotic: activity of the AP12-NIALTI fusion product appcars to bc mcdiatcd, 
at Icast in part, by dircct intcrfcrcncc of the proapoptotic activity of Smac 130 ,a 
mitochondrial protein that promotes cytochromc C-dcpcndcnt caspase activation 131 . 
In linc with the findings as discusscd abovc, that the AP12-NlALTI fusion products but 
not wild t)pc AP12 and NIALTI arc potcntial oncogcnic. It has bccn shown that the 
AP12-MALTI fusion protcin product was stablc, whcrcas both the full Icngth AP12 and 
MALTI wcrc unstabIC132. Thus, the AP12-MALTI fusion product gains propcrtics 
potcntially oncogcnic. 
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1.5.2 t(1; 14)(p22; q32)/IGH-BCLIO 
t(1; 14)(p22; q32) is a rarc but rccun-ent chromosomal translocation observcd cxclusively 
in? %IALTI)-mphoma. The lymphoma cells carrying t(1; 14)(p22; q32) usually show other 
chromosomal aberrations such as trisomies 3,12 and 18 and other chromosomal 
abcrrations'33 . Early cell culture cxpcriments showed that lymphoma cells carrying 
t(1; 14)(p22; q32) were capable of growing for a few days in the absence of any 
mitogcnic stimulations, in contrast thosc '%%ithout t(1; 14)(p22; q32) typically dicd by 
apoptosis under the same conditioný6. Interestingly, when stimulated with an anti- 
idiot)pc antibody, mimicking antigen receptor stimulation, turnour cells with 
t(1; 14)(p22; q32) actively proliferated, 50 times higher than those without the 
translocation". These findings suggest that t(1; 14)(p22; q32) involves a critical gene, 
that may bc closcly associatcd with antigcn rcccptor pathway. 
In 1999, Willis ct al'34 and Zhang ct al 135 independently cloncd the brcakToint of 
t(1; 14)(p22; q32) and showcd that the translocation brought the cntirc BCLIO gcne, a 
novel Scne at lp22, under the control of the Ig heavy chain gcne cnhanccr and 
dcrcgulatcd its cxprcssion. A subqucnt study also revealed translocation of the BCLIO 
36 
Scne to the IgK focus by t(1; 2)(p22; pl2ylGK-BCLIO in a casc rcport' . BCLIO 
contains a CARD in its N-tcnninal rcgion and is rich in scrine and thrconine in its C- 
terminal region. Subsequently, several research groups working on apoptosis also 
idcntiricd BCLIO through search of the EST databases for novel sequences containing 
CARD or yeast two-h)brid scrccningl37,141. Independent studies from different 
laboratories consistently showed that N%ild t)pc BCLI 0 was weakly proapoptotic despite 
that it also activated NFic, 3134.135.137-141. In line with this, wild type BCLIO was shown to 
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supprcss in %itro transformation of rat cmbryonic fibroblasts by H-ras and mutant 
p531-t4'135- The pro, -apoptotic acti%ity of BCLIO requires both an intact CARD and the 
C-tcrminal domain'-14. The truncated mutant BCLIO, identified from cDNA clones of 
MALT 1), mphoma uith t(1; 14)(p22; q32) lost the pro-apoptotic activity of the wild type 
but retained its ability to activate NFKB 134 . Moreover, truncated BCLIO mutants were 
sho%%m to syncrgisc %%ith H-ras and mutant p53 in rat embryo fibroblast (REF) 
transformation assa)sl-'4. Thus, mutation %%-as initially thought to bc important for 
BCLIO mcdiatcd oncogcncsis. 
1.5.2.1 BCLIO gene mutation 
The original mutation screening %%-as based on sequencing of individual cDNA clones 
34,135 from MALT Iymphomas %%ith t(1; 14)(p22; q32) and various tumour cell lines' 
Complcx mutations including inscrtions (particularly within a mononucleotide run of 
scvcn consccutivc th)midincs at nuclcotidcs 493-499), dclctions and point mutations 
wcrc found in cach case examined' -14,133. The majority of these mutations would result in 
truncatcd, BCLIO products similar to thosc showing oncogenic activity in in vitro 
cxpcrimcnts. 
To examine Nvhcthcr BCLIO gene mutation plays a role in lymphomagcncsis, Du ct al 
screened 227 cases of lymphomas of various subtypes based on the gcnomic DNA and 
found BCLIO gcnc mutation in 6.7% of cases. The majority of the mutations observed 
wcrc in the C-tcrminus and would rcsult in truncatcd BCLIO products, which wcrc 
confirmcd by %Vcstcm blot analysis in some cascs"2. Similar frequencies of BCLIO 
mutation at the gcnomic level were subsequently reported by sevcml independent 
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groups'41-1"6. However, most intriguingly, BCLIO genomic mutation is not an essential 
feature of MALT I)-mphoma uith t(1; 14)(p22; q32), being found in only I of the 3 cases 
examined 14.0 . Taken together, BCLIO gcnomic mutation may play a role 
in the 
devclopmcnt of a small subsct of I)-mphomas but is most likely not the only mechanism 
undcrl)ing the oncogcnic acti%ity of BCLIO. 
Comparison of BCLIO mutation at the genomic and transcript levels also revealed 
intziguingly that the mutations seen at the cDNA level were not observed at the genomic 
levcl"2. Subscquent studies showed that the BCLIO mutations found in cDNA cloncs 
from t(1; 14)(p22; q32) positivc MALT Iymphomas and various turnour ccll lincs werc 
also prcscnt in cDNA cloncs from normal peripheral blood lcukocytCS147'149 . Furthcr 
studies indicated that the mutations observed from individual cDNA clones including 
those or rccurrcnt. mutations, such as the insertion in the mononulcotide run, were not 
dctcctablc from uncloncd cDNA sampics cithcr by PCR-single-strand conformation 
polymorphism (SSCP) or dircct scquencing'"'"". Extcnsivc NVestcm blot analysis of 
MALT I)inphomas and various tumours ccIl lines also failed to detect truncated BCLIO 
products prcdictcd from mutations in the cDNA cloncs (Du ct al, unpublishcd data). It 
rcmains to bc a dcbatc whcther mutations sccn in cDNA cloncs wcrc the rcsults of 
"moiccular mismading7 during transcription or cloning artifacts. 
1.5.2.2 BCLIO In B and T cell development 
Studics of BCLIO knockout micclss'l-56 havc shoN%m that BCLI04' cclls rctaincd normal 
susccptibility to various apoptotic stimuli. ne BCLIO dcficicncy micc showcd 
profound dcfccts in both B and T ccll dcvclopmcnt. In the T cell lineage, the mice 
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showed an increased apoptosis of early immature thymocytes and a reduction of mature 
T cclls, while in the B cell lineage the mice displayed an impaired development of both 
follicular and marginal zone B cclis. BCL]e- lymphocytes have profound functional 
defects characterised by impaired antigen receptor mediated activation and proliferation 
of both T and B cclis. The BCLIe' mice showed dramatically reduced basal levels of 
scnun Igs and poor cellular and humoral responses tovirus infection, including Ig class 
s%%itch. These defects arc primarily due to impairment of antigen receptor mediated 
NFKB activation. It has been shoum that BCLIO specifically links the antigen receptor 
signaling to the NFxB pathway in both B and T cells. Thus, BCLIO acts as a positive 
rcgulator of D and T ccll proliferation and activation. Intcrcstingly, onc third of 
BCLIO-1. micc dicd at the cmbr)vnic stagc duc to ncural tubc closurc defcct. This 
finding suggests that BCLIO may confcr additional function othcr than I ng antigcn 
receptor mediated NFO activation in B and T cells. In linewith the above indings, 
transgcnic micc in which BCLIO is link-cd to an Ig cnhanccr-containing construct to 
program cxprcssion of the protcin in T and B cclis showcd a dramatic and spccific 
expansion or the spicnic marginal zone B cells, reminiscent of human marginal zone 
lymphomal". Intcrcstingly, t(1; 14)(p22; q32) positive lymphoma cells showed active 
prolifcration upon anti-idiot)pc antibody stimulation, 50 timcs highcr than thosc without 
the translocation". It is most likcly that the ovcr-cxprcssion of BCLIO in the cclis with 
t(I; I 4)(p22; q32) scnsitiscs the responses to the antigen rcccptor stimulation. 
Rcccnt studics havc unravclcd partially the rolc of BCLIO in antigcn rcccptor mediatcd 
NFxB activation and somc molecuics both up and down strcarn of BCLJO havc bccn 
idcntificd. TCR uith major histocompatibility complex (MHC)/antigen complex 
togcthcr with costimulation of CD28 initiates a tyrosinc phosphorylation cascade that 
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leads to the activation of protein kinase C (PKQ 0 and subsequent recruitment of the 
CARD domain-containing adaptor proteins CARMAI (CARD, membrane-associated 
guanylate kinasc, IýLAGUK, protein 1)1"7,158"59. CARMLAI subsequently recruits BCLIO 
via mteraction and induces BCLIO oligomerisation. This is followcd by 
BCLIO mediated MALTI oligomerisation, consequently triggering a cascade of events 
leading to NFjcB acti%-afion. It is believed that CARAW links B cell receptor (BCR) to 
BCLIO and MALTI in a similar way in B cells'60. Oligomerised MALTI binds to the 
tumour-nccrosis factor rcccptor associatcd factor 6 (rRAF6) through its C-tcrminus and 
induces the oligomcrisation of TRAF6, thereby activating its ubiquitin ligase activity. 
Activa F6 polyubiquitinatcs itsclf and NENIO at K63. Activatcd TRAF6 also 
acfivatcs TAKI, possibly by binding to TAB2 or TAB3 and promoting the 
autophosphorylation of TAKI. Poly-ubiquitination of NaIO may facilitate the 
rccruitment of the IKK complcx to the TAKl/TAB2 complcx, allowing TAKI to 
phosphorylatc IKK, 6 in the activation loop, thcrcby activating IKK. In MALT 
lymphoma with t(1; 14)(p22; q32), it is bclicvcd that ovcr-cxprcsscd BCLIO forms 
oligomcr through its CARD and activatcs do%%m strcam signaling Icading to NFxB 
activation widiout the need of antigen rcccptor stimulation 137. Nonetheless, the role of 
BCLIO in multistagc of MALT lymphorna dcvclopmcnt and the incidcncc of 
t(l; I 4)(p22; q32) in MALT I)inphoma of various sites remains to be investigated. 
1.5.3 1(14; 18)(q32; q2l)/IGII-, IftiLTI 
t(l4; l8)(q32; q2l) is characteristically seen in follicular lymphorna, in which it involves 
the BCL2 gene at 18q2l. The same chromosomal translocation, but not involving the 
BCL2 gcnc, was described in MALT lymphoma in 1997 97 . However, it was not until 
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2003 that Streubel et al and Sanchez-Izquierdo et al demonstrated that the translocation 
brings the entire MALT] gene under the control of the Ig heavy chain enhancer 161,162. 
Conventional cytogenetic and interphase cytogenetic studies showed that 
t(l4; l8)(q32; q2l)1IGH-MALTI positive MALT lymphomas, similar to those with 
t(1; 14)(p22; q32), frequently harbour other chromosomal aberrations such as trisomies 3, 
12 and 18 
161-163 
. 
Following identification of the gene involved in t(14; 18)(q32; q2l) of MALT lymphoma, 
interphase FISH has been developed for detection of this translocation. So far, there are 
only three studies that examined the incidence of the translocation in MALT 
lymphoma 161,163 . This translocation appears to occur more often in MALT lymphomas 
from extra-gastrointestinal sites. It has been described in MALT lymphomas of the liver 
(4/4), skin (3/11), ocular adnexa (3/8), lung (3/27) and salivary gland (2/11) but not in 
those of the gastrointestinal tract (19), thyroid (4) and breast (2)1 61,163 . In all cases 
reported, t(l. 4; 1 8)(q32; q2 1) is mutually exclusive from t(l. 1; 1 8)(q2 I; q2 1). 
In addition to chromosomal translocation, MALT] gene appears to be targeted by gene 
amplification. Using array CGH and FISH, MALT] gene amplification was 
demonstrated in cell lines from 2 splenic marginal zone B cell lymphomas (SSK41 and 
Karpas 1718) and I Burkitt lymphoma (KHMIOB)162. MALT1 over-expression in these 
cell lines was further confirmed by quantitative RT-PCR, suggesting that MALT] gene 
amplification may be involved in MALT lymphoma. However, the incidence of 
t(l4; l8)(q32; q2I)1IGH-MALTI and MALT] gene amplification in MALT lymphoma of 
various sites is largely unknown. MALTI. protein expression, its subcellular localisation 
and correlation with BCL10 expression pattern are unclear. 
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1.5.3.1 MALT1 in B and T cell development 
Most of our current understanding of MALTI function are derived from studies of 
MALTI knockout mice 124,164 . Similar to BCLIO -/' mice, MALT] -/" mice showed 
profound defects in antigen receptor mediated activation and proliferation of both T and 
B cells. MALTI. acts downstream of BCLIO to induce NFKB activation and is required 
for the normal development of both marginal zone B cells and peritoneal BI cells. In 
contrast to BCLIO disruption, however, inactivation of MALT1 has only mild effects on 
B cell activation and does not cause defects during neurodevelopment. In essence, 
similar to BCLIO, MALTI, is an essential regulator of adaptive immune responses. 
The above findings are supported by biochemical characterisation of BCL10 and 
MALTI induced NFKB activation. It has been shown that BCLIO binds Ig-like C2 
domain of MALTI and induces MALTI oligornerisation, consequently leading to NFKB 
123,127 
activation 
Interestingly, MALTI does not have a structure domain that can mediate self- 
oligomerisation and over-expression of MALTI alone does not activate NFKB. 
However, artificial oligomerisation of the C-terminus of MALTI, containing the caspase- 
like domain is sufficient for NFKB activation 127. Co-expression of MALTI and BCLIO 
shows synergistic activation of NEKB. It is believed that MALTI triggered NFKB 
activation depends on its oligomerisation mediated by BCL10. 
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1.5.3.2 Molecular link among the three MALT lymphoma associated chromosomal 
translocations 
As discussed above, MALT lymphoma is characterised by three specific chromosomal 
translocations involving different genes. Morphologically and immunophenotypically, 
MALT lymphomas with various chromosomal translocations do not show apparent 
differences, suggesting that these different chromosomal translocations may target the 
same or similar oncogenic pathways. 
Mounting evidence indicates that the oncogenic activity of these three MALT lymphoma 
associated chromosomal translocations is linked by the physiological role of BCLIO and 
MALTI in antigen receptor mediated activation. BCLIO fonns a complex with MALTI 
and the two molecules synergise in the activation of NRB 123,125 . BCL10 binds the Ig- 
like C2 domain of MALTI through a short region (aminoacids 107-119) downstream of 
its CARD domain and induces conformational changes that allow MALTI. 
125 
oligomerisation . In addition to the regions responsible for the interaction between 
BCLIO and MALTI, the CARD domain of BCL10 and the caspase-like domain of 
MALTI are crucial components for NFKB activation. Using knockout mice, Ruland et 
al in 2001 155 , subsequently Xue et all 
56 
, showed that BCL10 specifically transduces 
antigen receptor signaling to activate the NFKB pathway. Studies of MALTI-knockout 
mice by two different independent groups reinforced the above findings and showed that 
MALTI. operates downstream of BCL1 0124,164. Consistent with a role of BCLIO and 
MALT I in activating NFKB signaling, therefore regulating the proliferation and survival 
of B and T cells. 
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In 2001, three groups independently showed CARMAI as the upstream activator of 
BCL1 0127,165,166. CARMA1 (also known as CARD 11 or BIMP3) contains two potential 
protein-protein interaction domains: a CARD and a coiled-coil domain. It binds BCLIO 
through a CARD-CARD interaction and CARMAI, BCLIO, and MALT1 fonn a ternary 
complex 
127,165,166 leading to activation of IKK (section 1.5.2.2). Activation of the IKK 
complex leads to phosphorylation and subsequent ubiquitylation and proteolytic 
degradation of bfflaý and allows NFO to translocate to the nucleus and activate genes, 
such as those encoding cytokines, growth factors that are important for lymphocyte 
167,168 
activation and functions 
1.5.4 Other chromosomal aberrations 
In addition to the chromosomal translocations discussed above, conventional cytogenetic 
studies revealed other chromosomal aberrations in MALT lymphomas. Among those 
chromosomal alterations, the most recurrent changes are whole or partial trisomies 3,12, 
18 133 . Using interphase FISH, Wotherspoon et al. studied a large series of MALT 
lymphoma of various sites and showed trisomies 3 and 18 in 60% and 18% of cases 
33,169 
respectively' . In contrast, both trisomies 3 and 18 were only seen in 16% of nodal 
low grade B cell lymphomas. Dierlamm et al subsequently confirmed these findings and 
further showed that similar frequency of trisomy 3 was also found in nodal and splenic 
marginal zone B cell lymphoM29,170. By analysis of allelic imbalance using 
microsatellite markers, Starostik et al showed frequent chromosomal gain or 
amplification at 3q26-27 171 , where BCL6, an oncogene frequently deregulated in 
DLBCL by chromosomal translocation, is located. It remains to be examined whether 
BCL6 is the target of chromosomal gains at 3q26-27 in MALT lymphoma. Nonetheless, 
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chromosomal translocation involving BCL6 locus was reported in cases of MALT 
172,173 lyinphoma 
C-myc involved chromosomal translocation has been reported in cases of transformed 
MALT lymphoma 174 - However, this translocation appears not to be associated with 
174,175 MALT lymphoma 
1.5.5 p53 
Thep53 gene is located at chromosome l7p13 and encodes for a 393 amino acid nuclear 
phospho-protein. - The protein contains five highly conserved regions: phosphorylation 
sites at both amino and carboxyl terminus, a central zinc-binding core domain, nuclear 
localisation and tetramerization domain at the C-terminus. 
P53 is a transcriptional factor and plays a critical role in maintenance of the genome 
integrity. This is mainly achieved by control of the GUS and G2/M checkpoints. 
The GI/S checkpoint prevents cells from entering the S phase in the presence of DNA 
damage by inhibiting the initiation of replication and therefore, monitors DNA repair, 
and negatively controls cell cycle. Maintenance of the GI/S arrest is achieved byp53, 
which is phosphorylated on SerI5 by ataxia-telangiectasia mutated (ATM) / ataxia- 
telangiectasia and rad3-related (ATR) and on Ser20 by activation of checkpoint kinases 
ChKI or ChK2, respectively 176 . The phosphorylation of p53 inhibits its nuclear export 
and degradation, thus resulting in increased levels of p53. p53 activates its target genes, 
including p2l. 
WAF-I/Cipl 
, which binds to and inhibits the S-phase-promoting cyclin- 
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dependent-kinase (CdK2)-CyclinE complex 177 , thereby maintaining the GI/S arrest. 
p2l wAF-11c"' also binds to the CdK4-CyclinD complex and prevents it from 
phosphorylating retinoblastorna (Rb) 178 . The phosphorylation of Rb results in its release 
of the E2F transcription factor, which is required for the transcription of S-phase genes 
in order for S phase to proceed 
179 
. 
The G2/M checkpoint prevents cells from undergoing mitosis in the presence of DNA 
damage. Part of the mechanisms by which p53 blocks cells at the G2 checkpoint 
involves inhibition of Cdc2, the cyclin-dependent kinase required to enter mitosis 180 . 
The p53 cell cycle arrest pathways involve p2l(WAFI, Cip-1) and GADD45 (growth 
arrest and DNA damage). As mentioned above, p2l is an inhibitor. It binds to a number 
of cyclin - cdk complexes and PCNA to block cell cycle progession in G1 and G2. 
GADD45 also binds to PCNA and arrests the cell cycle in G2. Binding of Cdc2 to 
Cyclin Bl is required for its activity, and repression of the cyclin Bl by p53 also 
contributes to blocking entry into mitosis 179 . p53 also represses Cdc3, to 
help ensure 
that cells do not escape the initial block 179 . 
Overwhelming evidence indicates that p53 is a tumour suppressor. Inactivation of the 
p53 tumour suppressor gene is the most frequent event in human cancer 181 , and is 
commonly caused by mutation in one allele and loss of the other. This is exemplified by 
the findings in patients with familial Li - Fraumeni cancer syndrome: around 70% of 
cases carry a germline mutation and develop cancer following somatic loss of the 
remaining wild type allele of the p53 gene. The affected individuals typically present 
sarcoma, breast cancer, brain tumours, leukemia and adrenal gland tumours, often at a 
182,183 young age 
-40- 
Overall, p53 mutations are found in about 50% of all human cancers 181 and majority of 
these mutations are clustered in the regions critical for its function, such as the region for 
DNA binding 179 . In general, the incidence of p53 mutation in solid tumours is much 
higher than that in lymphoid malignancies. Various frequencies of p53 mutation have 
been documented in lymphoid malignancies. In aggressive lymphoma such as DLBCL 
and Burkitt's lymphorna, p53 mutation has been found in 26% cases 184 . Missense 
mutations of p53 usually result in the stabilisation of the protein; therefore; increased 
levels of p53 are typically detected in association with p53 gene mutations. Over- 
expression of the p53 protein is relatively common in high grade NHL (de novo as well 
as those that transform from a low grade lymphoma) but not in low grade turnours 185 . 
Inactivation of the p53 gene also plays a key role in the multistage development of 
MALT lymphorna and appears to be highly associated with its high grade 
transformation 68 . In MALT lymphoma, p53 allelic loss and mutation have been found in 
7% and 19% of cases, respectively, with concomitant allelic loss and mutation in only 
1/11 affected cases 68 . However, in transformed MALT lymphomas, p53 allele loss and 
mutation have been shown in 29% and 33%, respectively, with most affected cases (6/9) 
showing concomitant allelic loss and mutation". These findings show that p53 function 
is partly inactivated in low grade tumours, whereas complete inactivation of the p53 
gene is associated with high grade transfonnation. 
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1.5.6 C-MYC 
C-MYC is the major member of the Myc family that contains at least seven closely 
related genes (c-myc, n-myc, I-myc, p-myc, r-myc, s-myc and b-myc). The MYC-gene 
encodes for nuclear DNA binding proteins that are involved in transcriptional regulation. 
Myc proteins form homodirners or heterodimers with max, mad, and Mxl I through their 
186 C-terminal helix-loop-helix domains . Max binds Myc to repress the transcriptional 
activities of Myc, whereas mad and Mx 11 can bind Max and release Myc to function as 
a transcriptional activator 186 . Myc is implicated 
in the control of normal cell 
86 
proliferation, transformation and differentiation' . Myc expression is essential for 
progression through the cell cycle, thus, cellular proliferation. In addition, C-MYC is 
implicated in apoptosis regulation. In absence of growth factors, Myc expression 
induces apoptosis 
186 
. 
The C-MYC gene is located on chromosome 8q24 and consists of 3 exons, of which the 
first exon is non-coding. The abnormalities of C-MYC gene found in human cancer 
include chromosomal translocation, gene amplification and mutation. C-MYC involved 
chromosomal translocations are commonly found in Burkitt's lymphoma 187,188 and 
DLBCL'89. In 80% of cases, the translocation is between C-MYC and IGH on 
chromosome 14q32190, while in the remaining cases, the translocation is between C- 
MYC and IGK or IGL sequences on chromosomes 2p 12 and 22q 1 1191,192. 
In Burkitt's lymphoma, a high frequency of mutations has been observed in the non- 
93,194 S- ilar coding exon I and the exon I/intron I boundary region of the C-MYC gene' . im 
C-MYC mutations are subsequently observed in DLBCL including cases without the c- 
-42- 
myc involved translocation. The exon I and the exon I/intron I boundary region contains 
a transcriptional elongation block'95 ,a p67 protein initiation site, an intron splicing 
site 
196 
, and 3 myc 
intron factor (MIF) binding sites'97,198 . Therefore, it is considered as 
the C-MYC regulatory region. Somatic alterations in this region have been shown to 
194-198 
affect C-MYC expression based on in vitro study Thus, mutations in the 
regulatory region may alter myc transcription and expression in human tumour. 
Although cytogenetic and Southern blot studies have shown no C-MYC translocation or 
rearrangement in MALT lymphoma ? 7,98, translocation. involving the C-MYC locus has 
been reported in 3 of 24 transformed MALT lymphoma? 8. Sequence analysis of the 
regulatory regions of the C-MYC gene has shown somatic mutations in 16% of low 
grade tumours and 18% of transformed MALT lymphomas 54 . However, the importance 
of these mutations remains unclear. 
1.5.7 pl5lpl6 
Both genes localise at chromosome 9q2l and are adjacent to each other. They inhibit 
the cyclin-dependent kinases Cdk4 and Cdk6, and are the major negative regulators of 
the cell cycle. Inactivation of these genes is commonly caused by hypermethylation in 
the promoter region or by homozygous deletion. In MALT lymphoma, 
199,200 hypermethylation has been found in both the p15 (10%) and p16 (44%) genes 
Deletion of thep16 gene has been found only in transformed MALT lymphoma, (14%)201. 
The inactivation of p15 and p16 might cause the loss of inhibition of the cyclin d- 
dependent kinase (Cdk4 and Cdk6) complexes, which promote the GI-S transition, thus 
leading to a deregulated cell cycling. 
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1.5.8 Fas 
Fas (CD95; Apo-1) is a transmembrane receptor protein202,203 and triggers apoptosis 
upon binding to its natural ligand, Fas ligand (FasL)203-205 . The apoptosis signal is 
transmitted via an intracellular 'death domain' that interacts with a homologous motif in 
the adaptor protein Fas-associated death domain (FADD) which recruits pro-caspase 
8202,203 . Aggregation of pro-caspase 8 within the Fas signaling complex triggers 
its 
activation, which initiates a sequence of further downstream caspase activation, 
eventually causes apoptosis. 
An alternative Fas mediated apoptosis pathway has been identified that involves 
mitochondria. The pathway employed depends on the cell type (type I and II cells) and 
is partially dependend on the BCL2 family member BID 206 . BID is cleaved by caspase-8 
and its cleaved fragment p15 translocates to the mitochondria membrane and perturbs 
the integrity of the outer mitochondrial membrane, which results in the release of 
cytochrome C207. Cytochrome C in turn causes apoptotic protease activating factor-I 
208 (Apaf-1) to activate caspase-9, which results in downstream caspase activation . 
Fas is widely expressed in different cell types and tissues. A physiologic role of Fas has 
been demonstrated in the immune system. The depletion of autoreactive T cells 209 and 
the elimination of activated lymphocytes at the end of an immune response depends on 
, 205 Fas-FasL interaction204 . The importance of Fas and FasL in the immune system is 
illustrated by the MRUIpr-Ipr mouse (lympho-proliferation), which harbours a 
spontaneous mutation in the Fas gene and exhibits lymphoproliferation with massively 
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enlarged lymph nodes, splenomegaly, and various autoimmune disorders depending on 
the genetic background2lo. Similar clinical presentation is observed in patients with the 
auto-immune lymphoproliferative syndrome type I (ALPS I), also known as Canale- 
Smith syndrome, which is associated with mutations in the Fas gene 211,212 . The ALPS I 
is a rare inherited disease with manifestation in childhood. Affected patients show 
lymphoproliferation and autoirnmunities with variable clinical manifestations (spleno- 
and hepatomegaly, lymph node enlargement - but rarely 
lymphomaS)211,212. 
Lymphocytes from ALPS individuals are resistant or less sensitive to Fas mediated cell 
1,212 deatO 
Mutation of the Fas gene is also implicated in malignant diseases. Plasmacytornas 
harbour Fas mutations at a frequency of 10% (5/48)213. In a screen of different subtypes 
of B and T cell NHLs, Fas gene mutations were detected in 11% (16/150) of caseS214. 
Interestingly, majority of the cases with Fas gene mutation were extranodal lymphoma 
accompanied by autoirnmune diseases, such as hernolytic anemia and Sj6gren's 
syndrome 214 . However, subsequent studies showed that Fas gene mutation rarely 
occurred in MALT lymphoma including those originated from a background of 
autoimmune disorderý 15,216 .A recent study suggests that Fas gene mutation may be 
associated with high grade transformation of MALT lymphoma in a proportion of 
216 
cases 
1.5.9 Microsatellite instability 
Microsatellite instability (MSI) is a type of genomic instability. It is expressed as 
differences in the banding patterns of PCR amplified DNA from tumour cells versus 
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norinal cells at various microsatellite loci. MSI was first reported as tumour specific in 
17,21 17,219 hereditary non-polyposis colorectal. cancer2 8, and sporadic colon cancerý 
Subsequently, MSI was detected in many types of human solid turnours, albeit at 
different frequencies. MSI appears to be highly associated with defect in DNA 
mismatch repair geneS220,221. 
In lymphoid malignancies with the exception of MALT lymphoma, MSI appears to be 
an infrequent or rare event. In MALT lymphorna, MSI has been reported in 53% of 
cases 222 . However, MSI is not associated with mutation of the DNA mismatch repair 
223 
genes . It is believed that MSI seen in gastric MALT lymphoma is most likely the 
result of genetic insults caused by H. pylori induced inflammatory responses. 
1.6 Treatment of gastric MALT lymphoma 
Before mid- 1 990's, MALT lymphoma was treated by various methods including surgery, 
radiotherapy and chemotherapy. The finding of the critical role of H. pylori infection in 
the development of gastric MALT lymphomas prompted the initial investigation by 
Wotherspoon et al in 1993 224 , which examined the effect of H. pylori eradication on 
gastric MALT lymphoma. The study has led to not only novel therapy for gastric 
MALT lymphoma but also shed the light on development of potential therapeutic 
strategies for MALT lyrnphoma of other sites. 
-46- 
1.6.1 H. pylori eradication in gastric MALT lymphoma 
In 1993, Wotherspoon et al treated 6 patients with H. pylori positive gastric MALT 
lymphoma using antibiotics alone and carefully followed up these patients with repeated 
endoscopic biopsies and both histological and molecular examinations. They showed 
complete regression of gastric MALT lymphomas in five out of the six patients 4-6 
months after H. pylori eradication as judged by endoscopic and histological criteria. The 
histological remission was also accompanied by molecular evidence showing absence of 
tumour cells in the gastric biopsieS224. With further follow-up, the patient whose tumour 
had initially failed to regress also showed histological and molecular remission 18 
months after H. pylori eradication 225 . These six patients 
have been followed up for more 
225 than 6 years and they remain tumour free . 
Above findings have now been confirmed by a number of independent studies 
worldwide, based on a total of more than 550 cases reporte d226-240. Overall, about 75% 
of patients show complete remission after eradication of H. pylori. In most cases, 
complete remission is achieved within 12 months of H. pylori eradication. However, a 
latent response of up to 45 months has occurred in some cases. On average, patients are 
followed up for more than 3 years and the tumour remission is stable. In 10% of cases, 
lymphoma relapse occurs and this often associated with H. pylori re-infection and can be 
controlled by antibiotics again. In the absence of H. pylori re-infection, relapse is 
frequently a transient self-limiting event. In 50% of the patients, tumour cells are 
detectable by PCR from post-remission biopsy samples, even though there is no 
histological evidence of a tumour lesion. Early observations suggest that this 
monoclonal tumour-cell population disapears during longer foljoW UP241,242. 
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The role of H. pylori eradication in the treatment of transformed MALT lymphoma is a 
debate. Several early studies indicated that transformed MALT lymphoma and MALT 
5,131 
lymphomas with a high grade component did not respond to H. pylori eradication23 
However, recent studies have shown complete remission of transformed MALT 
lymphoma in some cases after H. pylori eradication78' 80. The value of H. pylori 
eradication as a treatment modality in transformed MALT lymphomas nonetheless 
remains to be further investigated. 
1.6.2 Prediction of the response of gastric MALT lymphoma to H. pylori 
eradication 
As discussed above, the time for a gastric MALT lymphoma to regress following H. 
pylori eradication can vary from a few weeks to 18 months. Prolonged follow-up with 
repeated endoscopy and gastric biopsy is essential to determine whether a lymphoma 
responds to H. pylori eradication or requires additional therapy. It is immensely 
beneficial, if the 25% of gastric MALT lymphoma that do not respond to H. pylori 
eradication can be identified at diagnosis. The prognostic value of clinical staging has 
been extensively examined by endoscopic ultrasonography, which allows assessment of 
227,230,238,239 
the extent of tumour invasion into the gastric wall and regional lymph nodes 
In general, lymphomas of stage HE or above do not respond to H. pylori 
eradication227,230,238,239. In stage IE cases, the prognostic value of staging is limited 
although tumours that involve the muscularis propria or serosa (stage IE2) show a higher 
failture rate than those restricted to the submucosa (stage IEI)227,230,238,239. 
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Attempts have been made to predict the response of gastric MALT lymphoma, to H. 
pylori eradication using histological and immunophenotypical features. As discussed 
above, early studies showed that MALT lymphomas with high grade components tended 
to resist to H. pylori eradication. However, recent studies showed that early stage of 
transformed MALT lymphoma may respond to H. pylori eradication. Thus, histological 
features do not provide a reliable indication to predict the response of gastric MALT 
lymphoma to H. pylori eradication. In view of the critical role of H. pylori specific T 
cells in the growth of MALT lymphoma B cells, De Jong et al compared the expression 
of co-stimulatory molecules between gastric MALT lymphomas that responded to H. 
pylori eradication and those that resisted to the treatment. These authors found that 
CD86 expression was significantly associated with H. pylori eradication responsive 
cases 243 . Nonetheless, it remains to be evaluated whether CD86 expression level can be 
used as a reliable marker for identification of gastric MALT lymphoma that will respond 
to H. pylori eradication. 
Majority of gastric MALT lymphomas are at stage IE at diagnosis. The response of these 
early stage gastric MALT lymphorna, to H. pylori eradication can not be predicted 
neither by clinical staging nor by histological or immunophenotypic investigation. 
Clearly, other markers that can predict the treatment response of gastric MALT 
lymphoma to H. pylori eradication are highly desired. Identification of such treatment 
predictive markers may also help to unravel the molecular events that are responsible for 
MALT lymphoma cells to gain H. pylori independent growth capacity. 
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1.6.3 Treatment of H. pylori eradication non-responsive gastric MALT lymphoma 
Surgery was widely and successfully used for treatment of gastric MALT lymphoma in 
the past 57. It is highly curative for localised turnours, with a 5-year overall survival of 
90-100% for those at stage IE and 82% for those at stage II E 
244,245 
. However, lymphorna 
cells are unlikely to be totally removed by partial gastrectomy because they disseminate 
widely within the gastric mucosa 41 . This 
is also evident by the frequent observation of 
tumour relapse in the gastric stump 244,245 . Thus, to eradicate the 
lymphoma cells, a total 
gastrectomy is required, which seriously compromises the quality of patients' life. In 
view of this, and the similar survival rates achieved by various conservative 
therapies 244,246 , surgical resection should be restricted to patients with complications 
such as gastric perforation and bleeding. 
Gastric MALT lymphoma is sensitive to radiotherapy and the use of low-dose localised 
radiotherapy alone is becoming increasingly popular. The 5-year disease-free survival is 
about 80% and 5-year overall survival is greater than 90%244,245. Very encouraging 
results have been reported with low- to moderate-dose local radiotherapy in patients with 
stage MI MALT lymphoma of the stomach, without evidence of H. pylori infection or 
with persistent lymphoma after antibiotics treatment, as well as in those with localised 
disease at non-gastric siteS247-251. 
Chemotherapy has never been adequately evaluated in gastric MALT lymphomas 
because it was usually not administered, or given after surgery or radiotherapy. Only 
few compounds have been tested in MALT lymphomas. A non-randomised study 
reported that oral alkylating agents (either cyclophospharnide or chlorambucil, with a 
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median treatment duration of one year) can result in a high rate of disease control with 
projected 5-year event-free and overall survival of 50% and 75%, respectivelý 52 . 
more recent phase II study demonstrated good anti-turnour activity of the purine analog 
cladribine (2-CDA) with a complete remission rate of 84%253. 
In the presence of disseminated disease, chemotherapy is an obvious choice. The role of 
the anti-CD20 monoclonal antibody rituximab in treatment of MALT lymphoma has 
also been explored in a phase II study, showing a response rate of about 70% (44% CR 
and 29% partial response)254 . This may represent an additional option for the treatment 
of systemic disease, but the efficacy of its combination with chemotherapy remains to be 
further studied25'. 
1.6.4 Treatment of MALT lymphoma of other sites 
Most of the available information on the management of MALT lymphoma has been 
obtained from studies of gastric lymphoma. Non-gastric MALT lymphomas have been 
difficult to characterise because these tumours are distributed so widely throughout the 
body and it is difficult to assemble adequate series of any given site. Yet, few series 
have recently addressed the characteristics of non-gastric MALT lymphomas 246 . The 
International Extranodal Lymphoma Study Group (IELSG) published a retrospective 
survey of a large series of patients who were diagnosed as non-gastric MALT lymphoma. 
The IELSG study confirmed the indolent course of non-gastric MALT lymphomas 
despite the fact that one quarter of cases presented with stage IV disease and regardless 
of treatment type the 5-year survival was approximately 90%256. 
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The optimal management of non-gastric MALT lymphomas has not yet been clearly 
established. Retrospective series included patients treated with surgery, radiotherapy 
and chemotherapy, alone or in combination. Whether different sites have a different 
246,256 
natural history remains an open question . Location can be an important factor 
because of organ-specific problems, which require different management strategies. 
Since optimal management of MALT lymphomas has not yet been clearly defined, the 
treatment choice should be patient-tailored, taking into account the site, the stage and the 
clinical characteristics of the individual patient. 
Growing interest has been paid to explore the role of eradication of putative aetiological 
factors in treatment of non-gastric MALT lymphoma. Cutaneous marginal zone B cell 
28,19 lymphoma has been shown to be associated with Borrelia burgdoferi infection 
Kutting et al reported complete remission in I of 2 cases of cutaneous marginal zone B 
cell lymphoma after antibiotic therapy. Lecuit et al recently showed that Campylobacter 
jejuni was associated with IPSID 30 . As shown from this preliminary study, IPSID could 
be effectively treated by eradication of Campylobacterjejuni with antibiotics. This is 
accordance with the fact that IPSID has been known to respond to antibiotic therapy for 
Many years257,258. A role for Chlamydia psittaci infection in the pathogenesis of ocular 
adnexal MALT lymphomas has been proposed by Ferreri et al3l. They demonstrated 
that 2 of 4 patients respond antibiotic therapy for Chlamydia psittaci. In summary, these 
findings indicate that eradication of putative aetiological. factors associated with non- 
gastric MALT lymphomas may have significant implication in treatment of these 
malignant diseases. 
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1.7 Pathogenesis of MALT lymphoma 
Most of our current understanding of the pathogenesis of MALT lymphoma has been 
gained based on studies of those from the stomach. H. pylori infection stimulates the 
production of lymphoid infiltrates: B cells, T cells together with neutrophils, which lead 
to the formation of acquired MALT in the gastric mucosa. As a result of both direct and 
indirect immunological stimulation (by auto-antigens and H. pylori specific T cells, 
respectively), infiltrating B cells actively proliferate and occasionally undergo malignant 
transformation because of the acquisition of genetic abnormalities, such as 
t(11; 18)(q2l; q2l), t(1; 14)(p22; q32), trisomies of chromosomes 3,12 and 18, allelic 
imbalance, partial p53 inactivation. In the presence of growth help from H. pylori 
specific T cells, this abnormal B cell clone may undergo clonal expansion and gradually 
form a frank MALT lymphoma. At this stage, the tumour is most frequently confined to 
the stomach and will regress following eradication of H. pylori. However, the 
lymphoma can progress, spread beyond the stomach and gain H. pylori independent 
growth capacity. By this stage, the lymphoma is no longer responsive to H. pylori 
eradication therapy. Nonetheless, the molecular events underlying the acquired H. 
pylori independent growth are not understood. Further genetic events such as complete 
inactivation of the p53 and pI 6 genes and other undetermined abnormalities can result in 
high grade transformation. 
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Figure 1.4. Multistage development of gastric MALT lymphoma 
1.8 Aims 
t(I 1; 18) 
t(1; 14) 
t(14; 18)? 
trisomies 3,12,18 
allelic imbalance 
This study attempted to investigate the molecular events involved in pathogenesis of 
MALT lymphoma. The specific aims were as follows: 
I. To investigate the frequencies of t(11; 18)(q2l; q2l), t(1; 14)(p22; q32) and 
t(14; 18)(q32; q2l) in MALT lymphoma of various sites and examine their roles during 
the multistage development of this turnour. 
2. To correlate chromosomal translocations with clinical stages and treatment 
responses of gastric MALT lymphoma to H. pylori eradication 
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3. To study BCLIO and MALTI expression pattern in normal and malignant 
lymphoid tissues, correlate their expression with different chromosomal translocations in 
MALT lyrnphoma and explore their value in detection of the translocations. 
-55- 
Chapter 2. Materials and methods 
2.1 Materials 
2.1.1 Solutions 
2.1.1.1 Solutions used in immunohistochernistry and Enzyme-linked 
immunosorbent assay (ELISA) 
Tris buffered saline pH 7.6 (TBS): Tris[hydroxymethyl] arninomethane (Sigma 
Chemical Co Ltd, Poole, Dorset, UK) of 6.05 g and NaCl (BDH Laboratory Supplies, 
Merck Ltd, Lutterworth, Leicestershire, UK) of 80 g were dissolved in 8 litres of 
distilled water, pH was adjusted to 7.6 with IM HCI (BDH) and the volume was 
brought to 10 litres with distilled water. 
TBS-Tween: Tween 20 (Sigma) was added to TBS to give a final concentration of 
0.05%. 
Phosphate buffered saline (PBS) pH 7.2: One tablet of PBS (Sigma) was dissolved in 
200 ml of distilled water, giving pH 7.2. 
Peroxidase block solution: This solution was always prepared fresh just before use and 
composed of 200 /A of 30% H202 (hydrogen peroxide) (Sigma) in 12 ml. of methanol 
(BDH). 
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3,3-Diaminobezidine tetrahydrochloride (DAB) substrate solution: This solution was 
always prepared fresh just before use. One tablet of DAB (Kem-En-Tec A/S, Denmark) 
was dissolved in 10 ml of distilled water. 10 jil of 30% H202solution was added to the 
solution just before application. 
Alkaline phosphatase substrate solution: 8 mg of Naphthol AS-MX phosphate (Sigma) 
was dissolved in 0.2 ml of dimethyl formamide (Sigma). This was added to 10 ml of 0.1 
M tris solution. The pH was adjusted to 8.2 with 1M HCL Just before use, 2.5 mg of 
levamisole (Sigma) and 10 mg of Fast Blue (Sigma) or Fast Red (Sigma) were dissolved 
and the solution was filtered. 
Citrate buffer pH 6.0: Sodium citrate tribasic dihydrate (Sigrna) of 8.82 g was 
dissolved in 3 litres of distilled water and pH was adjusted to 6.0 with 1M HCl- 
Tris-EDTA buffer pH 9.0: 24 g of tris and 2g of EDTA (BDH) were dissolved in 9 
litres of distilled water, pH was adjusted to 9.0 with 1M HCI (BDH) and the volume 
was brought to 10 litres with distilled water. 
Dako target retrieval solution pH 6.0: 60 ml of Dako target retrieval solution pH 6.0 
(DakoCytomation, UK) was mixed with 540 ml of distilled water. 
Dako target retrieval solution pH 9.9: 60 ml of Dako target retrieval solution pH 9.9 
(DakoCytomation, UK) was mixed with 540 ml of distilled water. 
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Chymotrypsin (CT) solution: CT (BDH) of 0.1 g and 0.1 g calcium chloride (BDH) 
were dissolved in 100 ml of distilled water and pH was adjusted to 7.8 with 0.1 N NaOH 
(BDH). The solution was warmed up to 37'C in a water bath before use. 
Protease solution: Protease (Sigrna) of 0.1 g was dissolved in 100 ml of distilled water 
and pH was adjusted to 7.8 with 0.1 N NaOH. The solution was warmed up to 37'C in a 
water bath before use. 
3% Paraformadehyde solution: 3g of paraformadehyde (Sigrna) was dissolved in 100 
ml of PBS. 
0.08% Triton 100 solution: 800 jil of triton 100 was mixed with 1000 ml of PBS. 
Blocking buffer used in ELISA assays: 3% of heat inactivated horse serum (Sigma) in 
TBS-Tween was used to block the non-specific binding sites in ELISA assays. 
O-Phenylenediamine substrate solution: The solution was the mixture of 2.45 ml of 
0.1 M citric acid (Sigma) and 2.55 ml of 0.2 M dibasic sodium phosphate (Sigma) with 
the volume adjusted to 10 ml with distilled water. Prior to use, 3.4 mg of o- 
phenylenediamine (Sigma) and 2 Al of 30% H202 solution were added. 
2.1.1.2 Solutions used in tissue culture 
10% Sodium azide solution: Ig of sodium azide (Sigma) was dissolved in 10 ml of 
distilled water. 
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Polyethylene glycol (PEG) solution: 10 g of polyethylene glycol 1500 (BDH) was 
autoclaved and 10 ml of sterile serum free RPMI 1640 medium (Imperial Laboratories, 
Andover, Hampshire, UK) was added. 
Trypan blue solution: Trypan blue was purchased from Sigma as a 0.4% solution for 
counting the viable cells. 
Calcium-magnesium Hanks's balanced salts solution (HBSS): HBSS with 0.35 g/L 
sodium bicarbonate was purchased from Imperial Laboratories, Andover, Hampshire, 
UK, in sterile 500 ml bottles. 
2.1.1.3 Solutions used in Western blotting 
Cell lysis buffer (2 X): Lysis buffer was composed of 100 mM tris-HCI (pH 8.0), 300 
mM NaCl, 0.04% sodium azide, 0.2% sodium deoecyl sulfate (Sigma), 2% nonidet P-40 
(BDH), 1% sodium deoxycholate (BDH), 2 mM EDTA, 100 mg/ml 
phenylmethylsulfonyl fluoride (Sigma), and I mg/ml leupetin (Sigma). 
AcryIamideAbis-acrylamide stock solution: Ready mixed 40% acrylamide/bis- 
acrylamide stock solution was purchased from BDH and kept at 40C until required. 
Stacking gel buffer stock (0.5 M Tris-HCI pH 6.8): 6.0 g of tris was dissolved in 40 
ml of distilled water, titrated to pH 6.8 with 1M HCI and brought to 100 ml final 
volume with distilled water. The solution was stored at 4T until required. 
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Resolving gel buffer stock (1.5 M Tris-HCI pH 8.0): 18.2 g of tris and 48.0 ml of 1M 
HCI were mixed and brought to a final volume of 100 ml with distilled water. The 
solution was kept at 4"C. 
10% Sodium dodecyl sulphate (SDS) solution: 10 g of SDS (BDH) was dissolved in 
100 ml of distilled water and stored at room temperature. 
10% Ammonium persulphate solution: Ig of ammonium persulphate (Bio-Rad) was 
dissolved in 10 ml of distilled water. The solution was always prepared fresh just before 
use. 
Electrophoresis running buffer pH 8.3: Electrophoresis running buffer was prepared 
as a 10 X concentrated stock solution and diluted to a working concentration in distilled 
waterjust before use. The 10 X concentrated running buffer was prepared by dissolving 
30.3 g of tris, 150.14 g of glycine (Sigma), 10 g of SDS (BDH) and 3.7 g of EDTA in 
distilled water in a final volume of 1 litre. The solution was kept at room temperature. 
Blocking buffer: Blocking buffer for Western blotting was composed of 5% skimmed 
mi MARVEL) and 3% bovine albumin (Sigma) in TBS-Tween. 
Blotting buffer pH 9.2: Blotting buffer pH 9.2 was made by dissolving 5.82 g of tris, 
2.93 g of glycine and 0.375 g of SDS in distilled water followed by addition of 200 ml of 
methanol (BDH). The volume was adjusted to I litre with distilled water. 
-60- 
Nitroblue tetrazolium chloride (NBT) - 5-Bromo-4-Chloro-3-Indolyl Phosphate 
(BCIP) substrate solution: Substrate kit was purchased ready-made from Gibco. The 
substrate solution was prepared before application by mixing 44 Al of NBT solution and 
33 Al of BCIP solution to 10.0 ml of 0.1 M Tris-HCI (pH 9.5), 0.1 M NaCl, 50 mM 
MgC12 (Sigma). 
2.1.1.4 Solutions used in interphase fluorescence in situ hybridization (FISH) 
I mM EDTA buffer (pH 8.0): The solution was composed of 2 ml of 0.5 M EDTA 
(pH 8.0) (Merck) in 1 litre of distilled water. 
Pepsinsolution: 100 mg of pepsin was dissolved in 100 ml of distilled water and added 
0.5 ml of 2M HCI (Merck). 
1% paraformaldehyde solution: Ig of paraforrnaldehyde was dissolved in 100 ml of 
distilled water. 
0.4 X SSC/0.3% IGEPAL CA-630: The solution was the mixture of 2 ml of 20 X SSC 
(Sigma) and 300 1A of IGEPAL CA-630 (Sigma) with the volume adjusted to 100 ml 
with distilled water. 
2X SSC/0.1 % IGEPAL CA-630: The solution was the mixture of 10 ml of 20 X SSC 
and 100 lil of IGEPAL CA-630 with the volume adjusted to 100 ml with distilled water. 
2X SSC: 10 ml of 20 X SSC was mixed with 90 ml of distilled water. 
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2.1.2 Cell and culture media 
RPM1 1640: Dutch modified RPMI medium 1640 with 20 mM HEPES was used as the 
standard medium in all cell culture experiments. In most cases it was supplemented with 
10% heat inactivated fetal calf serum (FCS) (Imperial Laboratories), 2.05 mM L- 
glutamine (Sigma), 50 U/ml. Penicillin G and 50lig/ml streptomycin (Sigma). 
Hypoxanthine-aminopterin-thymidine (HAT) medium: 50 X HAT media 
supplement (Sigma) was reconstituted in 10 ml of RPMI 1640 and was added to 500 ml 
of RPMI 1640 plus 10% FCS to achieve final concentration of 100 jtM hypoxanthine, 
400 nM aminopterin and 16 AM thymidine. 
Dulbeccols Modified Eagle's Medium (DMEM): Dulbecco's modified Eagle's 
medium with high glucose (Sigrna) was used to culture HEK 293 cells and stable 293 
transfected cell lines. It was supplemented with 10% heat inactivated FCS, I mg/ml 
G418 (Sigma), 100 g/mI of penicillin and 100 /. tg/ml of streptomycin. 
Freezing medium: FCS containing 5% dimethyl sulphoxide (DMSO) (BDH) was used 
to freeze down cells for cryo-preservation in liquid nitrogen. 
2.1.3 Antibodies 
wi e range of murine monoclonal antibodies was used in the studies described in this 
thesis. The antibodies used and their specificities, dilutions, and sources are summarised 
-62- 
in Table 2.1. The secondary and third antibodies and reagents used to detect the 
reactivity of primary antibodies are shown in Table 2.2. 
Table 2.1. The characteristics of primary monoclonal antibodies used in 
immunohistochemistry (IHQ, immunoblotting (IB) 
SPCIFICITY CLONE DILUTION PRETREATMENT SOURCE/REFERENCE 
BCLIO 151 1/60 (IHC) 
1/2000 (EB) 
MW* pH 6.0 Raised in House 
CD 3 UCHT-1 1150 (lHC) PC** 3 mins DakoCytomation Ltd 
CD20 L26 1/400 (IHC) MW 20 mins 
Citrate buffer 
DakoCytomation Ltd 
C'-MALTI 25 Neat (IHC) 
1/100 (IB) 
MW pH 9.9 Raised in House 
Neutrophil elastase 1150 (IHC) PC 3 mins DakoCytomation Ltd 
N'-MALTI 1150 (IHQ 
1/2000 (I]B) 
PC 3 mins Genetech, USA 
*MW: microwave oven **PC: pressure cooking 
Table 2.2. Characteristics of secondary and third reagents used to demonstrate 
the primary antibody immunoreactivity in IHC, ELISA and IB. 
SECONDARY REAGENTS DILUTION SOURCE 
Rabbit anti-mouse Ig, biotinylated 1/300 (1HC) 
1/4000 (IB) 
DakoCytomation Ltd 
Rabbit anti-mouse 1g, peroxidase 11500 (ELISA) DakoCytomation Ltd 
Extra-avidin, peroxidase 1/200 (IHQ Sigma 
Extra-avidin, alkaline phosphatase 1/1000 (If1c) 
1/10000 (IB) 
Sigma 
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2.1.4 Cell lines 
NSO: HAT sensitive, non-immunoglobulin-secreting mouse myeloma cell line NSO 
(European Collection of Animal Cell Cultures (ECACC), PHLS Centre for applied 
Microbiology and Research, Salisbury, Wilts, UK) was used as the fusion partner in all 
hybridoma workS259. NSO cell line was gown in RPMI 1640 plus 10%FCS, maintained 
at a density of 3-9 X 105 cells/ml and was used for fusion during exponential growth 
phase. 
BCLIO stable expression HEK 293 cell lines: Full length BCLIO, N and C terminal 
truncated BCLIO stable expression HEK293 cell lines and HEK 293 cells transfected 
with vector pcDNA3.1 were gift of Prof Martin J. S. Dyer and colleagues. They were 
cultured in high-glucose Dulbecco's modified Eagle's medium containing 10% FCS and 
G418 antibiotics. These cell lines were used for Western blotting to test the specificity 
of mouse BCLIO monoclonal antibodies. In some experiments, these cells were pelleted, 
fixed in 10% of formalin and paraffin-embedded. Sections from these paraffin- 
embedded cell pellets were used for BCLIO immunohistochernistry. 
MALT1 or AP12-MALT1 stable expression cell lines 260 : Full-length MALTI and 
AP12-MALT1 stable expression Epstein-Barr virus (EBV)-negative BJAB human B cell 
lymphoma cell lines and BJAB transfected with vector pCDNA3.1 were gift of Dr L. Ho 
(Geneva, Switzerland). They were gown in RPMI-1640 with 10% FCS. These cell 
lines were used for Western blotting to test the specificity of mouse N-terminus of 
MALTI and C-terminus of MALTI monoclonal antibodies. 
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2.1.5 Tissues 
Frozen specimens: All frozen tissue specimens were obtained from the tissue banks of 
the Department of Histopathology, Royal Free and University College Medical School, 
London, UK; Service de Gastro-enterologie/Service d'Anatomie Pathologique, Hotel- 
Dieu, Ap-Hp, Paris, France; Groupe d'Etude des Lymphomes Digestifs, Fondation 
Francaise de Candrologie Digestive, France; the Department of 
Pathology/Gastroentorology, The Netherlands Cancer Institute, Arnsterdarn, The 
Netherlands; Servizi di Anatomia Patologica e Gatsroenterologia, UniversitA degli Studi 
di Bologna, Italy; Labor Molekulare Diagnostik, Universitatsklinikurn Carl Gustav 
Carus, Dresden, Germany; and Service d'Anatomie Pathologique, Hopital Lariboisiere, 
Paris, France. 
Paraffin embedded specimens: All paraffin embedded tissue specimens were obtained 
from the surgical archives of Department of Histopathology, Royal Free and University 
College Medical School, London, UK; Department of Histopathology, The Royal 
Marsden NHS Trust , London; Department of Internal Medicine/Clinical Pathology, 
University of Vienna, Vienna, Austria; Service de Gastro-enterologie/Service 
d'Anatomie Pathologique, Hotel-Dieu, Paris, France; Department of 
Pathology/Gastroentorology, The Netherlands Cancer Institute, Amsterdwn, The 
Netherlands; Servizi di Anatomia Patologica e Gastroenterologia, Universita degli Studi 
di Bologna, Italy; Labor Molekulare Diagnostik, Universitatsklinikum Carl Gustav 
Carus, Dresden, Germany; Service d'Anatomie Pathologique, Hopital Lariboisiere, Paris, 
France; The Department of Haernatology, Oncology and Immunology, Philipps 
University Marburg, Marburg, Germany; Institut fur Pathologie, Klinikum Bayreuth, 
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Germany; Department of Pathology, Institute of Pathological Anatomy and 
Histopathology, Ancona, Italy; Department of Pathology, Raigmore Hospital, Inverness, 
UK; Department of Haematology, University of Leicester, UK and Department of 
Pathology, Chi-Mei Medical Centre, Taiwan. 
2.1.6 Animals 
Six weeks old female Balb/c strain mice (Harlan, London, UK) were used for 
immunisation with recombinant BCLIO and MALTI proteins, and production of mouse 
BCLIO and MALT1 monoclonal antibodies. 
2.2 Methods 
2.2.1 Immunobistochemistry 
For immunohistochernical studies, microscopic slides (DakoCytomation) were used, and 
6 Am frozen or 4 Am paraffin sections were cut from the tissue blocks. To stain non- 
adherent cells in culture, cytospins were prepared on slides. Monolayer cultures were 
grown on 1% gelatin-coated sterile coverslips in tissue culture dishes. At the end of the 
culture period, they were washed with TBS and air-dried. 
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2.2.1.1 Immunohistochemistry on formalin-fixed and paraffin-embedded tissue 
sections 
Most of immunohistochemical studies were carried out on paraffin-embedded tissue 
sections using protocols described below unless specified. 
Paraffin sections (4 Am) were deparaffinised in xylene (BDH), rehydrated using 
decreasing concentrations of ethanol (BDH), and incubated in peroxidase block solution 
for 10 minutes to block the endogenous peroxidase activity. Where indicated, antigen 
retrieval was carried out prior to immunostaining. To optimise a new primary antibody 
for immunohistochemistry, several antigen retrieval methods and a serial dilution of the 
primary antibody were systematically tested, and the conditions that gave the best 
staining were used in subsequent experiments. The antigen retrieval methods used for 
different antibodies are summarised in Table 2.1. Sections were then incubated with 
primary antibody at optimal dilution for I hour followed by biotinylated secondary 
antibody (1/200-1/300) and peroxidase conjugated ExtroAvidin (1/200) for 30 minutes, 
respectively. Finally, the staining was visualised with DAB in H202 and counter-stained 
with Mayer's haernatoxylin. Throughout all immunohistochemistry procedures, the 
slides were washed in TBS-Tween, three times for 5 minutes each between all 
incubation steps. 
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2.2.1.2 Immunohistochemistry on frozen tissue sections, cytospin preparations and 
monolayer cell cultures 
In some cases, frozen tissue sections, cytospin preparations and monolayer cell cultures 
were used for immunohistochernistry. This was carried out essentially as described for 
paraffin-embedded tissue sections with following modifications. 
Frozen sections (6 Arn), cytospins and monolayer cultures on coverslips were air dried 
for 30 minutes and were either immediately stained or wrapped in cling film and kept at 
-20"C until required. Frozen sections were routinely fixed in acetone (BDH) for 10-20 
minutes and air-dried. Cytospins and coverslips were fixed either in acetone for 10-20 
minutes or in 3% paraformadehyde for 10 minutes followed by 0.5% Tirton-100 for 5 
minutes. The staining process is similar to that for formalin-fixed and paraffin- 
embedded tissue sections except that they were washed in TBS instead of TBS-Tween. 
It is important not to use Tween or other surfactant on frozen sections, cytospins and 
coverslips as this will cause detachment of cells. 
2.2.1.3 Double staining 
The procedure of the first primary antibody was the same as that of 
immunohistochemistry on formalin-fixed and paraffin-embedded tissue sections. Afler 
developernent with DAB, slides were incubated with the second primary antibody at an 
appropriate dilution for 1 hour followed by biotinylated secondary antibody and alkaline 
phosphatase anti-alkaline phosphatase for 30 minutes, respectively. Finally, the staining 
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was visualised with Fast Red or Fast blue substrate solution for 10-20 minutes and 
mounted with an aqueous mountant. 
2.2.1.4 Quantification of neutrophil infiltration 
Neutrophil infiltration in MALT lymphoma and its preceding diseases was quantified 
with the help of immunohistochernistry. Neutrophils were detected with a mouse 
monoclonal antibody to the neutrophil elastase. The extent of neutrophil infiltration was 
estimated in 10 randomly chosen fields using a Lennox eyepiece graticule (Graticules 
Ltd., Tonbrige, Kent, UK) under high power magnification and expressed as a mean 
number of neutrophils per high power field. 
2.2.1.5 ELISA 
ELISA was used to screen hybridoma clones to identify those expressing the Ig to the 
antigen of interested. 
50 Ag of protein used as antigen for mouse immunisation was coated on 96 well ELISA 
plates overnight at 4*C or one hour at room temperature. After incubation, non-specific 
reactivity was blocked by incubation in 3% heat inactivated horse serum in PBS for 
ovemight at 4*C or I hour at room temperature. The hybridoma cells were allowed to 
grow to confluence in 96-well and 24-well culture plates. One hundred microlitres of 
culture supernatant of hybridoma clones as primary antibody against the antigen being 
investigated were applied to the plate coated with antigen for one hour at room 
temperature followed by peroxidase labelled rabbit antibody against mouse 
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immunoglobulins for one hour. Peroxidase reaction was visualised using o- 
phenylenediamine as substrate for 40 minutes and stopped by 50 lil of 0.5 M H2SO4- 
The reactivity was measured at 492 mn with TitertekS Uniscan II microplate reader 
(ICN). Final optical density was calculated as the difference between reactivity of the 
antibody against the antigen being investigated and the negative controls. 
2.2.2 Microdissection 261 
Tissue sections were dewaxed and weak stained by Haematoxylin. A drop of 50% 
ethanol was subsequently applied to cover the defined area using a drawn out glass 
pipette (cotton plugged) controlled by suction through a rubber tube. The selected cell 
populations were scraped gently under the microscope and transferred to Eppendorf 
tubes. The 50% ethanol solution was essential for floating the dissected cells and 
preventing them from adhering to the slide. 
To avoid cross-contamination, sections were rinsed with ethanol fresh new pipettes were 
used for each microdissection. The microdisseted cells were spinned down, dried and 
subjected to DNA and RNA extraction where indicated. . 
2.2.3 Western blotting analysis 
2.2.3.1 Preparation of protein homogenate for Western blot 
Frozen tissues and transfected HEK 293 cells were homogenised in lysis buffer. 
Transfected 293 cells were grown in a 15 ml small flask. The monolayer cells were 
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washed with HBSS and incubated in trypsin-EDTA solution at 370C for 10-15 minutes. 
The loosened cells were then recovered, washed in tissue culture medium by 
centrifugation and resuspension. 
The cells were transferred to 1.5 ml. eppendof tubes, washed once with PBS, and 100 to 
200 [d of cell lysis buffer (prechilled to 41C) was added. The tubes were incubated on 
ice for 1 hour with occasional rocking. At the end of the incubation period, the samples 
were spun at 10,000 g for 10 minutes. The supernatant was transferred to a fresh tube 
and immediately used in immunoblotting studies as described below or kept at -70"C 
until required. 
2.2.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The whole cell lysates as described above were analyzed by SDS-PAGE followed by 
immunoblotting. A vertical slab gel apparatus, mini-Protean II Dual Slab CeIIV (Bio- 
Rad), was used. Separating (12%-5%) and stacking (4%) gels were prepared as shown 
in Table 2.3 and amonium persulphate solution and TEMED were added just before the 
nýxture was poured to the gel apparatus. 
Resolving gel solution was poured leaving 1 cm space below the teeth of the comb for 
the stacking gel. The resolving gel solution was overlaid with distilled water and left to 
polymerise for 45 minutes. When set, the overlay was rinsed off with distilled water. 
The stacking gel monomer was poured and the comb was placed in the gel sandwich. 
After polymerisation, the comb was removed and the wells were washed with running 
buffer; the gel apparatus was assembled and filled with running buffer. The cell lysates 
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were mixed with 6X loading buffer and loaded to each well. In each run at least one 
well contained standard molecular weight markers (Amersharn Life Science). The gel 
was run for approximately 45 minutes to 2 hours at a constant voltage of 150 volts (V). 
At the end of the run the gel was separated from the plates and blotted as described 
below. 
Table 2.3. Preparation of stacking (Total=5 ml) and 12%-5% resolving 
gels (TotaI=1 0 ml) for SDS-PAGF,. 
Stacking 
Gel 
12% 10% 7.5% 5% 
40% Acrylamide/ 
bisacrylamide 
0.5 ml 3 ml 2.5 ml 1.875 ml 1.25 ml 
Stacking gel buffer stock 1.25 ml - - - - 
Resolving gel buffer stock - 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10% SDS 50 [d 100 Al 100,11 100 ILI 100111 
Distilled Water 3.17 ml 4.5 ml 4.85 ml 5.475 ml 6.095 ml 
10% APS 25 ul 50 ul 50 ul 50 ul 50 ul 
UrN TEMED 5 1A 5 Itl 5 jil 5 jil 5 Itl 
2.2.3.3 Western blotting 
The proteins run on the SDS-PAGE as described above were transferred to 
nitrocellulose membranes (Bio-Rad) for immunostaining using a Trans-Blot SD semi- 
dry electrophoretic transfer cell (Bio-Rad). 
The gel was equilibrated in blotting buffer for 5 minutes. It was then put on a wet 
nitrocellulose membrane and placed in the blotting apparatus between layers of filter 
paper. The transfer was completed in 1 to 2 hours at a constant voltage of 10 V. The 
membrane was washed in TBS-Tween and non-specific binding was blocked by 
-72- 
incubation in a blocking solution (5% skimmed milk and 3% bovine albumin) overnight 
at 4*C or for 1 hour at room temperature with constant shaking. After blocking, the 
specific antibodies were applied for 1 hour at room temperature with constant shaking 
followed by biotinylated rabbit anti-mouse Ig for 30 minutes. Finally, alkaline 
phosphatase-conjugated avidin was added for 30 minutes, and NBT-BCIP solution was 
added for 5-10 minutes. At the end of the detection reaction, the blots were washed 
under running tap water and air-dried. 
2.2.4 Tissue culture 
2.2.4.1 Cell culture 
All tissue culture plastic-wares were purchased from Coming Inc., Coming, New York, 
USA. Unless otherwise stated, all tissue cultures were carried out at 37'C in 5% C02 
using a humidified, automatically controlled incubator (Leec Ltd., Colwick, Nottingham, 
UK). Manipulation of the cultures was always handled in a class II laminar flow cabinet 
(ICN Biomedicals). 
2.2.4.2 Protocol for freezing cells 
Cells to be frozen were spun down, the supernatant decanted and the pellet resuspended 
in cold medium up to a volume of 500 Al depending on the cell density. The cell 
suspension was transferred to a cryovial and appropriately labelled. Ideally, cells to be 
frozen were in a logarithmic growth and at a density of at least 106 cells per vial. Cells 
were placed in a polystyrene container to control the rate of cooling and first frozen 
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down in a -70'C freezer. On the following day, vials were transferred into liquid 
nitrogen until required. 
2.2.4.3 Protocol for thawing cells 
The vial to be thawed was retrieved from the liquid nitrogen Bank and rapidly warmed 
in a 37T water bath. The cell suspension was transferred to a sterile container and 
media added slowly to the cells with gentle agitation. The cells were spun down to 
remove media and then were transferred to an appropriate culture flask in the required 
medium. 
2.2.5 Generation of monoclonal antibody 
2.2.5.1 Recombinant BCL10 protein 
The recombinant BCLIO protein was generated by Professor Ming-Qing Du. Briefly, the 
full length (amino acids 1-233) and amino terminus (amino acids 1-122) of BCLIO were 
PCR-amplified from a BCLIO cDNA clone using a forward primer containing NcoI site 
(5'ATCCATGGAGCCCACCGCACCGGTCC3') and a reverse primer containing Noff 
site 5ATGCGGCCGCTTGTCGTGAAACAGTACGTGA3' for the full length and 
5'ATGCGGCCGCACAACTGCTACATTTTAGTC3' for the amino terminus. The 
PCR products were cloned into the TA cloning vector pGEM(D-T, subcloned into 
PUC 1 19/Myc-His at the NcoI and NotI sites and then transformed into E. coli HB215 1. 
Colonies were screened using PCR with vector primers (M13 forward and reverse) and 
positive clones were sequenced to check for correct sequence and reading frame. Ten 
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positive clones were induced to express BCL10 protein in a5 ml culture with ImM 
IPTG at 28'C for 10-16 hours and their BCL10 expression was assessed by Western 
blotting with 9ElO antibody (Sigina, Poole, U. K. ), which recognises the c-Myc tag. The 
clone expressing the highest level was subjected to induction in a2 litres culture under 
the same conditions. BCL10 was purified using Ni-NTA (QIAGEN, Crawley, U. K. ) 
affinity chromatography under denaturing conditions with 8M urea according to the 
manufacturer's instructions. Purified BCLIO was dialyzed against 30 mM Tris-HCI (pH 
8.0) and concentrated using Centriplus concentrators (Amicon, Beverly, MA). The 
purity and yield were checked by SDS-PAGE. 
2.2.5.2 Immunisation protocol 
Balb/c strain mice were immunised by intraperitoneal. injection of 50 jig of full-length 
recombinant BCLIO or C-tenninal MALTI. protein (The gifts from Prof. Ming-Qing Du 
and Ms Sima Shirali) in complete Freund's adjuvant followed by two boost injections 
with 50 jig of the respective recombinant protein in incomplete Freund's adjuvant two 
weeks and 4 weeks after the priming. Three days after the second boost injection, the 
mice were sacrificed and the spleen was aseptically removed for production of 
hybridoma. 
2.2.5.3 Preparation of feeder layer for growing hybridoma cells 
To support growth of hybridoma cells, feeder cells were used. They were obtained by 
was ing te peritoneal cavity of Balb/c mice with 10 ml of HAT medium. These feeder 
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cells were grown in 96 well plates for 1 day before they were used to support the growth 
of hybridoma cells. 
2.2.5.4 Hybridoma fusion 
Single cell suspension was prepared from the spleen of the immunised mice by cutting 
the splenic tissue with a steriled scalpel and washed in RPMI 1640 serum free medium 
for three times. NSO cultured under the standard condition were harvested and washed 
in RPMI 1640 serum free medium for three times. Mouse splenocytes (typically 1 
10 7) were mixed with NSO cells in a ratio of 1.4: 1 in 20 ml RPMI 1640, and 1 ml of pre- 
warmed (37*C) PEG 1500 solution was slowly added to the mixture with gentle shake. 
Immediately after this, 2 ml of HAT medium (pre-warmed to 37"C) was slowly added to 
the cell suspension followed by a further 18 ml of HAT medium within the next 2 
minutes. The cells were spun down and resuspended in 10 ml of HAT medium and the 
number of live fusion cells was calculated by trypan blue exclusion method. The fusion 
cells were dispensed into 96 well tissue culture plates containing feeder cells at the final 
cell concentrations of IX 105cells/well, 5x 104 cells/well and 2.5 X 104 cells/well. 
2.2.5.5 Hybridoma screening and single cell cloning 
From 7 to 21 days after fusion, the 96-well plates were inspected daily and clones visible 
to naked eyes were subjected to ELISA screening. ELISA positive clones were 
transferred to a 24-well culture plate containing feeder cells. When they reached the 
exponential growth phase, supernatants from these wells were screened again by ELISA. 
Positive clones were then subjected to single cell cloning and the supernatant from these 
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clones were tested for immunohistochemistry of paraffin sections from tonsil and MALT 
lymphoma with relevant translocations. Positive clones after the second ELISA 
screening were cloned twice with limiting dilution. Briefly, hybridoma cells were plated 
into two 96-well plates at four concentrations so that 0.5,1,2 or 5 cells would be present 
in each well. The arising clones were screened using ELISA and immunohistochemistry 
as outlined above. Those with the desired reactivity were first transferred into a 24-well 
plate, and then grown in tissue culture flasks. Once a stable antibody secreting 
hybridoma was achieved, cells were transferred to standard medium RPMI 1640 plus 
10% FCS. The superriatants from hybridoma cultures were used for 
immunohistochernistry and Western blotting and they were kept at -20'C until required. 
Once defrosted, sodium azide solution was added at a final concentration of 0.02% and 
the hybridoma supematant was stored at 4"C. 
2.2.5.6 Determination of isotypes of monoclonal antibodies 
The isotype of the mouse monoclonal antibodies generated was determined using the 
ImmunoType monoclonal antibody isotyping kit (Sigma) according to manufacturer's 
instructions. 
2.2.6 DNA and RNA based molecular analysis 
2.2.6.1 DNA extraction 
DNA extraction from paraffin-embedded tissue sections: Paraffin-embedded tissue 
sections were deparaffinised in xylene for 5 minutes at room temperature and washed 
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three times with 100% ethanol and air-dried at room temperature. Samples were then 
digested with proteinase K Qiagen solution (10 mM Tris pH9,50 mM KCI, 0.1% Triton 
and 200 Ag/ml proteinase K) at 37'C ovemight or for three hours at 55"C. The 
proteinase K was inactivated at 95"C for 10 minutes. 
2.2.6.2 RNA extraction 
RNA extraction from frozen tissues or fresh cells: This was carried out using Qiagen 
RNeasy Mini kit (Qiagen, West Sussex, England) according to manufacturer's 
instructions. Briefly, fresh cells, or frozen tissue sections (<5 itm) were lysed in 
appropriate volume (600 Al) of RNeasy lysis buffer (Buffer RLT) containing fl- 
mercaptoethanol (1%). Cells or tissues were homogenised by spinning the crude lysate 
through a QIAshredder column (Qiagen, UK). After addition of an appropriate amount 
of 100% ethanol, the samples were applied onto a RNeasy spin column. The column 
was washed with buffer RW1 and then Buffer RPE before elution with RNase-free water. 
RNA is quantified and stored at -70'C. 
RNA extraction from paraffin-embedded tissue sections: This was carried out using 
Ambion RNA Isolation Kit (AMS Biotechnology, Oxon, England, United Kingdom). 
Paraffin embedded tissue sections were deparaffinzed in xylene for 20 minutes at room 
temperature and washed three times with 1 ml. 100% ethanol and air-dried at room 
temperature. Samples were then digested with proteinase K (I mg/ml) at 45T for two 
hours and solubilised in a guanidium-based buffer. RNA was extracted with acid 
phenol/chloroforrn and precipitated in isopropanol with linear acrylamide as carrier. 
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RNA was washed with 75% ethanol, redissolved in 20 ld of RNA storage solution, 
quantified and stored at -70*C. 
2.2.6.3 Quantification of RNA 
2.5 ILI of RNA extracted from frozen tissues or fresh cells or paraffin-embedded tissue 
sections was mixed with 77.5 1A of distilled water and quantified using GeneQuant pro 
(Amersham Pharmacia Biotech, Sweden) according to manufacturer's instructions. 
2.2.6.4 Complementary DNA (cDNA) synthesis 
cDNA synthesis from RNA Samples prepared from frozen tissues and fresh cells: 
This was carried out with oligo(dT) primer using SuperScript Preamplification System 
(Invitrogen Ltd, Paisley, Scotland, United Kingdom). Briefly, I /A dNTP, I jil 
Oligo(dT), 2 jig RNA were mixed in 10 jil volume together and incubated at 65T for 5 
minutes, and placed on ice. If the amount of total RNA was below the measurable level, 
such as from biopsy tissue samples, a maximum volume of RNA preparation was used 
for cDNA syhthesis. After at least 1 minute, 2 jil 10 X RT buffer, 4 jil 25 MM M902,2 
/0 0.1 M DTT and I Al RNase inhibitor were added to the above RNA/primer mixture 
and incubated at 42*C for 2 minutes, and followed by additional of 1 Al of SuperSCRIP 
II RT enzyme and incubation at 42"C for 50 minutes. The reaction was terminated at 
70"C for 15 minutes and 1 jil RNase H was applied and incubated for 20 minutes at 
37T. 
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cDNA synthesis from RNA samples prepared from paraffin-embedded tissue 
sections: For paraffin-embedded samples, cDNA was synthesised using SuperScriptTm 
Preamplification System with the following modifications. In the case of detection of 
t(11; 18), all three anti-sense primers (p-ASI, p-AS2 and p-AS3) to the MALT] gene 
together with anti-sense primer to the control gene glucose-6-phosphate dehydrogenase 
(G6PD) were included in the reverse-transcript (RT) reaction (Table 4.2). In addition, 
the temperature for primer annealing and cDNA synthesis was at 50"C rather than 42"C 
used for reverse transcription with oligo(dT) primer. 
2.2.6.5 PCR and analysis of PCR products 
PCR optimisation: Most PCR was carried out using standard routine procedures 
following optimisation. A typical PCR reaction was carried out in a 25 1A reaction 
volume containing 1 itl of cDNA extracted from fresh frozen tissues, 0.2 mM dNTP 
(Promega, Southampon, United Kingdom), 2 MM M902,0.2 AM sense and anti-sense 
primers each and 1 unit Platinurng Taq DNA polymerase (Invitrogen Ltd) and amplified 
on a Phoenix thermal cycler (Helena BioSiences, U. K. ). The PCR was conducted using 
a "hot-start touch-dowif' program, comprising hot start at 94*C for 4 min followed by 
denaturing at 94"C for I minute, annealing at 65-59*C (one degree down each cycle) for 
1 minute and extension at 72*C for 1.5 minutes, and then 35 cycles of denaturing at 
94"C for 1 minute, annealing at 58"C for I minute and extension at 72T for 1.5 minutes. 
A final extension step at 72"C for 10 minutes concluded the reaction. 
Two sets of primers were used for detection of the API2-MALTI fusion transcript from 
frozen tissues (Table 2.4). The first set of primers, consisting of sense primer 5'-CTG 
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GTG TGA ATG ACA AGG TC from coding region 897-916 of API2 (GeneBank, 
Accession No. NM_001 165) and anti-sense primer 5'-TAG TCA ATT CGT ACA CAT 
CC from coding region 1124-1143 of MALTI (AF130356), were used for primary PCR 
covering all breakpoints of the fusion transcripts recorded in literature 
97,98 101,104,106,108- 
110,262 
. To improve specificity and sensitivity, the primary PCR products were further 
amplified using a nested set of primers consisting of sense primer 5'-ACA TTC TTT 
AAC TGG CCC TC from coding region 1505-1524 of AP12 and anti-sense primer 5'- 
CAA AGG CTG GTC AGT TGT TT from coding region 1030-1049 of MALT1. All 
PCR reactions were performed in at least duplicate. 
A 256 base pair fragment of G6PD gene was amplified in parallel as a control to verify 
RNA quality and RT-PCR efficiency for each sample, using sense primer 5'-GAG GCC 
GTG TAC ACC AAG ATG AT and anti-sense primer 5'-AAT ATA GGG GAT GGG 
CTT GG (Table 2.4). The primers were chosen to flank a region containing introns 10 
(104bp) and 11(105bp) (GenBank X55448-1, M12996) so that amplification of 
contaminating DNA could be differentiated from that of cDNA by electrophoresis on 
agarose gels 
For paraffin-embedded samples, in order to amplify the AP12-MALT1 fusion product, 
primers were designed to flank a short segment of the fusion junction and hence were 
suitable for amplification of small fragments of cDNA typically prepared from RNA 
isolated from paraffin-embedded tissues. Three sets of PCR primers were designed: a 
common API2 sense primer (p-S) that covered 93% of the known API2 breakpoints, and 
three anti-sense primers that targeted all the four variable breakpoints on the MALTI 
gene (Table 2.4). A separate set of primers was designed for RT-PCR of the G6PD gene 
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(Table 2.4). The size 23,263 of fragments amplified with these primer pairs is shown in 
Table 2.4. PCR was performed separately with each primer pair using the same "hot- 
start touch-down" progrmn as described above. 
Table 2.4. Primers for RT-PCR of the API2-MALT1 fusion transcript and GOD 
Tissue type 
Gene target 
Primer Primer sequence 
Expected major PCR 
products (base pairs) (bp)" 
AP12- Sense 5'-ACA TTC TTT AAC TGG CCC TC 
Frozen tissue MALTIb Anti-sense 5'-TAG TCA ATT CGT ACA CAT CC 
669; 730; 1006; 1279 
Sense 5'-GAG GCC GTG TAC ACC AAG ATG AT 
G6PD Anti-sense 5'-AAT ATA GGG GAT GGG CTT GG 
258 
AP12- Sense 5'-GGA AGA GGA GAG AGA AAG AGC A 
Paraffin Anti-sense I 5'-CCA AGA CTG CCT TTG ACT CT 83 
Tissue NULTI Anti-sense 2 5'-GGA TTC AGA GAC GCC ATC AA 67; 340 
Anti-sense 3 5'-CAA AGG CTG GTC AGT TGT TT 73; 100; (133; 197; 230); 409 
G6PD Sense 5'-ACG GCA ACA GAT ACA AGA AC 
Anti-sense 5-CGA AGT GCA TCT GGC TCC 87 
"Alternative splice variants are shown in parentheses 
b Gene sequence used for primer design: API2, NM-00 1165; MALT], AF 13 03 5 6; GOD, 
X55448.1 and M12996. 
Most of the primers used in this thesis were designed with Oligo 6.1 software (institute 
of Biotechnology, University of Helsinki, Finland) based on published sequences except 
the primer sets used for the amplification of the H. pylori urease A and the CagA genes 
of H. pylori which were adapted from published sequences89264. All primers were 
synthesised by Oswel (Southampton, United Kingdom) or (Thermo Electron 
Corporation, Sedanstrafle, Germany). 
Various laboratory procedures and precautions were strictly followed in order to prevent 
potential cross contamination. Briefly, RNA and DNA extraction and PCR experiment 
set up were carried out on a dedicated bench area in a "clean" laboratory, which is free 
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of PCR and cloning products. Once PCR experiments were set up, the PCR plates or 
tubes were transferred to a themo-cycler in a separate room, where the PCR 
amplification and PCR product analysis took place. In each PCR experiment, 
appropriate positive and negative controls were included. 
Analysis of PCR products: RT-PCR products amplified from RNA of frozen tissues 
were analysed by electrophoresis on 0.9% agarose gels. Briefly, 3-10 jil of PCR product 
was mixed with loading buffer, loaded on a gel, electrophoresed at 100-150 V for 30 
minutes and viewed under ultraviolet light after staining with ethidium. bromide. 
PCR or RT-PCR products amplified from RNA of paraffin embedded tissue sections 
were analysed by electrophoresis on 10% polyacrylamide gels. Briefly, 5-10 jil of PCR 
product was mixed with loading buffer, separated on polyacrylamide gel at 200 V for I 
hour and stained with ethidium. bromide for 5 minutes and visualised under ultraviolet 
light. 
2.2.6.6 PCR of H. pylori associated urease and CagA genes 
For H. pylori associated urease gene, a pair of primers (sense primer 5-CAT CTT GTT 
AGA GGG ATT GG-T; anti-sense primer 5'-TAA CAA ACC GAT AAT GGC GC-3') 
were used, which yielded a 203bp product and was thus suitable for DNA samples 
264 
prepared from formalin-fixed and paraffin-embedded tissues . Similarly, the CagA 
gene was amplified with a primer set (sense primer 5'-TCAGAAATTTGGGGATCAG- 
Y; anti-sense primer 5'-TCATCARGGATAGGGGGTT-3') which gave rise to a 132bp 
product 89 . For both genes, PCR was carried out in a 25gl reaction on a thermocycler 
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(ThermaHybaid Px2) under the following conditions: 4 minutes at 94"C for initial 
denaturation, 40 cycles of 30 seconds at 940C, 30 seconds at 53"C for and 45 seconds at 
72*C, and finally 10 minutes at 72"C to conclude the reaction. PCR products were 
analysed on 10% polyacrylamide gels. 
2.2.6.7 Purification of PCR products 
PCR products were purified using a Concert Rapid PCR Purification System (Life 
Technologies) according to manufacturer's instructions. Briefly, the PCR products were 
dissolved in 400 Al of Binding Solution (HI) and loaded onto a spin cartridge and 
centrifuged in a microcentriflage at ý!: 12,000g for I minute. The mixture was then 
washed with 700 1A of wash buffer (H2) by spinning at ý--12,000g for I minute twice and 
added 50 Al of warm TE Buffer and incubated at room temperature for I minute 
followed by centrifuging at 12,000g for 2 minutes. 
2.2.6.8 Cloning 
Some of PCR products from the alternative splicing variants of the API2-MALT] fusion 
transcript were cloned and sequenced. Briefly, PCR products were purified from 1.5% 
agrose gels using QIA Quick Gel Extraction Kit (Qiagen, UK) and ligated into the 
TOPO-TA cloning vector and transformed into One Shot competent Escherichia coli 
(Invitrogen, Chrlsbad, CA). The transfonned cells were selected on Luria-Bertani (LB)- 
ampicillin agar plates and colonies were screened by PCR using vector primers T7 (5'- 
GTAATACGACTCACTATAGGGC-3') and T3 (5'-AATTAACCCTCACTAAAGGG- 
3'). The PCR products showing the expected insert size were sequenced in both 
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oricritationswith dRhodamine terminators (Perkin-Elmer, Foster City, CA) on an ABI 
377 DNA sequenccr (Pcrkin-Elmer, CA, USA). 
2.2.6.9 Sequencing of PCR products 
The RT-PCR products of the AP12-MALTI fusion transcript were directly sequenced 
from both orientations using ABI 377 DNA Sequencer. Briefly, 4 to 5 pl of PCR 
products (minimum of 800 ng in total) were mixed with 4 pI of dRhodamine Dye 
Terminator Mix and 5 pNI (each) primers. Afler denaturation for 30 seconds at 96*C, 
each rcaction mixturc was amplificd for 25 cycics as follows: 30 scconds at 96C, 15 
seconds of annealing at 50*C, and I minute of extension at 60T. PCR products were 
c1caned by prccipitaion Uith 100 pi of 80% cthanol and 6 pl of 3M NaAc (pH 5.2) and 
analyscd on an ABI 377 DNA scqucncer. 
Computer anal)iis of the DNA sequences obtained was carried out using BLAST onlinc 
(bttv: //%v-. v-%v, ncbi -DIM nib. rov/B LAS and the Wisconsin GCG sofINvarc 
(providcd by 
the Human Genome Mapping Projcct, Cambridgc, UK). 
Ile RT-PCR method for detection of t(I 1; 18) was established by Dr Hongxiang Liu. A 
proportion of MALT lyrnphoma cascs wcrc scrccned by Dr Hongxiang Liu. Most of the 
scqucncing work was analyscd by Dr Hongxiang Liu, somc by Nlr Rifat A. Hamoudi. 
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21.6.10 Interphase FISH 
Interphasc FISH was carried out using different probes. BCLIO (BAC clones RPII- 
IOSOII and RPII-4OK4 for telomeric as well as RPII-1077CIO and RPII-361A for 
ccntromcTic) and IGK (BAC RPCI-I I 316G9 for telomeric as wcll as RPCI-I 1 1021F1 I 
and RPCI-I I 525LI6 for centromcric) break--apart probes were the gifts of Dr Reiner 
Siebert (Institute of Human Genetics, University Hospital Schleswig-Holstein Campus 
c, Gcrmany) and IGHIBCLIO (BAC 158A2 for IGH and BACs RP 11-1080111 and 
RP I 14OK4 tclomcric to BCLIO) dual colour, dual fusion translocation probes were 
from Ellen D. Rcmstcin (Divisions of Anatomic Pathology and Hcrnatopathology, 
Mayo Clinic, Rochester, USA). The diagnostic reliability of the newly developed 
BCLI 0 brcak--apart assay was recently proven in a series of controls including four cases 
of cytogcnctically proven t(1; 14)(p22; q32) (Siebert ct al., personal communication). 
IGII and MALTI brcak--apart probes, IGIIIAMLT] probes, and AP121MALTI probes 
were purchased from Abbott Dignostic (Dovmcrs Grove, IL, USA). Interphasc FISH 
was pcrforTncd on paraffin embedded tissue sections. Bricfly, dcparaffinised sections 
wcrc prctrcatcd by prcssurc cooking for 2 minutcs and 40 scconds in I mM EDTA, PH 
8.0 and subsequently incubated in pepsin solution for 20 minutes at 370C to increase 
accessibility. Sections were then rixcd in 1% paraformaldchyde for I minute, 
dchydratcd and air-dricd. Probe was applied to the tissuc section, which was then 
covcrcd with a 10 mm round coverslip. The probe and target DNA were thwn denatured 
at 80*C for 25-30 minutes and incubated for 3 days at 37"C. Sections were washed with 
0.4 X SSC/0.3% IGEPAL CA-630 at 72*C for 2 minutes and 2X SSC/0.1% IGEPAL 
CA-630 at room temperature for I minute, followed by 2X SSC at room temperature 
for 2-5 minutcs. Finally, the scctions wcrc countcrstaincd with 4,6-Diamidino-2- 
phenylindole (DAPI) and mounted in Vcctashicld antifade mounting medium (Vector 
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ratorics, Burlingame, CA). Sections were viewed under an Olympus Axioskop2 
fluorescence microscope (Japan) using a 100 X oil immersion lens and appropriate 
filters and images were captured with ISIS imaging system (NletaSystems, Altlussheim, 
Germany). 
21.6.11 Real-time RT-PCR. 
Real-timc RT-PCR was uscd to quantify AULT] and BCLIO mRNA cxpression and 18S 
rRNA was used as an internal control. Total RNA was isolated from turnour cells 
microdisscacd from paraffin-cmbcddcd tissue scctions261. cDNA was synthcsiscd using 
random hcxamer primers for MALTIMS rRNA and gene specific primer for 
BCLIOA8S rRNA. Real-time PCR was performed using an iCyclcr iQ system (1310- 
RAD, UK) with SYBR Grccn 1. One of each primer pair was designed to span an cxon- 
cxon junction to prcvcnt any contaminated DNA from amplification (Table 5.2)265. The 
primcrs for the AMLTI gene targct its N-tcrminus, thus 'will only amplify wild type 
MALTI but nottIP12-, IMLTI transcripts. 
-87- 
T2ble 2.5. Primers used for real-time qU2ntit2tive PCR of ALILTI 2nd BCLIO 
mRIN"A 
Genes Primer sequence Amplicon size (bp) 
Sense S' ctc cgc ctc agt tgc cta ga MALTI* 104 
anti-sense S' caa cct ttt tca ccc att aac ftc a 
BCLIO Scnsc 5' gaa gtg aag aag gac gcc tta g 80 
---anti-scnsc 
5' aga tga tca aaa tgt ctc tca gc 
Scnsc 5' tga ctc aac acg gga aac c 18SrILNA 
anti-sensc 
114 
5' tcg ctc cac caa cta aga ac 
0 ne primers for the AULT] gene uvre designed to target its N-terminus (nucleotidcs 363466 
according to its cDNA sequence AF130356), therefore will only amplify the wild type MALTI 
but not the AP12-, %MLTI transcripts. 
The conditions for real-time PCR were optimiscd prior to data collection. The 
spccificity of the RT-PCR products for each primcr set was confirmcd by mclt-curvc 
ana ysis. The standard curvcs wcrc gcneratcd by two-fold scrial dilutions of 100 ng/pI 
AMLTI cDNA and I ng/pl I SS rRNA cDNA prepared from fresh frozen tonsils, and 100 
ng/pi BCLIO cDNA and I nglpl ISS rRNA cDNA preparcd from t(1; 14)(p22; q32) 
positivc frozcn tumor tissucs. The avcragc cocfficicnt valuc (R) for cach standard curvc 
was abovc 0.99 and the rclative cfficicncy of =plirication of MALTI and BCLIO was 
close to that of I SS rRNA since the absolute value of the slope of log-input amount of 
cDNA vs. ACT was bclow 0.1. 
Oncc the cxpcrimental conditions optimiscd, rcal-time PCR was pcrforTncd in a 25 pl 
rcaction-mixturc containing 12.5 pl SYBR Grccn Supcr-Mix (BIO-RAD), 200 nM of 
cach scnsc and anti-scnsc primcr, and 100 ng (AIALTI and BCLIO) or I ng (18SrRNA) 
cDNA. All samples were amplificd in triplicates using following parameters: 
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denaturation at 95"C for 3 minutes and annealing and extension at 60"C for I minute. 
Real-time PCR of 18S rRNA was run in parallel for each sample. Melt-curve analysis 
was performed immediately after the amplification protocol for each case and only 
samples that showed specific amplification were included in the data analysis. The CT 
numbers were obtained from each sample and ACT value was calculated by subtracting 
the CT value of 18S rRNA from the CT value of MALT] or BCLIO. 
2.2.7 Statistical analysis 
One-way Anova and student-test were used to examine the mean difference among 
different groups. Fisher exact, y, 2, and pearson's correlation were used to analyze the 
correlation between different groups. Non-parametric Mann-Whitney U-Wilcoxon Rank 
SumW test was used to evaluate quantitative difference between groups. 
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Chapter 3. t(11; 18)(q21; q2IyAPI2-MALTI: incidence in MALT lymphoma of 
various sites and role in gastric MALT lymphoma development 
3.1 Introduction 
This study aimed to screen t(I 1; 1 8)(q2 I; q2 1) in a large series of MALT lymphomas 
from different sites including the stomach, lung, salivary gland, thyroid, conjunctiva, 
orbit, skin and liver, as well as in IPSID and examine the incidence of the MALT 
lymphoma of different sites. In gastric MALT lymphoma, we also correlated the 
translocation with CagA strains of H. pylori, which are more virulent and pathogenic 266 . 
Based on gastric MALT lymphoma, we correlated the translocation with clinical staging 
and high grade transformation. We also correlated the translocation with the treatment 
response of gastric MALT lymphoma to H. pylori eradication and investigated its value 
as a molecular marker to identify those that do not respond to H. pylori eradication. 
3.2 Case selection 
Two large cohorts of MALT lymphoma cases were studied. The first cohort was consist 
of 417 cases randomly retrieved from collaborator's institutions (section 2.1.5 of Chapter 
2) and used for investigation of the natural incidence of t(11; 18)(q2l; q2l). Theywere 
composed of 173 cases from the gastrointestinal tract including 22 cases of IPSID, 47 
from lung, 27 from conjunctiva, 28 from orbit, 72 from salivary gland, 18 from thyroid, 
27 from skin, 6 from liver, and 19 from other rare sites (Table 3.1). Fresh frozen tissue 
was available in 72 cases, and the formalin-fixed and paraffin-embedded tissues were 
available in all cases. Clinical staging was available in 15 cases, whereas the extent of 
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tumour spread was determined in 26 gastric cases in which sufficient surgical materials 
were available for histological exarnination. In addition, frozen tissues were retrieved 
from 26 cases of mucosal DLBCL including 16 cases from stomach and 6 from lung. 
Paraffin-embedded tissues were retrieved from 22 cases of lymphoepithelial sialadenitis 
and 22 cases of Hashimoto's thyroiditis. Fresh-frozen gastric biopsies from 39 patients 
with gastritis were collected from Hospital of Ancona, Middle Italy. The diagnosis of 
gastritis was made on histological examination and lymphoid infiltration was mild in 25 
cases and severe with aggregated follicles in 14 cases. Gastric ulcer was seen in 3 cases 
including 2 mild and 1 severe gastritis. H. pylori was identified in 33 of 39 gastric 
biopsies by Warthin Starry staining and histology. 
The second cohort was composed of a series of 111 H. pylori-positive gastric MALT 
lymphoma patients, who were first treated with antibiotics alone, retrospectively 
recruited from Department of Histopathology, Royal Free and University College 
Medical School and our collaborators's institutions (section 2.1.5 of Chapter 2). They 
were used for investigation of the value of t(11; 18)(q2l; q2l) in predication of the 
treatment response of gastric MALT lymphoma to H. pylori eradication. The selection 
of patients was biased towards those who showed no response to H. pylori eradication 
and the proportion of H. pylori eradication non-responsive cases from different 
participating centres was similar. Clinical staging was carried out according to the Ann 
Arbor system modified by Musshoff in each case prior to therapy67 . In 64 cases, the 
extent of lymphoma invasion of the gastric wall and regional lymph nodes was 
determined by endoscopic ultrasonography, which allowed further division of stage IE 
tumours into IEI (restricted to the sub-mucosa) and IE2 (extended to mucularis or 
seroSa)230. H. pylori eradication was achieved by administration of patients with a2 
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week course of arnoxycillin (3 x 750 mg daily) and orneprazole (3 x 40 mg 
daily)224,238,268. One month after completing the antibiotic therapy, the first gastric 
endoscopy and biopsy were performed to detect H. pylori by histology, culture and PCR 
of the H. pylori-associated urease gene and turnour regression by histology and 
molecular analysis. These investigations were repeated every 3-4 months until 
lymphoma showed complete regression or was judged as non-responsive. After 
achieving complete regression, patients were examined further every 6 months. 
Lymphomas showing both complete endoscopic and histological regression were 
regarded as complete remission (CR). Those failed to show histological regression 12 
months after successful eradication of H. pylori or progressed during follow-up were 
judged as non-responsive (NR). 
Tissue specimens from diagnostic biopsies, including frozen tissues from 22 patients and 
formalin-fixed and paraffin-embedded tissues from 89 patients were retrieved for 
molecular analysis. Where indicated, follow-up biopsies were also analyzed. 
In all cases, the diagnosis of MALT lymphoma was made according to the histological 
criteria described by Isaacsoni. Where necessary, the histology and 
immunohistochemistry were reviewed by Professor P. G. Isaacson and Professor A. 
Dogan 
3.3 Results 
3.3.1 Establishment of RT-PCR for detection of t(11; 18)(q2l; q2l) 
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RT-PCR of the API2-MALTI fusion transcript was first carried out on frozen tissues in 
72 cases of gastric MALT lymphoma and 5 cases of tonsils as negative controls. RT- 
PCR was successful in all cases. No amplification was seen from all negative control 
cases. However, 25 of 72 cases of gastric MALT lymphoma were positive. Eleven 
cases showed a single band and the remaining 14 cases showed one dominant band with 
up to 4 faint smaller products (Figure 3.1). Direct sequencing or cloning and sequencing 
of the RT-PCR products confirmed the presence of API2-MALTI fusion transcript in all 
positive cases. The faint bands were alternative splice variants of the fusion transcript. 
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AP12-MALT1 
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1.0 kb - 
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Figure 3.1. Detection of API2-MALT] fusion transcript by RT-PCR from frozen tissue 
samples. A: 25 t(11; 18)(q2l; q2l) positive MALT lymphoma cases. -, negative control. B: 
Examples of RT-PCR using primer f-S and f-AS. Cases 1,2 and 3 show a single AP12-MALTI 
fusion band and cases 4 and 5 harbour an API2-MALT] fusion with breakpoint immediately 
upstream of the exon 5 of the MALT] gene and show alternative splice variants of the fusion 
transcript. M: molecular weight marker. C: RT-PCR with primer p-S and f-AS in case 5 shows 
alternative splice variants of the API2-MALTI fusion. Deleted exons are indicated. D: 
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Sensitivity of RT-PCR for detection of the AP12-MALTI fusion transcript. Tumour cells 
harbouring t(l 1; 18)(q2l; q2l) were serially diluted with tonsillar cells and were then subjected to 
RNA extraction and RT-PCR. Using the first set of PCR primers (f-S and f-AS), the 4PI2- 
MALT] ftision transcript was detectable when the t(I 1; 1 8)(q2 I; q2 1) positive cells were diluted 
down to a concentration of 1 in 106 tonsillar cells. M, molecular weight marker; Ton, tonsillar 
cell; 10-6to 10", various turnour cell concentration; T, undiluted tumour cells negative 
control 
To assess the sensitivity of the RT-PCR for detection of the API2-MALT1 fusion 
transcript from fresh tissues, cell suspensions of two gastric MALT lymphomas with 
different t(11; 18)(q2l; q2l) were serially diluted with tonsillar lymphocytes. The cell 
mixtures, each containing a total of 2x 106 cells but variable amount of tumour cells, 
were subjected to RNA isolation and RT-PCR for the G6PD and API2-MALTI fusion 
transcript. The RT-PCR used for detection of the API2-MALTI fusion transcript was 
highly sensitive. In each of the two dilution experiments with MALT lymphomas 
harbouring different t(11; 18)(q2l; q2l), the API2-MALTI fusion transcript was 
detectable when the t(11; 18)(q2l; q2l) positive cells were diluted down to a 
concentration of 1 in 106 tonsillar cells using a single set of PCR primers (Figure 3.1). 
Having established RT-PCR of the API2-MALT] transcript from frozen tissues and 
identified a number of cases with t(I 1; 1 8)(q2 l; q2 1), we evaluated RT-PCR for detection 
of the fusion transcript from paraffin-embedded tissues. This was carried out on 20 
t(I 1; 1 8)(q2 I; q2 l)-positive and 10 negative cases. In each of t(l 1; 1 8)(q2 I; q2 1) positive 
cases, RT-PCR based on paraffin-embedded tissues showed specific products from one 
or two primer sets (Figure 3.2). Some of the PCR products showed one dominant band 
with up to 3 faint smaller products. Sequencing analysis confirmed that the dominant 
band was API2-MALTI fusion product. The faint bands were alternative splicing 
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variants. None of the t(l 1.1 8)(q2 I; q2 1) negative cases showed an amplified product. 
Given that specific sized products are anticipated from each primer set, analysis of PCR 
products based on polyacrylamide gels can provide reliable evidence of presence or 
absence of the translocation in majority cases without the need of sequencing of PCR 
products. To further determine whether the system can be applied to tissues from small 
biopsies. we carried out RT-PCR on microdissected cells (100 - 200 cells) from 3 
t(I 1; 1 8)(q2 I; q2 1) positive cases and the translocation was detected in each occasion. 
Having established the reliability of the system, we screened unknown cases for 
t(I 1; 1 8)(q2 I; q2 I). The molecular detection of t(11; 18)(q2l; q2l) was carried out 
without the knowledge of the clinico-pathological data. 
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VA I GAA ITACCATTAAC'ACAT(iA(iACCAAAAAGC'I AI ACATGG"l GCCTTATGTGGATTT(lGA 
\('.. XCC'AA(iC, AACC'I'A('I'G(', T(', T('ý\T(', T. AT -NT A. ATGATCGAG, A('.. N(, T('AA(, ATA(, ('AAG., N., \(; (i 
I. V, -VAA I (A I CA I V, (l V, V \(, \IhV, I (, (, V, 16( \( 16 \ V, \I(, \\II\\\I 
I(II (AI I(\I (( I (, \II\V, \k, ( \\ \1 \V I (, V( \ý, ý (IIi (A, (MALT I -AS3-814) 
4 
ý. AP12-sensc)GCiAAGAGGAGA(iA(iAAAGAGCAACTGAGGAAAAAGAATCA I OAA 
\\\I\\I(II(, ý, IIkII VI V \(I-( 
(\IALTI-AS3-1123) 
(AP12-sense)GGAAGAGGAGAGAGAAAGAGCAAC'F(iA(i(iAAAAAGAAI'CA'% 1 
\\V, \(, ( \\V\VI (i V( \(, (( III(, (MALT I -AS3-1150) 
Figure 3.2. Detection of the API2-MALTI fusion transcript from paraffin-em bedded 
tissues by RT-PCR. PCR products derived from primers p-AS2 or p-AS3 show splice variants, 
which are indicated by white arrowheads. The sequences of AP12-MALTI fusion products are 
shown on the right side. Letters in blue are from the API2 gene, while letters in red are from 
the AML TI gene. The letters underlined are primer sequences. M: molecular weight marker. 
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3.3.2 Frequencies of t(11; 18)(q2l; q2l) in MALT lymphoma of different sites 
All the cases included in Table 3.1 were successful for RT-PCR of the reference gene 
G6PD. RT-PCR products of the API2-MALT1 fusion transcript from frozen tissues were 
further confirmed by sequencing, while those from paraffin-embedded tissues were 
characteristic for each breakpoint on polyacrylamide gels, allowing confident detection 
of t(11; 18)(q2l; q2l) without the need of sequencing confinnation in 95% cases as 
discussed above. 
Table 3.1. Frequency of t(11; 18)(q2l; q2l) in MALT lymphoma of different sites 
Site of MALT lymphoma No. of cases t(I 1; 1 8)(q2 1; q2 1) (%) 
Gastrointestinal tract 
Stomach 138 33(23.9) 
Small intestine 8 5(62.5) 
IPSID 22 0(0) 
Large intestine 5 1(20) 
Lung 47 18(38.3) 
Conjunctiva 27 5(18.5) 
Orbit 28 4(14.3) 
Salivary gland 72 1(1.4) 
Thyroid 18 0(0) 
Skin 27 0(0) 
Liver 6 0(0) 
Other* 19 0(0) 
Total 417 67(16.2) 
*Including brain (4), bladder (4), tonsil (2), thymus (2), lacrimal (1), eye lid (2), breast (1), gall 
bladder (1), lip (1), and ovary (1). 
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The cases included for the purpose of this investigation were selected sequentially from 
the contributor's archive and thus the frequency of t(l 1; 1 8)(q2 I; q2 1) found in MALT 
lymphoma of different sites reflected their natural incidences (Table 3.1). Of the 8 
major sites from which MALT lymphoma commonly arises, t(11; 18)(q2l; q2l) was 
found at the highest frequencies in those derived from the lung (38.3%) and stomach 
(23.9%), and at a moderate frequencies in those from the conjunctiva (18.5%) and orbit 
(14.3%). The translocation was seen in only I case of salivary gland MALT lymphoma 
(1.4%) but was absent in those from the thyroid, skin, liver and other rare sites, as well 
as in IPSID. 
t(I 1; 1 8)(q2 I; q2 1) was not found in 39 cases of H. pylori associated gastritis, 22 cases of 
lymphoepithelial sialadenitis and 22 cases of Hashimoto's thyroiditis, the preceding 
disease associated with gastric, salivary gland and thyroid MALT lymphomas 
respectively. 
3.3.3 t(11; 18)(q2l; q2l) positive gastric MALT lymphoma is significantly 
associated with CagA stains of H. pylori 
Because CagA positive strains of H. pylori are more virulent and pathogenic, we 
correlated t(11; 18)(q2l; q2l) with CagA status in gastric MALT lymphomas. DNA 
samples from all gastric MALT lymphomas were first screened for the presence of H. 
pylori by amplification of the urease gene and the positive samples were subsequently 
subjected to PCR of the CagA gene. Overall, CagA positive strains of H. pylori were 
found in 28 of the 42 cases (67%) of gastric MALT lymphoma in which PCR of the H. 
pylori urease gene was positive. CagA positive strains of H. pylori were significantly 
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higher in t(11; 18)(q2l; q2l) positive gastric MALT lymphoma (14/15=93.3%) than the 
translocation negative cases (14/27=51.9%) (p<0.01). 
3.3.4 Neutrophil infiltration in MALT lymphoma preceding diseases and its 
implication in occurrence of t(11; 18)(q2l; q2l) 
In view of the finding that t(l. 1; 1 8)(q2 I q; 2 1) occurred at markedly variable frequencies 
in MALT lymphomas of different sites, it is highly likely that the occurrence of the 
translocation is influenced by the preceding disease associated with MALT lymphomas. 
In gastric MALT lymphoma, t(11; 18)(q2l; q2l) is significantly associated with CagA 
positive strains of H. pylori that are strong inducers of interleukin-8, a potent chemokine 
for neutrophil activation266. Activated neutrophils are known to release reactive oxygen 
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species, which can cause a wide range of DNA damage including double strand breaks . 
We therefore examined the extent of neutrophil infiltration in H. pylori associated 
gastritis, lymphoepithelial sialadenitis and Hashimoto's thyroiditis to further understand 
whether there is any difference in the exposure of potential genetic insults among these 
pre-malignant diseases. As expected, neutrophil infiltration was significantly higher in 
H. pylori associated gastritis (8.19±0.92 neutrophils/high power filed) than in 
IYMPhoepithelial sialadenitis (0.09±0.03 neutrophils/high power field) and Hashimoto's 
thyroiditis (0.38±0.04 neutrophils/high power filed) (p<0.01 for both) (Figure 3-3). 
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Figure 3.3. Neutrophil infiltration in MALT lymphoma preceding diseases. Neutrophil 
infiltration in H. pylori associated gastritis (A), lymphoepithelial sialadenitis (B) and 
Hashimoto's thyroiditis (C). 
3.3.5 t(11; 18)(q2l; q2l) is associated with gastric MALT lymphoma at advanced 
stage 
Among various groups of MALT lymphoma examined for t(I 1; 1 8)(q2 I; q2 1), those from 
the stomach constituted the largest group. In total, 249 cases of gastric MALT 
lymphoma were studied and the extent of turnour spread could be assessed by clinical 
staging or histological examination of surgical resected specimens in 158 cases. We 
corrected t(I 1; 1 8)(q2 I; q2 1) with clinical stage of gastric MALT lymphorna in order to 
understand its role in the multistage development of this tumour. 
Of the 158 cases with clinical staging, the translocation was found in 32/45 (71%) cases 
at stage IlEor above, but only in 29/113 (26%) cases at stage IF (Figure 3.4). Statistical 
analyses showed that t(11; 18)(q2l; q2l) was significantly associated with cases at 
advanced stages than those at early stage (P<0.0001, ý test). Despite that 
t(l 1; 1 8)(q2 I; q2 1) is significantly associated with MALT lymphorna at advanced stage, 
the translocation was not detected in 26 DLBCL including 16 and 6 cases from the 
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stomach and lung, respectively, where the translocation was most frequently seen in 
MALT lymphoma. 
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Figure 3.4. Correlation between clinical staging of gastric MALT lymphorna and 
t(I I-, I 8)(q2 I; q2 1). The number of cases in individual subgroups is indicated. p<0.005. 
3.3.6 t(11; 18)(q2l; q2l) is a marker for gastric MALT lymphomas that do not 
respond to H. pylori eradication 
This investigation was carried out on the second cohort of gastric MALT lymphomas, 
for which H. pylori eradication was used as the first line treatment and clinical follow up 
data were available. 
To examine whether t(l 1; 1 8)(q2 I; q2 1) bears any value in predication of the treatment 
response of gastric MALT lymphoma to H. pylori eradication, we investigated the 
translocation in III cases of H. pylori positive gastnc MALT lymphoma treated with 
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antibiotics. The clinical and histological features of these cases with stage IE are 
summarised in Table 3.2. H. pylori infection was successfully cured in all cases as 
confirmed by histology and culture of gastric biopsies taken after completion of the 
antibiotic therapy. Following H. pylori eradication, patients were followed up by 
repeated endoscopy and biopsy. The mean period between H. pylori eradication and 
achievement of CR or commence of other treatment in NR patients was 12 months 
(range 1-75) and mean follow-up period to date was 35 months (range 9-85). During 
follow-up, 48 cases showed CR while 63 cases displayed NR. There is no difference in 
age and sex between the CR and NR group. Both groups had similar length of follow- 
up. Histologically, focal transformed high grade components were seen in 3 NR but not 
in any of the CR cases. Of the CR group, 2 of the 48 cases showed turnour relapse and 
in both cases the lymphorna harboured t(I 1; 1 8)(q2 I; q2 1). 
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Table 3.2. Clinical and histopathological features of stage IE gastric MALT 
lymphomas and their responses to H. pylori eradication therapy. 
Complete regression No regression 
Number of patients 47 43 
Age (years) 
Mean 60 57 
Range 25-85 30-88 
Sex 
M 29 21 
F 18 22 
Histology with high grade component 0 3 
Stages by endoscopic ultrasonography 
IE1 29 30 
IE2 3 2 
Follow-up period (months) 
Intervals* 
Mean 8.2 15 
Range 1-26 5-75 
Follow-up to date 
Mean 38 30 
Range 10-82 9-85 
*The time between H. pyloti eradication and complete regression or commence of other 
treatment in non-responsive cases. 
Among the 48 CR cases, 47 were at stage IE with only the remaining one being at stage 
IIE. The stage HE CR case is one of the two that showed lymphoma relapse. Of the 63 
NR cases, 20 were at stage HE or above and the remaining 43 cases were at stage IE. 
Despite that the vast majority of lymphomas, at stage HE or above (20/21=95%) did not 
respond to H. pylori eradication (P<0.001), there were almost half of stage IE tumours 
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which also did not respond to H. pylori eradication (43/90=48%, P>0.05). Therefore, 
the staging failed to predict the response of stage IE gastric MALT lymphoma to H. 
pylori eradication. Among cases with stage IE lymphoma, there was no difference in age, 
sex and follow-up periods between CR group and NR groups (P>0.05) (Table 3.2). The 
extent of lymphoma invasion within the gastric wall was assessed by endoscopic 
ultrasonography in 64 cases with stage IE lymphoma. There was no difference in the 
response of gastric MALT lymphoma to H. pylori eradication between cases showed 
stage IEI and stage Im disease (P>0.05) (Table 3.2). 
Detection of t(I 1; 18)(q2l; q2l) was carried out by RT-PCR of the API2-M, 4LT] fusion 
transcript from frozen tissues in 22 cases and from paraffin-embedded tissues in 89 cases. 
All 111 cases showed successful RT-PCR of the reference gene GOD. In majority of 
cases, the characteristic PCR product pattern on polyacrylamide gels allowed confident 
detection of t(11; 18)(q2l; q2l). However, in 13 cases, PCR bands were weak and 
sequencing confinnation was carried out. Overall, t(11; 18)(q2l; q2l) was positive in 
40% (44 of I 11) of cases detected. 
Of the 48 CR cases, 2 were t(I 1; 1 8)(q2 I; q2 1) positive (Figure 3.5). One of these 2 cases, 
a stage IE tumour, achieved CR 25 months after H. pylori eradication. The remission 
lasted for 56 months but tumour reoccurred later in the absence of H. pylori re-in ection. 
PCR of the rearranged Ig gene confirmed the clonal lineage between the original 
lymphoma and the recurrence. t(11; 18)(q2l; q2l) was detected only in follow-up 
biopsies showing the tumour relapse but not in those that displayed complete remission. 
The other t(11; 18)(q2l; q2l)-positive case was a stage RE tumour, in which CR was 
achieved 9 months after H. pylori eradication and the remission was maintained so far 
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for 32 months. However, t(11; 18)(q2l; q2l) was detected in the last follow-up biopsy. 
A review of histology of the biopsy revealed a small crushed fragment of lymphoid 
tissue suspicious of turnour relapse. H. pylori was not seen. 
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Figure 3.5. Correlation bet-ween response of gastric MALT lymphoma to H. pylori 
eradication therapy and clinical staging and presence of t(11; 18)(q2l; q2l). Clinical staging 
has little value in predication of the response of stage 1,, gastric MALT lyinphoma to H. pylori 
eradication therapy. In contrast, the translocation can predict 60% of H. pylori therapy non- 
responsive cases at stage 'E' 
In contrast to the CR group, 42 of the 63 (67%) NR cases were positive for the 
translocation, including 26 of the 43 (60%) stage IE tumours (Figure 3.5). Thus, 
t(11; 18)(q2l; q2l) could predict the response of the majority of early gastric MALT 
lymphomas to H. pylori eradication (P<0.001). As expected, the frequency of 
t(I 1; 1 8)(q2 I; q2 1) was much higher in lymphomas at stage HE or above (I 6/20=80%) 
than those at stage IE. (P<0.001) (Figure 3.5). 
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3.3.7 Characteristics of t(11; 18)(q2l; q2l) breakpoint 
In total, there were III t(I 1; 18)(q21; q21) positive cases including 77 from stomach, 18 
from lung, 9 from ocular adnexae, 5 from small intestine, I from colon, and I from 
salivary gland. The distribution of breakpoints in both the API2 and MALT] genes 
among MALT lymphomas of different sites was similar (Figure 3.2). The breakpoint 
was invariable at nucleotide 2048 (intron 7) on the API2 gene (NM_001 165) except one 
case at nucleotide 2345 (intron 9) but varied at nucleotides 413 (Intron 2,2/111 =2%), 
715 (Intron 4,67/111=60%), 991 (Intron 7,23/111=21%) and 1018 (intron 8, 
18/111 = 16%) on the MAL TI gene (AB0261 18)107 (Figure 3.6). 
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Figure 3.6. Characteristics of t(I I; 18)(q2l; q2l) breakpoints. Representative API2-MALTI 
fusion products detected by RT-PCR from paraffin-embedded tissues are illustrated 
scheniatically and their breakpoint and frequency of occurrence are shown. 
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Because the API2-MALTI fusion products with intact Ig-like C2 domains are more 
potent activators of NFKB than those without Ig-like C2 domains 123 and therefore may 
be more oncogenic 125 , we correlated the type of API2-MALTI fusion with clinical 
staging in gastric MALT lymphoma. Of the 44 t(11; 18)(q2l; q2l) positive cases for 
which clinical staging was available, 33 fusion transcripts had one or two intact Ig-like 
C2 domains, while 11 did not contain Ig-like C2 domains (Figure 3.3). Tumours bearing 
the fusion product with intact Ig-like C2 domains (22/43=5 1 %) were more often at stage 
HE or above than those harbouring the fusion product without Ig-like C2 domains 
(5/18=28%) although statistical analysis did not reveal any significant difference 
(P>0.05). 
3.4 Discussion 
Incidence of t(11; 18)(q2l; q2l) in MALT lymphoma of various sites and implication 
of aetiological factors in its occurrence 
Chromosomal translocations associated with B cell lymphomas, commonly involve the 
Ig locus, which most likely occur during the VDJ recombination process and are 
believed to be the primary event in lymphomagenesis"'. At least some of these 
translocations are known to occur in pre-lymphomatous lesions. For example, 
t(14; 18)(q32; q2l) that is associated with up to 90% follicular lymphomas has also been 
found in about 50% lymphoid hyperplasias and peripheral blood lymphocytes from 
270-272 
normal individuals To examine whether t(11; 18)(q2l; q2l), a frequent 
translocation in MALT lymphoma 104,107,108,119 
s 
is present in pre-lymphomatous lesions, 
we examined H. pylori-associated gastritis from Italy where the frequency of H. pylori 
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associated gastric MALT lymphoma is hiW 3 and lymphoepithelial sialadenitis and 
Hashimoto's thyroiditis, the preceding disease associated with salivary gland and thyroid 
MALT lymphomas respectively. Our results indicate that t(11; 18)(q2l; q2l) is absent or 
at least not a frequent event in H. pylori associated gastritis, lymphoepithelial 
sialadenitis and Hashimoto's thyroiditis. 
Previous studies showed t(l 1; 1 8)(q2 1; q2 1) in 35-50% of gastric MALT lymphomas and 
55-75% of pulmonary MALT lymphomas, but the incidence of t(11; 18)(q2l; q2l) in 
MALT lymphoma of other sites is largely unknown as only limited cases have been 
examined' 06-109,1 19. By screening 417 cases of MALT lymphoma of 9 major sites for 
t(11; 18)(q2l; q2l), and we showed that the translocation occurred at the highest 
frequencies in those from the lung (38.3%) and stomach (23.9%) and at moderate 
frequencies in those from the conjunctiva (18.5%) and orbit (14.3%). The translocation 
was present in only a single example of salivary gland MALT lymphoma but was absent 
in those from the thyroid, skin, liver and other rare sites, and in IPSU). 
The incidence of t(l 1; 1 8)(q2 I; q2 1) in both pulmonary and gastric MALT lymphoma in 
the present study is much lower than reported previously even taking into account the 
fact that our RT-PCR approach for paraffin-embedded tissues would miss approximately 
7% of rare breakpoints on the API2 gene. The number of cases studied in the previous 
reports was relatively small and the investigations were commonly based on those 
treated by surgery and were therefore biased towards the advanced cases. At least in 
gastric MALT lymphoma, t(11; 18)(q2l; q2l) has been shown to be significantly 
associated with cases of more advanced stage. Thus, the previous studies may have 
over-estimated the incidence of t(11; 18)(q2l; q2l) in pulmonary and gastric MALT 
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lymphomas. In the present study, the cases included were randomly selected and a large 
cohort were examined and thus the frequency of t(l 1; 1 8)(q2 1; q2 1) reported here should 
be much closer to its natural incidence. In line with this, the frequencies of 
t(I 1; 1 8)(q2 1; q2 1) in MALT lymphoma of various sites as shown in this study are very 
similar to those reported by a recent study in which 252 cases of MALT lymphoma 
randomly selected were studied"'. The t(11; 18)(q2l; q2l) was found at the highest 
frequencies in MALT lymphomas derived from the lung (53%) and stomach (24%), at a 
moderate frequencies in those from the intestine (13%), and rarely in those from the 
III salivary gland (2%), liver and other rare sites . 
The higher incidence of the translocation in pulmonary MALT lymphoma. may be in part 
the result of the disease being diagnosed at relatively more advanced stages. 
Approximately 50% of patients with pulmonary MALT lymphoma are asymptomatic 
and 25-47% of cases are at stage III or above at the time of diagnoSiS273 
274. In contrast, 
patients with gastric MALT lymphoma commonly present upper stomach discomfort 
273 and only 13% of cases are at stage III or above at diagnosis 
Unlike the majority of chromosomal translocations associated with lymphoma, 
t(I 1; 1 8)(q2 I; q2 1) does not involve the Ig locus and its occurrence is most likely not 
associated with the VDJ recombination event. The finding of dramatically variable 
incidences of t(11; 18)(q2l; q2l) in MALT lymphoma of various sites indicates that the 
occurrence of the translocation is influenced by different preceding diseases associated 
with MALT lymphoma. H. pylori associated gastritis is strongly related to the 
development of gastric MALT lymphoma, while lymphoepithelial sialadenitis and 
Hashimoto's thyroiditis are closely associated with the genesis of salivary gland and 
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thyroid MALT lymphoma, respectively. The mechanisms underlying the pathogenesis 
of these diseases are different. Lymphoepithelial sialadenitis and Hashimoto's 
thyroiditis are principally due to generation of auto-reactive B cells, while H. pylori 
infection causes damage of gastric mucosa through bacterial toxins and host responses. 
CagA positive strains of H. pylori are known to be more virulent and pathogenic and are 
significantly associated with increased risk of development of gastric cancer and peptic 
ulcer. 
The role of infection of CagA strains of H. pylori in the development of gastric MALT 
IYMphoma remains unclear since controversial results have been reported 87-89. To 
examine whether the occurrence of t(l 1; 1 8)(q2 I; q2 1) is related to aetiological factors, 
we first correlated the translocation with CagA status in gastric MALT lymphoma. Our 
results showed that CagA positive strains of H. pylori were significantly associated with 
t(11; 18)(q2lq; 21), suggesting that CagA positive strains of H. pylori may be highly 
potent in promoting the occurrence of t(11; 18)(q2l; q2l). H. pylori strains harbouring 
the CagA island may cause strong inflammatory responses, of which the key element is 
induction of interleukin-8, a potent chemokine for neutrophil activation 266 . Activated 
neutrophils release reactive oxygen species, which can cause a wide range of DNA 
damage including double strand breaks9o. It is possible that the occurrence of 
t(11; 18)(q2l; q2l) is related to oxidative damage induced byH. pylori infection. Inline 
with this hypothesis, the genomic breakpoints of t(11; 18)(q2l; q2l) on both derivative 
chromosomes were random and showed no association with sequence motifs known to 
126,262 be associated with chromosomal recombination . 
Furthermore, deletions ranging 
from a few to several kilo-base pair is a common finding at the breakpoint for both the 
API2 and MALTI IoCiI26,262. 
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To further examine whether there is any difference in the potential exposure of genetic 
insults among different prc-malignant diseases associated with MALT lymphorna, we 
examined the extent of neutrophil infiltration in H. pylori associated gastritis, 
lymphoepithelial sialadenitis and Hashimoto's thyroiditis. As expected, neutrophil 
infiltration was prominent in H. pylori associated gastritis but not in lymphoepithelial 
sialadenitis and Hashimoto's thyroiditis. The difference in neutrophil infiltration among 
these pre-malignant diseases correlated well with the incidence of t(11; 18)(q2l; q2l) 
detected in prospective MALT lyinphoma. Thus, it is possible that the presence or 
absence of genotoxic factors such as activated neutrophils in the pre-nialignant disease 
may influence the incidence of t(I 1; 1 8)(q2 I; q2 1) in prospective MALT lymphoma. 
The above hypothesis may also explain the finding of a high incidence of 
t(11; 18)(q2l; q2l) in pulmonary MALT lymphoma. Acquired MALT in the lung is seen 
in the inflammatory disease known as follicular bronchiolitis 275 . Although the etiology 
of follicular bronchiolitis is unknown, in at least 50% of cases, histological examination 
shows suppurative exudates in bronchiolar lumina and neutrophils in adjacent alveoli275, 
suggesting that genotoxic factors could well be present. 
t(11; 18)(q2l; q2l) is associated with gastric MALT lymphoma at advanced stage 
and those failed to respond to H. pylori eradication 
To understand the role of t(11; 18)(q2l; q2l) in multistage development of MALT 
lymphoma, we correlated the translocation with clinical stage of gastric MALT 
lymphomas and their treatment response to H. pylori eradication. In line with the 
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expected oncogenic role of t(11; 18)(q2l; q2l), we showed that the translocation was 
significantly associated with gastric MALT lymphoma, at advanced stage and those 
failed to respond to H. pylori eradication. 
H. pylori eradication leads to complete regression of gastric MALT lymphoma in 75% 
of cases and is widely accepted as the first line treatment for this tumoUl 
224,228- 
230,238,239,268 
. One of the major dilemmas in clinical management of patients with this 
disease is the identification of those that will not respond to H. pylori eradication and 
require cherno- or radiotherapy. At present, this requires prolonged follow-up with 
repeated endoscopy and gastric biopsy. Clinical staging is helpful in predicting the 
response since lymphomas at stage HE or above rarely respond to H. pylori eradication. 
However, the predictive value of clinical staging for stage IE tumours is limited 
224,228- 
230,238,239,268 
and better prognostic markers are needed. We have shown that 
t(I 1; 1 8)(q2 I; q2 1) is a marker for non-responsive gastric MALT lymphomas including 
those at stage IE- In the stage IE cases, the translocation allows this prediction in 60% of 
non-responsive cases. None of the CR cases were positive for t(11; 18)(q2l; q2l) with 
the exception of the 2 equivocal cases described. 
Our findings indicate that t(I 1; 1 8)(q2 1; q2 I)-positive gastric MALT IY'nphomas do not 
undergo regression following H. pylori eradication and require other conventional 
therapies up front. However, Fischbach reported that 4 cases of gastric MALT 
lymphomas bearing t(I 1; 1 8)(q2 I; q2 1) responded to H. pylori eradication with durable 
remission 276 . Nevertheless, H. pylori should be eradicated in all cases as this not only 
eliminates reactive lymphoid infiltrates but most likely has an adjuvant effect since in 
vitro experiments have shown that H. pylori also stimulates t(I 1; 1 8)(q2 I; q2 I)-positive 
- 112- 
lymphoma cells to proliferate via T cell heIP73,263. Moreover, eradication of H. pylori and 
reactive lymphoid infiltrates may reduce the risk of developing secondary tumours in the 
stomach. 
Among the NR cases, 33% failed to show t(11; 18)(q2l; q2l) byRT-PCR. OurRT-PCR 
strategy for frozen tissues would theoretically detect 100% of known breakpoints in both 
the API2 and MALTI genes. However, the RT-PCR methodology for paraffin- 
embedded tissues would miss three minor API2 breakpoints, which account for 7% of 
the total API2-MALT1 fusions 101-104,106-109,1 19. Thus, our current results may slightly 
underestimate the true frequency of t(11; 18)(q2l; q2l) in H. pylori eradication non- 
responsive gastric MALT lymphoma. For prospective clinical screening, PCR with 
primers for these minor breakpoints should be included and multiplex amplification in a 
single tube may offer a practical approach 277 . Alternatively, the translocation can 
be 
detected by interphase FISH. 
In about 25% of cases, resistance of gastric MALT lymphoma to H. pylori eradication 
appears to be due to other factors. MALT lymphomas with chromosomal translocation 
involving the BCLIO locus, such as t(1; 14)(p22; q32)1 34,135 and t(1; 2)(p22; pl2) 136, are 
I typically those at advanced stages and are unlikely to respond to H. pylori eradication 
142 
(Chapter 4). H. pylori associated gastric MALT lymphoma in patients with autoimmune 
disease has been shown to be resistant to antibiotic treatmen t278 . The fas gene 
is 
frequently mutated in MALT lymphoma in patients with autoimmunitY'14 and fas gene 
mutations may confer resistance of gastric MALT lymphoma to H. pylori eradication. 
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In view of the significant role of t(11; 18)(q2l; q2l) during MALT lymphoma 
progression, it is intriguing that the translocation is only rarely found in transfonned 
MALT lymphoma 104,107-110,279 - Although mucosal DLBCL may arise de novo, at least a 
proportion of mucosal DLBCL are transformed from low grade MALT lymphomaS5354. 
It is unlikely that such an important translocation is lost during high grade 
transformation. Alternatively, t(11; 18)(q2l; q2l) positive MALT lymphoma is a distinct 
subgroup of this lymphoina entity that does not or rarely undergoes high grade 
transformation. There are clear differences in both gross chromosomal and 
microsatellite alterations between t(11; 18)(q2l; q2l) positive and negative MALT 
lymphomas: the former do not usually show any chromosomal aberrations other than 
t(11; 18)(q2l; q2l) and allelic imbalances, whereas the latter including those with 
t(1; 14)(p22; q32) display various abnormalities including both recurrent and rare 
aberrations and frequently allelic imbalances 97,98,133,171 . It remains to 
be determined 
whether further differences in histology, immunophenotype and genetic abnormalities 
such as genetic instability exist between the two groups. 
Characteristics of t(11; 18)(q2l; q2l) breakpoint and their implication in the 
oncogenetic activity of the AP12-MALT1 fusion product 
All the breakpoints in the API2 gene occur between the third BIR domain and the C- 
CA]p terminal RING, with 91% being just upstream of the 'D 
104,107-109,119. In contrast, the 
breakpoints in the MALT1 gene are more variable but are always upstream the carboxyl 
104,107-109,119 
caspase-like domain . Thus, the resulting API2-MALTI fusion transcripts 
always comprise the amino terminal API2 with three intact BIR domains and the 
carboxyl terminal MALT1 region containing an intact caspase-like domain. The specific 
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selection of these domains of the API2 and MALTI genes to form a fusion product 
strongly suggests their importance and synergy in oncogenesis. The BIR domain of 
API2 has been shown to be anti-apoptotic 120. However, the anti-apoptotic activity of the 
API2 BIR domain was weak and has been shown to be suppressed by its C-terminal 
RING finger domain 120 . As a result, wild type API2 did not protect cells from apoptosis 
upon stimulation by death signals 120. The negative effect of the RING finger on BIR 
function may be associated with its ability to promote auto-ubiquitination and 
degradation' 18,120 . Replacement of the C-terminal of AP12 with the C-terminal of 
MALTI by the fusion product would release the intrinsic anti-apoptotic activity of the 
BIR domain and therefore make the new molecule anti-apoptotic. Indeed, the AP12- 
MALT1 fusion product, but not API2 or MALTI alone, has been shown to activate 
NFKB and the caspase-like domain is required for this function 123 . Moreover, the fusion 
products with intact Ig-like C2 domains are more potent activators of NFKB than those 
without Ig-like C2 domains 123,125 . In keeping with this, we 
found that tumours bearing 
the fusion product with one or two intact Ig-like C2 domains were more often at stage HE 
or above than those harbouring the fusion without the Ig-like C2 domain. 
3.5 Conclusion 
In summary, our results demonstrate that t(I 1; 1 8)(q2 1; q2 1) occurs at markedly variable 
frequencies in MALT lymphoma of different sites, suggesting that the occurrence of the 
translocation is influenced by the nature of pre-malignant diseases associated with 
MALT lymphoma. Oxidative damage might play a role in development of 
t(11; 18)(q2l; q2l). In gastric MALT lymphoma, t(11; 18)(q2l; q2l) occurs more 
frequently in those at stage HE or above than cases at stage IE- Irrespective of its 
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association with staging, the translocation is a reliable marker for all stage gastric MALT 
lymphomas that do not respond to H. pylori eradication. 
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Chapter 4. t(1; 14)(p22; q32)/BCLIO-IGH and BCL10 deregulation in MALT 
lymphoma 
4.1 Introduction 
This study attempted to study BCLIO protein expression pattern in normal and 
malignant lymphoid tissues, particularly those with t(1; 14)(p22; q32) and investigate the 
incidence of t(1; 14)(p22; q32) in MALT lymphoma of various sites and its role in 
multistage development of gastric MALT lymphoma. 
4.2 Case selection 
Formalin-fixed and paraffin-embedded tissue specimens from 463 cases of lymphomas 
comprising of 331 MALT lymphomas (Table 4.1), 20 mucosal DLBCLs (14 of them 
with low grade MALT lymphoma component), 21 follicular lymphomas, 17 mantle cell 
lymphomas, 18 nodal DLBCLs. 31 normal lymphoid tissues including 8 fetal thymuses 
at 16-40 weeks of gestation, 4 appendices, 8 tonsils, 6 lymph nodes and 5 spleens, and 
74 normal non-lymphoid tissues of 21 different types were retrieved from the surgical 
files of Department of Histopathology, Royal Free and University College Medical 
School and our collaborators's institutions (section 2.1.5 of Chapter 2). Among MALT 
lyrnphoma cases, 4 cases were known positive for t(1; 14)(p22; q32) 133,280 and 1 case 
positive for t(1; 2)(p22; pl2) 136 by conventional cytogenetic investigation. The histology 
of all lymphoma cases was reviewed by specialised haernatopathologists: Professor P. G. 
Isaacson and Prof Ahmet Dogan. 
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III cases of H. pylori-positive gastric MALT lymphomas initially treated with 
antibiotics alone were retrospectively retrieved from the surgical files of Department of 
Histopathology, Royal Free and University College Medical School and our 
collaborators's institutions (section 2.1.5 of Chapter 2). 
Table 4.1. Frequency of BCL10 nuclear expression in MALT lymphoma of 
various sites 
BCLIO nuclear expression 
Site of MALT No. of Strong like in Moderate with AP12- Moderate but lacking 
Lymphoma cases t(1; 14) (%) MALTI API2-MALTI fusion 
Fusion (%) N 
Gastrointestinal tract 
Stomach 123 6(4.9) 30 of 30 (100) 26 of 87 (30) 
Small intestine 4 0 1 of 1 (100) 0 of 3 (0) 
IPSID 5 0 - I of 5 (20) 
Large intestine 3 0 1 of 1 (100) 0 of 2 (0) 
Lung 41 5(12) 17 of 17 (100) 5 of 19 (26) 
Conjunctiva 19 0 3 of 3 (100) 8 of 16 (50) 
Orbit 19 0 3 of 3 (100) 1 of 15 (6.7) 
Salivary gland 70 0 1 of 1 (100) 15 of 69 (21.7) 
Thyroid 14 0 0 of 14 (0) 
SIdn 13 1(7.7) 0 of 12 (0) 
Liver 4 0 1 of 4 (25) 
Other* 16 0 - 3 of 16 (18.7) 
Total 331 12(3.6) 56 of 56 (100) 60 of 263 (23) 
*Includes brain (4), bladder (4), tonsil (2), thymus (2), lacrimal (1), eye lid (2), breast (1), 
gall bladder (1), lip (1), and ovary (1). 
-Not applicable 
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4.3 Results 
4.3.1 Characterisation of BCLIO antibodies 
The 8 positive single clones were examined for their specificity by Western blotting 
analysis with the fiill length recombinant BCLIO protein. Seven clones showed specific 
recognition of the BCL1 0 protein. To map the amino acid residues recognised by these 
monoclonal antibodies, Western blotting analysis of the HEK 293 cells transfected with 
various BCLIO deletion constructs as well as the recombinant amino terminal BCLIO 
product was carried out. Three clones including clone 151 recognised the full length 
(amino acids 1-233), the truncated (1-168) and the carboxyl terminal (amino acids 101- 
233) BCL10 products expressed in HEK 293 cells, but did not react with the 
recombinant amino terminal BCLIO product (1-122) (Figure 4.1), indicating that these 
clones recognised amino acids between 123-168. The remaining 4 clones recognised the 
full length and the carboxyl terminal BCLIO product but only weakly reacted with or did 
not recognise the truncated BCLIO product, suggesting that these antibodies recognised 
amino acid residues further toward the carboxyl terminus than those recognised by clone 
15 1. No clones recognised epitopes within the amino-terminal CARD. All 7 
monoclonal antibodies were further tested by immunohistochemistry of formalin-fixed 
paraffin-embedded tissue sections from MALT lymphomas with t(1; 14)(p22; q32) and all 
7 showed characteristic staining. The staining was specific as no staining was seen if 
hybridoma culture supernatant was omitted or immunoabsorbed with the recombinant 
BCLIO protein prior to immunohistochemistry. Of the 7 monoclonal antibodies, clone 
151 gave the best immunostaining on paraffin embedded tissue sections and was used 
for all subsequent experiments. Western blotting analysis of frozen tissues from tonsil, 
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lymph node and spleen showed that BCL 10 was present as a predominant 32kD with a 
weaker 3 7kD band (Figure 4.1). 
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Figure 4.1. Western blotting analysis. Mouse BCLIO monoclonal antibody clone 151 
recognises the expressed BCL 10 products in 293 cells by constructs containing the full length 
wild type (293 BCL 10 wt, amino acids 1-233), the truncated (293 m 106, amino acids 1- 168) and 
the carboxyl ten-ninal BCLIO sequence (293 C-terminus, amino acids 101-233), and does not 
react with the recombinant BCLIO amino terminal product (BCLIO N-terminus, amino acids I- 
122). Tonsil, MALT lymphoma and the 293 cells transfected with control vector show two 
forms of BCL 10: a predominant 32 kD and a weaker 37 kD band, indicated by arrow heads. 
4.3.2 BCL10 expression in normal tissues 
BCLIO protein was expressed in normal spleen, reactive tonsil, lymph node and MALT 
of the appendix. In B cell follicles, the protein was expressed abundantly in the genninal 
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centre B cells, moderately in the marginal zone but only weakly in 40-60% of the mantle 
zone B cells (Figure 4.2 A-D). Within the genninal centre, dark zone centroblasts 
expressed more BCLIO than light zone centrocytes (Figure 4.2 A). Both the germinal 
centre and marginal zone B cells expressed BCLIO protein in the cytoplasm (Figure 4.2 
B and D). The subcellular localisation of BCLIO in the mantle zone B cells could not be 
confidently determined due to their low expression level and scanty cytoplasm. 
BCLIO protein was also expressed in foetal thymus. At early stages of gestation (16-25 
weeks), BCLIO was expressed in the medulla and occasionally in the cortex (Figure 4.2 
E), whereas at late stages of gestation (>28 weeks), the protein was found exclusively in 
the medulla. Double immunostaining for BCLIO and CD20 or CD3 (Dako, U. K. ) 
revealed that BCL10 positive cells are both B and T cell lineages, with the majority of 
positive cells being T cells (Figure 4.2 G and H). In both cases, BCL10 was expressed 
only in the cytoplasm (Figure 4.2 F). 
Of 21 types of normal solid tissues examined, including tongue, oesophagus, duodenum, 
rectum, liver, gall bladder, pancreas, bronchus, heart, lung, thyroid, breast, adrenal 
gland, kidney, bladder, uterus, cervix, ovary and tube, placenta and cord, testis and skin, 
only breast showed BCL10 protein expression. BCLIO expression appeared to be 
restricted to the cytoplasm of the luminal epithelial cells of breast. 
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Figure 4.2. BCLIO protein expression in normal lymphoid tissues. A: A low magnification 
(x 150); of tonsil shows the level of BCL 10 expression is much higher in centroblasts of the dark 
zone (DZ) than in centrocytes of the light zone (LZ); B: Germinal centre B cells show BCLIO 
expression in the cytoplasm (magnification x480); C-. A low magnification (x250) of spleen 
shows differential BCLIO expression in marginal zone (MGZ), mantle zone (N4Z), and follicle 
centre (FC) B cells; D: Splenic marginal zone B cells show BCL 10 expression in the cytoplasm 
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(magnification x480); E: Thymus (16 weeks of gestation) shows BCLIO expression mainly in 
the medulla (M) and occasionally in the cortex (C) (magnification x80); F: Cytoplasmic BCLIO 
expression in medullar lymphocytes (magnification x480); G: Double immunostaining with 
BCLIO and CD3 antibodies (magnification x480); BCLIO is in brown, showing parenuclear 
staining, while CD3 is in blue, displaying a membrane staining pattern; H: Double 
immunostaining with BCLIO and CD20 antibodies (magnification x480). BCLIO is in brown, 
showing paranuclear staining, while CD20 is in blue, displaying a membrane-staining pattern. 
4.3.3 BCLIO expression in MALT lymphoma 
(1) BCL10 expression in MALT lymphoma with t(1; 14)(p22; q32) 
Unlike marginal zone B cells, each of the 4 MALT lymphomas known with 
t(1; 14)(p22; q32) showed strong BCLIO expression in both the nucleus and cytoplasm in 
all tumour cells (Figure 4.3 A-D). Strong BCLIO nuclear expression in these tumour 
cells distinguished them from non-lymphomatous reactive lymphocytes, which showed 
either weak or no cytoplasmic BCLIO expression. The BCLIO expressing tumour cells 
invaded gastric glands forming lymphoepithelial lesions (Figure 4.3 Q and disseminated 
to other parts of the gastric mucosa intermingling with reactive lymphocytic infiltrates 
(Figure 4.3 E). Discrete turnour cells identified by strong BCLIO nuclear expression 
were also found in the marginal zone of the spleen in one gastric MALT lymphoma 
where splenic tissue was available. Strong nuclear BCL10 expression in turnour cells 
was in sharp contrast to the weak cytoplasmic BCLIO expression in normal marginal 
zone B cells (Figure 4.3 F). Presence of the turnour cells in the marginal zone has been 
confirmed in a previous study by microdissection and PCR of the rearranged Ig gene 43 . 
The gastric MALT lymphoma with t(1; 2)(p22; pl2) showed BCLIO staining pattern 
identical to that of t(1; 14)(p22; q32) positive tumour cells. 
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Figure 4.3. BCLIO protein expression in malignant B cell lymphoma. A& B: A pulmonary 
MALT lymphoma with t(1; 14)(p22; q32) (A: magnification x150; B: magnification x480); C& 
D: A gastric MALT lymphoma with t(1; 14)(p22; q32). Arrow-head indicates lymphoepithelial 
lesion (C: magnification x150; D: magnification x480); E: BCLIO expressing tumour cells 
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disseminate to other part of the gastric mucosa intermingling with reactive lymphocytes 
(magnification x25O). F: Discrete turnour cells are also found in the marginal zone of the spleen, 
where the strong nuclear BCLIO expression in turnour cells is in sharp contrast to the weak 
cytoplasmic BCLIO expression in normal marginal zone B cells (magnification x150); G: A 
gastric MALT lymphoma without t(11; 18)(q2l; q2l) shows moderate BCLIO expression 
predominantly in the nucleus (magnification x480); H: A gastric MALT lymphoma. without 
t(1; 14)(p22; q32) and t(11; 18)(q2l; q2l) shows BCLIO expression in the cytoplasm 
(magnification x480). 
(2) Incidence of t(1; 14)(p22; q32) in MALT lymphoma of various sites 
In order to understand whether strong BCLIO nuclear staging is characteristic of MALT 
lymphoma cells with t(1; 14)(p22; q32) and to determine the incidence of 
t(1; 14)(p22; q32), BCL10 immunohistochemistry was carried out in 331 cases of MALT 
lymphorna of 8 sites (Table 4.1). In all the cases, BCLIO staining was performed on 
either surgical resected specimens, or large tissue biopsies to confidently interprete 
BCLIO staining. Strong nuclear BCL10 expression similar to that seen in 
t(1; 14)(p22; q32) or t(1; 2)(p22; pl2) was observed in 12 cases and they were from 
stomach (6), lung (5) and skin (1) (Table 4.1 and Figure 4.4). All these cases were 
negative for t(11; 18)(q2l; q2l) as described in section 3.3.2 of Chapter 3. Of the 
remaining cases, 116 showed moderate BCLIO nuclear staining and the rest displayed 
cytoplasmic staining. 
To further ascertain whether the cases showing a strong BCL10 nuclear staining harbour 
a BCLIO-involved chromosomal translocation, interphase FISH was performed to detect 
chromosomal breakpoint affecting the BCL10 locus, like t(1; 14)(p22; q32) or variants. 
The reliability of the BCLIO break-apart assay for detection of the BCLIO involved 
chromosomal translocation was first validated in 4 t(1; 14)(p22; q32)/IGH-BCLIO and 1 
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t(1; 2)(p22; p I 2)IIGK-BCL 10 positive MALT lymphomas proven by conventional 
cytogenetics, and 5 negative controls. BCLIO break-apart assay showed BCLIO 
involved translocation in 515 positive cases but not in any of the negative controls. The 
BCLIO break-apart assay was then performed on 4 pulmonary and 3 gastric cases 
showing strong BCLIO nuclear expression with which sufficient tissue materials were 
available. Five cases showed a signal constellation, indicating a chromosomal 
translocation affecting the BCLIO locus (Figure 4.4). The remaining 2 cases lacked 
evidence for a breakpoint involving the BCLIO gene, and one case contained a heavy 
reactive component that may have compromised the FISH analysis. None of these cases 
showed BCLIO gene amplification. 
Figure 4.4. Strong BCLIO nuclear expression and Break-apart double colour interphase 
FISH for the detection of breakpoints in the BCLIO locus. A: A gastric MALT lymphoma 
shows strong BCLIO nuclear expression similar to that found in those with t(1; 14)(p22; q32). B: 
A case with cytogenetically proven t(l; 14)(p22; q32). The arrow points to a tumour cell in which 
the dissociation of the red and green signals indicates the presence of a chromosomal breakpoint 
in the BCLJO locus. The nucleus on the right displays 2 colocalised signals pointing to 2 intact 
copies of the BCLJO locus. C: The gastric MALT lymphoma with strong BCLIO nuclear 
expression as shown in A. Interphase nuclei show that several cells (arrows) display a split of 
the red and green signals, suggestive of t(l; 14)(p22; q32) or variants. 
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To further investigate that t(1; 14)(p22; q32) -or variants was truly negative in MALT 
lymphoma lacking strong nuclear expression of BCLIO, we performed interphase FISH 
using BCLIO break-apart dual colour probes on 12 and 18 cases showing moderate 
nuclear BCLIO staining and cytoplamic staining pattern, respectively. All cases were 
negative for both BCLIO involved chromosomal translocation and gene amplification. 
These observations confinned that strong BCLIO nuclear expression pattern is 
characteristic of MALT lymphoma. with t(1; 14)(p22; q32) or variants. 
Based on BCLIO staining of 331 cases of MALT lymphoma from 8 major sites, the 
overall incidence of t(1; 14)(p22; q32) was around 4%, with the highest frequency (12%) 
in pulmonary MALT lymphoma. 
(3) BCLIO expression in MALT lymphoma without t(1; 14)(p22; q32) or variants 
As mentioned above, of the 331 cases examined for BCLIO expression, 319 cases did 
not show strong BCLIO nuclear expression. However, 116 cases showed a moderate 
nuclear BCLIO expression in 20 - 90% tumour cell population (Figure 4.3 G) and the 
rest displayed cytoplasmic BCLIO expression (Figure 4.3 H). In all cases, 
t(11; 18)(q2l; q2l) was detected by RT-PCR for the API2-MALT] fusion transcripts from 
I 
formalin-fixed and paraffin-embedded tissues, where possible, frozen tissues were 
preferentially used for RT-PCR. We correlated BCL10 expression pattern with presence 
or absence of t(11; 18)(q2l; q2l). It was found that all 56 cases of t(11; 18)(q2l; q2l)- 
positive lymphoma showed moderate BCLIO expression in the nuclei of most tumour 
cells (Figure 4.3 G and Table 4.1). BCLIO nuclear expression, similar to that seen in 
t(I 1; 1 8)(q2 1; q2 I)-positive cases, was also found in 60 (23%) of the 263 cases that were 
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negative for the translocation by RT-PCR. The remaining 203 cases displayed only 
BCLIO cytoplasmic expression (Figure 4.3 H). 
In view of the significant association between t(11; 18)(q2l; q2l) and nuclear BCLIO 
expression, we re-examined the 7 cases showing nuclear BCLIO expression but not 
t(I 1; 1 8)(q2 I; q2 1) by RT-PCR to ascertain whether the absence of the translocation in 
these cases was due to failed detection by the primer set used. A new MALTI primer 
(MALTI-3: 5'-TTT TTC AGA AAT TCT GAG CCT G-3), which targets the 3' end of 
its coding region, together with the API2 primer was used for PCR (Table 2.4 in Chapter 
2). All the seven cases consistently showed absence of the AP12-MALTl fusion. In 
addition, a lack of t(I 1; 1 8)(q2 I; q2 1) in these cases was further confirmed by interphase 
FISH with MALTI break-apart probes (Chapter 5). 
(4) BCLIO nuclear expression is associated with MALT lymphoma at advanced 
stage 
The findings of BCL10 nuclear expression in MALT lyrnphoma with t(1; 14)(p22; q32) 
and a subset of MALT lymphoma without evidence of t(1; 14)(p22; q32) suggest that 
nuclear BCL10 expression may be associated with its oncogenic activity. To further 
explore the role of BCLIO nuclear expression in multistage development of MALT 
lymphoma, we correlated BCLIO expression pattern with clinical staging in gastric 
MALT lymphoma. Of 41 gastric MALT lymphomas in which the lymphoma staging 
was available, nuclear BCL10 expression was found in 37% (7 of 19) tumours confined 
to the mucosa or sub-mucosa, 43% (3 of 7) cases in which tumour invaded to muscular 
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layer or serosa, and in 93% (14 of 15) cases in which tumour disseminated beyond the 
stomach (P<0.005, Chi-square test) (Figure 4.5). 
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Figure 4.5. Correlation between clinical staging of gastric MALT lymphoma and BCLIO 
nuclear expression. The number of cases in individual subgroups is indicated on the top of the 
corresponding histogram. *p<0.005. 
(5) Gastric MALT lymphoma with strong BCLIO nuclear expression failed to 
respond to H. pylori eradication 
The cohort of gastric MALT lymphoma, which treated by H. pylori eradication and 
investigated for t(I 1; 18)(q21; q21) as detailed in Chapter 3, were also studied for BCL 10 
expression pattern. Of the III cases of gastric MALT lymphoma examined, 35 from the 
complete regression group and 40 from the non-response group had tissue sections 
containing an adequate turnour cell population for evaluation of BCLIO staining. Two 
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cases showed strong BCL10 nuclear staining in virtually all turnour cells (Figure 4.4 A), 
similar to that seen in t(1; 14)(p22; q32) positive cells, while the remaining cases 
displayed either weak cytoplasmic or weak nuclear staining. Both cases that showed 
strong BCLIO nuclear staining belonged to H. pylori eradication non-responsive group: 
one cases (case 1) had a stage HE disease and showed no response 8 months after H. 
pylori eradication, while the other (case 2) had a stage IE disease and displayed no 
response 12 months after H. pylori eradication. As shown in Chapter 3, both cases were 
t(l 1; 1 8)(q2 I; q2 1) negative. 
To ascertain whether the two cases that showed strong BCL10 nuclear staining were 
positive for t(1; 14)(p22; q32) or variants. Interphase FISH with break-apart dual colour 
probes for BCLIO, IGH and IGic was performed. Both cases failed to show evidence of a 
breakpoint at the BCLIO locus nor BCLIO gene amplification. However, case 2 showed 
a breakpoint at the IGH locus in 10% of tumour cells. Given the strong BCLIO nuclear 
staining and evidence of an IGH brcakpoint in one case, a false negative result of 
interphase FISH with BCLIO break-apart probes cannot be excluded. To further 
investigate whether these cases harboured a BCLIO involved chromosome translocation, 
we carried out real time quantitative RT-PCR of BCLIO mRNA expression. 
Unfortunately, adequate tissue materials were only available in case 2. The level 
(ACt=3.4) of BCLIO mRNA expression in this case was compatible to MALT 
lymphoma with t(1; 14)(p22; q32) (mean ± standard deviation = 1.60 ± 2.37), well above 
those without the chromosomal translocation (mean ± standard deviation = 6.94 ± 1.72) 
(section 5.3.3 of Chapter 5). 
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To further assess the value of t(1; 14)(p22; q32) in prediction of the response of gastric 
MALT lymphoma to H. pylori eradication, we retrospectively reviewed the clinico- 
pathological features of gastric MALT lymphoma with t(1; 14)(p22; q32) or variants, 4/5 
cases were at stage HE or above at the time of diagnosis. 
(6) BCL10 expression in other NHLs 
Similar to the BCLIO expression in normal germinal centre B cells, 19/21 follicular 
lymphomas, exftessed the protein in the cytoplasm and the remaining 2 expressed the 
protein in both the nucleus and cytoplasm in 30% and 80% of turnour cells, respectively. 
Mantle cell lymphomas showed either weak (14/17=82%) or no (3/17=18%) BCLIO 
expression. As the expression level is low, the sub-cellular localisation of BCL10 
protein in this lymphoma subtype could not be confidently determined. All DLBCL of 
mucosal sites showed weak cytoplasmic BCLIO expression. Of nodal DLBCL, 14 of the 
18 cases expressed BCLIO protein in the cytoplasm and the remaining 4 cases expressed 
the protein in both the nucleus and cytoplasm in 10-20% of turnour cells. 
4.4 Discussion 
BCL10 expression in normal lymphoid tissues 
BCL10 mRNA, as previously shown by in-situ hybridization, was highly expressed by 
germinal centre B cells, moderately by marginal zone but weakly by mantle zone B 
cells' 
34,135 
. BCLIO protein, as shown in the present study, was also differentially 
expressed among various B cell subsets of the B cell follicle, from abundant expression 
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in antigen activated highly proliferating germinal centre centroblasts to low or no 
expression in non-dividing naYve mantle zone B cells. The BCLIO protein was also 
differentially expressed at various stages of T cell maturation in thymus. At an early 
stage, the T cells, which reside in the cortex and undergo T cell receptor rearrangements 
and positive selection, lacked BCLIO expression; while at a late stage, T cells, which 
move to the medulla and undergo negative selection to delete those highly reactive to 
self-major histocompatibility complex (MHQ and self peptides 281 , expressed BCLIO in 
the cytoplasm. Our findings of different BCLIO expression during both B and T cell 
maturation are in line with the physiological role of BCLIO in antigen receptor mediated 
155,156 NFKB activation in both B and T cells 
Among other normal tissues, BCL10 protein was found by immunohistochernistry only 
in breast but not in 20 other types of tissues exwnined. The lack of BCLIO protein 
expression in these normal tissues is intriguing. It is possible that BCLIO protein is 
expressed in these normal tissues but at a low level below the detection limit of the 
current immunohistochernical system. Alternatively, BCLIO protein expression may be 
tissue and cell type specific. 
BCLIO deregulation in MALT lymphoma 
As mentioned above, BCL10 is found primarily in the cytoplasm of non-nal B cells, 
including the marginal zone B cells which are the normal cell counterpart of MALT 
lymphoma. By contrast, BCLIO is predominantly expressed in the nuclei of MALT 
lymphoma cells with t(1; 14)(p22; q32) or variants. Moreover, BCLIO nuclear expression 
is associated with the presence of t(11; 18)(q2l; q2l) and up to 20% of MALT 
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lymphomas without the translocation, predominantly in the nucleus, at a moderate level. 
BCL10 nuclear expression is found in a higher proportion of lymphomas with 
dissemination to local lymph nodes or distal sites (14 of 15 cases, 93%) than those 
confined to the gastric wall (10 of 26 cases, 38%). t(1; 14)(p22; q32) and t(1; 2)(p22; pl2) 
are typically those at advanced stages. Furthermore, BCLIO has been found to be 
expressed at high levels in the nuclei of splenic marginal zone B cells in the transgenic 
mice in which BCLIO expression is driven by an Ig enhancer (M-Q. Du and S. Morris, 
unpublished observations). These findings suggest that the nuclear expression may 
relate to its oncogenic activity. However, the molecular mechanisms underlying the 
deregulated BCLIO nuclear expression in malignant B cells are unclear. Overall, 
BCLIO genomic mutation is an infrequent event, occurring in about 5% of MALT 
142,143 lymphoma . Intriguingly, BCLIO genomic mutation is not a common feature of 
MALT IYMphoma with t(1; 14)(p22; q32) and has been found in only one of three cases 
examined 142 . The findings that the frequency of nuclear BCLIO expression is 10 times 
as high as that of BCLIO gene mutation in MALT lymphoma suggest that events other 
142,143 than genomic mutations are responsible for the nuclear localisation of the protein 
BCLIO nuclear expression is independent of both t(1; 14)(p22; q32) and the level of 
protein expression, as well as BCLIO gene amplification. BCLIO does not contain any 
known nuclear localisation. signalS282 . The translocation of BCLIO from cytoplasm to 
nucleus is mostly likely mediated by its interaction proteins. The presence of nuclear 
BCL1 0 suggests that the protein may have functions other than those identified so far. 
The studies of BCLIO-knockout mice have shown that BCL10 is essential for both the 
development and function of mature B and T cells, linking antigen receptor signaling to 
124,125 the NFO activation . NFKB activation in lymphocytes leads primarily to cellular 
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activation, proliferation, survival and induction of effector function. In line with these 
observations, the findings of an association between BCL10 nuclear expression and 
nuclear localisation of NFKB in nasal NK/T cell lymphomas and DLBCLs of the 
stomach suggest that nuclear BCLIO expression may be related to NRB transcription 
283,284 
activation 
Unlike MALT lymphoma, both mantle cell and follicular lymphomas generally showed 
BCLIO expression patterns comparable to those seen in their normal cell counterparts, 
suggesting that BCL10 is unlikely to be involved in the development of these turnours. 
Incidence of t(1; 14)(p22; q32) in MALT lymphoma of various sites 
In the present study, we showed that BCLIO was expressed strongly in both the nuclei 
and cytoplasm of turnour cells with t(1; 14)(p22; q32). Based on BCLIO staining of 331 
cases of MALT lymphorna from 8 major sites followed by interphase FISH, the overall 
incidence of t(1; 14)(p22; q32) is approximately 4% of MALT lymphomas, with the 
highest frequency in those from the lung (12%) followed by stomach (5%), but absent in 
those from the salivary gland, thyroid, conjunctive and orbit. Like translocation- 
negative MALT lymphomas, t(1; 14)(p22; q32)-positive cases usually contain other 
280 
chromosomal aberrations such as trisomies 3,12 and 18 . In view of the finding of 
t(1; 14)(p22; q32) in DLBCL, MALT lymphomas with this translocation may undergo 
high grade transformation (The Cancer Genome Anatomy Project by National Cancer 
Institute). 
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Gastric MALT lymphomas with strong BCL10 nuclear expression do not respond 
to H. pylori eradication 
H. pylori eradication can cure 75% of patients with gastric MALT lymphoma and is now 
the first line therapy for this disease. Because the assessment of the treatment response 
requires a prolonged follow-up with repeated endoscopy and gastric biopsies, it would 
be inunensely beneficial if the H. pylori eradication non-responsive cases can be 
identified at diagnosis. In Chapter 3, t(11; 18)(q2l; q2l) was shown to be nearly always 
associated with H. pylori eradication non-responsive gastric MALT lymphomas and 
detection of this translocation could identify 75% of such cases. In the present study, it 
was further shown that detection of t(1; 14)(p22; q32) could identify a further 5% of 
gastric MALT lymphomas that did not respond to H. pylori eradication. 
The finding that t(1; 14)(p22; q32) is associated with H. pylori eradication non-responsive 
gastric MALT lymphoma is, to a certain extent, expected and is in line with the 
molecular and cellular properties of tumour cells carrying the translocation and their 
clinical presentation. The translocation deregulated the expression of the BCLIO gene, 
which, like the API2-MALT 1 fusion product of t(I 1; 1 8)(q2 I; q2 1), is a potent activator 
of the transcriptional factor NFKB. NFKB activation in lymphocytes leads to expression 
of genes important for cellular activation and proliferation. A previous in vitro study 
showed that tumour cells with t(1; 14)(p22; q32) could survive longer than those without 
this translocation in absence of any mitogenic stimulationS66. Clinically, 
t(1; 14)(p22; q32) positive gastric MALT lymphomas are typically those that show 
dissemination to regional lymph nodes or remote sites as shown by both previous and 
current studies 
134 
. 
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t(1; 14)(p22; q32) is a relatively infrequent chromosomal translocation in gastric MALT 
lymphoma, occurring in approximately 4% of cases. In view of that MALT lymphoma 
cells carrying t(1; 14)(p22; q32) or variants show characteristic strong BCLIO nuclear 
expression, this translocation may be screened by BCLIO immunohistochemistry 
followed by interphase FISH analysis. The interpretation of BCLIO immunostaining 
particularly on small tissue biopsies can be difficult, however, those with 
t(1; 14)(p22; q32) or variants are easily recognisable as they show strong homogeneous 
BCLIO nuclear staining in tumour cells but weak or no staining in the accompanied 
reactive T cells. For MALT lymphoma with t(11; 18)(q2l; q2l), BCLIO 
immunohistochemistry does not provide a strong indication for the presence of the 
translocation as up to 20% of t(11; 18)(q2l; q2l) negative cases also show a moderate 
BCL10 nuclear expression. Detection of this translocation is best carried out by RT- 
PCR of the AP12-MALT] fusion transcripts or interphase FISH, both of which can be 
applied to formalin-fixed and paraffin-embedded tissue biopsies as described in section 
2.2 of Chapter 2. Detection of both chromosomal translocations can identify 80% of 
gastric MALT lymphomas that will not respond to H. pylorl eradication. 
The molecular mechanisms underlying the remaining 20% of H. pylori eradication non- 
responsive gastric MALT lymphomas are not clear. It has been shown that H. pylori 
associated gastric MALT lymphoma in patients with autoimmune disease was resistant 
to antibiotic treatmene 78 andfas gene was mutated in MALT lymphorna, of patients with 
autoimmunity114 . Additional novel chromosomal translocations may also be present in 
MALT lymphoma. Study of these genetic targets may allow identification of further 
molecular markers for H. pylori eradication non-responsive gastric MALT lymphoma. 
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Recently, two novel chromosomal translocations have been described in MALT 
lymphornas. One is t(l4; l8)(q32; q2l)1IGH-MALTI involving the MALT] gene 161,162 0 
the other is t(3; 14)(pl4; q32) involving FOXPI gene 285 . These translocations appear to 
occur more often in non-gastrointestinal sites, particularly those of the lung, liver, 
thyroid and ocular adnexa. However, their incidence in MALT lymphoma of various 
sites and their clinical relevance remain to be investigated. 
4.5 Conclusion 
In summary, the present study showed that BCLIO was expressed differentially among 
different B cell populations of the B cell follicle, in line with its role in NFKB activation 
and B cell activation. The sub-cellular localisation of BCL10 is frequently altered in 
MALT lymphoma in comparison with its normal cell counterparts, suggesting that this 
may be important in lymphomagenesis. Strong nuclear BCL10 expression is seen in 
MALT lymphoma. with t(1; 14)(p22; q32) or variants, while moderate nuclear BCLIO 
expression is found in t(l 1; 1 8)(q2 I; q2 1) positive MALT lymphorna and 20% of cases 
without evidence of both t(1; 14)(p22; q32) and t(11; 18)(q2l; q2l). Although the 
mechanisms underlying the BCLIO nuclear expression are unclear, nuclear BCL10 
expression appears to be significantly associated with cases at advanced stages. In 
gastric MALT lymphoma, those expressing strong nuclear BCL10 do not respond to H. 
pylori eradication. 
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Chapter 5. t(14; 18)(q32; q2I)/IGH-MALTI and MALT1 deregulation in MALT 
lymphoma 
5.1 Introduction 
This study aimed to investigate the incidence of t(14; 18)(q32; q2l)/IGH-MALTI in 
MALT lymphoma of various sites and examine MALTI. expression in both normal and 
malignant lymphoid tissues and correlated its expression pattern with that of BCL10 as 
well as the presence of the three chromosomal translocations in MALT lymphomas. 
5.2 Case selection 
These included 30 cases of formalin-fixed and paraffin-embedded non-nal lymphoid 
tissues, 490 cases of B cell lymphomas including 423 cases of MALT lymphornas of 
eight sites (Table 5.1), 22 cases of follicular lymphoma, 18 cases of mantle cell 
lymphoma, and 27 cases of DLBCL. Of the MALT lymphoma cases, 6 cases were 
known to be t(14; 18)(q32; q2l)/IGH-MALTI positive as shown in previous studies 161,286 . 
In addition, 86 normal non-lymphoid tissues of 21 different types were studied. 
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Table 5.1. MALT1 expression pattern in MALT lymphomas with different chromosomal 
translocations 
Site of MALT Number Translocation Number Intensity of MALTI expression 
lymphoma of cases status* of cases Strong Moderate Weak/negative 
t(I 1; 18) +ve 40 2 38 
t(l; 14) +ve 8 - 8 Stomach 185 
t(I 4; 18) +ve - - - - 
translocation -ve, 137 - 7 130 
t(I 1; 18) +ve 18 - - 18 
t(l; 14) +ve 4 - - 4 Lung 47 
t(l. 4; 18) +ve 3 3 - - 
translocation -ve 22 - - 22 
t(I 1; 18) +ve 7 1 6 
t(l; 14) +ve - - - - ocular adnexae 73 t(l. 4; 18) +ve 5 5 - 
translocation -ve 61 - 7 54 
t(I 1; 18) +ve I - I 
t(l; 14) +ve - Salivary gland 59 t(l. 4; 18) +ve - - - 
translocation -ve 58 8 50 
t(l 1; 18) +ve - - - 
t(l; 14) +ve - Thyroid 12 
t(I 4; 18) +ve - - 
translocation -ve 12 2 10 
t(I 1; 18) +ve - - - 
t(l; 14) +ve 
Skin 37 
t(l. 4; 18) +ve - - - 
translocation -ve 37 9 28 
t(I 1; 18) +ve - - 
t(l; 14) +ve - Liver 6 
t(l 4; 18) +ve 1 1 - 
translocation -ve 5 - 5 
t(l. 1; 18) +ve I - - 
t(l; 14) +ve - - - Intestine 4 
t(I 4; 18) +ve - - - 
translocation -ve 3 - - 3 
Total 423 9 (2.1%) 36 378 
t(l4; l8)(q32; q2l)1IGH-MALT1 and BCLIO break/t(1; 14)(p22; q32) were primarily detected by 
MALTI and BCLIO immunohistochemistry followed by interphase FISH with appropriate 
probes. t(11; 18)(q2l; q2l)IAP12-MALT1 positive cases was detected by RT-PCR of the API2- 
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MALT] fusion transcript with exception of one pulmonary case that was initially identificd by 
interphase FISH with MALT] break-apart probes. 
5.3 Results 
5.3.1 Characterisation of MALTI antibodies 
The N-tenninal MALTI antibody recognises wild type MALTI but not the AP12- 
MALTI fusion product, while the C-terminal MALTI antibody reacts with both 
MALT I and AP12-MALT I fusion product (Figure 5.1). 
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Figure 5.1. Western blot analysis of the human B cell lymphoma cells (BJAB) transfected 
with NIALTI or AP12-MALTI expression construCt260 , and MALT lymphoma with and 
without t(11; 18)(q2I; q2I). The mouse monoclonal antibody (mAb) to the N-terminus of the 
MALTI recognises full length MALTI, but not the AP12-MALTI fusion product, while the 
mouse monoclonal antibody to the C-terminus of MALTI reacts with full length MALTI as well 
as the AP12-MALT I fusion product (indicated by arrows). 
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5.3.2 MALT1 expression in normal tissues 
Immunohistochernistry with both N-terininal and C-terminal MALT1 mouse monoclonal 
antibodies showed that the protein expression pattern was identical to that of BCLIO in 
both B cell follicles and thymus (Figure 5.2 and section 4.3.2 of Chapter 4). In B cell 
follicles of tonsil, lymph node and spleen, both MALTI. and BCLIO are differentially 
expressed in various germinal centre B cells, strong in centroblasts, moderate in 
centrocytes, and weak/negative in mantle zone B cells (Figure 5.2). In thymus, MALTI 
was weakly, while BCLIO was moderately expressed in medullar T cells. Irrespective of 
different cell types, both MALTI. and BCL10 are predominantly expressed in the 
cytoplasm. 
MALTI protein expression appeared to be restricted to lymphoid tissues. It was not 
found by immunohistochernistry in 21 types of normal tissue, including tongue, 
oesophagus, duodenum, rectum, liver, gall bladder, pancreas, bronchus, heart, lung, 
thyroid, breast, adrenal gland, kidney, bladder, uterus, cervix, ovary and tube, placenta 
and cord, testis and skin. 
5.3.3 MALT1 expression in MALT lymphoma 
MALTI expression in MALT lymphoma was investigated with N-terminal MALTI 
antibody, which recognises the wild type MALTI but not the API2-MALTI fusion 
product (Figure 5.1). As reactive lymphoid follicles are commonly seen in MALT 
lymphorna, MALTI and BCLIO expression in B cells of reactive genninal centres 
provides an excellent internal control. The level of MALTI and BCLIO expression in 
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lymphoma cells was therefore recorded with reference to that in centroblasts (strong), 
centrocytes (moderate), and mantle zone B cells (weak) of reactive lymphoid follicles. 
The expression of these proteins was studied in 423 cases of MALT lymphoma and their 
expression was correlated with the presence of chromosomal translocations. For all 
cases, data for BCLIO expression, BCLIO rearrangement indicating t(1; 14)(p22; q32) or 
variants, and t(l 1; 1 8)(q2 I; q2 1) were from previous studies (Chapter 3 and Chapter 4). 
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Figure 5.2. MALTI and BCLIO expression in reactive tonsil and MALT lymphomas with 
and without chromosomal translocations. Both MALT] and BCLIO are similarly expressed 
in the cytoplasm of various B cells in reactive tonsil, high in centroblasts, moderate in 
centrocytes and weak/negative in the mantle zone B cells. In MALT lymphoma with 
t(l4; l8)(q32; q2l)/IGH-AL4LT1, all tumour cells show strong MALTI and BCLIO cytoplasmic 
-143- 
expression. In MALT lymphoma with BCLIO break/t(l; l4)(p22; q32), tumour cells express 
weak MALT1 but strong nuclear BCLIO. In MALT lymphoma with t(11; 18)(q2l; q2l)/API2- 
MALT], tumour cells generally show lack of MALTI expression but moderate nuclear BCLIO. 
In MALT lymphoma without the above chromosomal translocations, turnour cells show weak 
MALT1 and moderate BCLIO expression in the cytoplasm. FC: follicle centre. (magnification 
x 200); Insert (magnification x 400). 
A. MALTI and BCL10 expression pattern in MALT lymphoma with 
t(14; 18)(q32; q2l)/IGH-MALTI and incidence of the translocation in MALT 
lymphoma of various sites 
Of the 344 cases lacking evidence of t(1; 14)(p22; q32) by BCLIO immunohistochernistry 
and t(I 1; 1 8)(q2 I; q2 1) by RT-PCR, 9 cases including 5 from the ocular adnexac, 3 from 
the lung and I from the liver showed strong homogeneous cytoplasmic expression of 
both MALTI and BCLIO in virtually all tumour cells. The intensity of MALTI. staining 
was similar to or stronger than that seen in centroblasts of the reactive germinal centre 
(Figure 5.2). Remarkably, these tumour cells also showed strong homogenous BCLIO 
cytoplasmic expression (Figure 5.2). Of the remaining cases, 33 showed moderate and 
302 displayed weak/negative MALTI cytoplasmic staining. Cases showing moderate 
MALTI expression were from the stomach (7/185=3.8%), ocular adnexae (7/73=9.6%), 
salivary gland (8/59=13.6%) thyroid (2/12=16.7%), and skin (9/37=24.3%) (Table 5.1). 
Of the 9 cases that showed strong homogeneous cytoplasmic expression of both MALTI, 
and BCL10,6 were subjects of previous studies and shown to harbour t(14; 18)(q32; q2l). 
For the remaining 3 cases without previous information on t(14; 18)(q32; q2l) status, we 
perfonned interphase FISH using IGH/MALTI dual colour, dual fusion translocation 
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probes. In each case, signal patterns indicating presence of the chromosomal 
translocation were detected (Figure 5.3). 
Figure 5.3. Detection of t(l4; 18)(q32; q21)1IGH-MALTJ by interphase FISH with dual 
colour, dual fusion translocation probes. An ocular MALT lymphoma with strong 
cytoplasmic expression of both MALTI and BCLIO shows co-localisation of green and red 
signals in interphase nuclei, suggestive oft(l4; l8)(q32; q21)/IGH-AMLT1. 
To investigate further that t(l 4; 1 8)(q32; q2 I)IIGH-AIALT] was truly negative in MALT 
lymphoma lacking high cytoplasmic expression of MALTI and BCLIO, we performed 
interphase FISH using MALT] break-apart dual colour probes. The reliability of the 
MALT] break-apart assay for detection of chromosomal translocation involving MALT] 
was first validated in 34 cases of t(l 1; 1 8)(q2 I; q2 1) positive MALT lymphorna, 5 cases 
of t(l4; l8)(q32; q2l)/IGH-MALTI positive MALT lymphoma and 5 negative controls. 
MALT] break-apart assay showed MALT] involved chromosomal translocation in 39/39 
positive cases but not in any of the negative controls. 
The AL4LT] break-apart assay was performed in 174 cases of MALT lymphoma that 
showed no evidence of t(I 1; 1 8)(q2 I; q2 1) by RT-PCR and t(l; I 4)(p22; q32) or variants 
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by BCLIO immunohistochemistry. They included 48 from salivary gland, 45 from 
ocular adnexae, 23 from lung, 31 from stomach, 12 from thyroid, 12 from skin, 2 from 
liver and I from small intestine. With the exception of one case, none of the remaining 
cases, including 26 cases that showed a moderate MALTI. expression, displayed 
evidence of a chromosomal breakpoint affecting the MALT] gene. The only case 
showed a breakpoint at the MALT] locus was from lung and subsequently confirmed to 
be t(11; 18)(q2l; q2l) by interphase FISH with API21MALTI dual colour, dual fusion 
translocation probes. This case was not detected by RT-PCR of the AP12-MALTI fusion 
transcript on RNA samples prepared from the formalin-fixed and paraffin-embedded 
tissues. It is well documented from our previous studies that the RT-PCR protocol used 
misses 7% of rare breakpoints on the API2 gene (Chapter 3). Nonetheless, 28 cases 
showed three-copies of the MALT] gene in more than 80% of tumour cells, but only 3 of 
them displayed a moderate MALTI expression, with the remaining cases exhibiting 
weak MALTI expression. There was no evidence of MALTI gene arnplification in all 
the cases exmnined by interphase FISH. Figure 5.4 surnmarises the frequencies of 
t(14; 18)(q32; q2l)1IGH-MALTI, t(I 1; 1 8)(q2l; q2l)IAPI2-MALTI and BCLIO 
break/t(1; 14)(p22; q32) in MALT lymphomas of various sites. 
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Figure 5.4. Frequency of t(14; 18)(q32; q21)/1GH-MALT1, BCL10 break/t(1; 14)(p22; q32) 
and t(11; 18)(q21; q21)/AP12-MALT1 in MALT lymphomas of various sites. OA: Ocular 
adnexae: SG: sall-v-arl-N gland. Number in bracket indicates the number of cases studied. 
t(14,18)(q32; q2l)/IGH-AMLT1 and BCL10 break/t(1; 14)(p22; q32) were detected by MALTI 
and BCLIO immunohistochernistry followed by interphase FISH. t(11; 18)(q2l; q2l)/API2- 
AMLTJ was detected by RT-PCR of the API2-MALT] fusion transcript with exception of one 
pulmonary case that was identified by interphase FISH with MALT] break-apart probes. 
B. MALTI and BCLIO expression pattern in MALT lymphoma without 
t(14; 18)(q32; q2 I)IIGH-MAL TI 
Sixty seven cases were t(I 1; 1 8)(q2 I; q2 1) positive as proven by RT-PCR of the API2- 
MALT] fusion transcript or interphase FISH. As detailed in previous Chapter (Chapter 
3), tumour cells in these cases showed moderate or weak BCLIO nuclear staining 
(Figure 5.2). Among t(I 1; 1 8)(q2 I; q2 1) positive cases, 3 showed moderate and the 
remaining cases displayed weak/negative MALT I cytoplasmic staining (Table 5.1). 
In total, 12 cases showed strong BCLIO nuclear staining, and among them 10 showed 
evidence of t(1; 14)(p22; q32) by conventional cytogenetics or BCLIO interphase FISH. 
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(185) (47) (73) (69) (12) (37) (6) (4) 
None of these cases showed BCLIO gene amplification. Tumour cells in each of these 
cases showed weak/negative MALTI cytoplasmic staining (Figure 5.2 and Table 5.1). 
Of the remaining 335 cases lacking t(14; 18)(q32; q2l), t(1; 14)p22; q32) and 
t(11; 18)(q2l; q2l), MALTI. was weakly expressed in the cytoplasm, while BCLIO was 
expressed at weak/moderate level in the nucleus in 20% cases and in the cytoplasm in 
the rest of the cases. 
5.3.4 Correlation of MALT1 and BCLIO protein expression with their mRNA 
expression 
In keeping with MALT1 protein expression, MALTI mRNA expression was the highest 
in MALT lymphomas, with t(l4; l8)(q32; q2l)1IGH-MALTI, significantly higher than 
those with t(11; 18)(q2l; q2l) (p<0.01) and those without any of the chromosomal 
translocations studied (p<0.05) (Figure 5.5). Interestingly, MALT1 mRNA expression 
was also significantly higher in MALT lymphomas without any of the chromosomal 
translocations than those with t(I 1; 1 8)(q2 I; q2 1) (P<0.0 1) (Figure 5.5). 
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Figure 5.5. MALT] and BCLIO mRNA expression in MALT lymphoma with different 
chromosomal translocations. A: Examples of real-time quantitative RT-PCR with SYBR 
Green I using an iCycler iQ system. This was carried out in triplicates using RNA samples 
extracted from the tumour cells microdissected from paraffin embedded tissue sections. For 
simplicity, reference control 18S rRNA is not shown in the figure. Y-axis: relative fluorescent 
units; X-axis: number of PCR cycles; trans. -ve: translocation negative case. B: Comparison 
of MALT] and BCLIO mRNA expression in MALT lymphomas with different chromosomal 
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translocation status. *indicates statistical significant difference. The medians are indicated by 
the horisontal bars in the rectangular boxes. 
Similarly, BCLIO mRNA expression was the highest in MALT lymphomas with 
t(l; 14)(p22; q32), significantly higher than those with t(I 4; 1 8)(q32; q2 1)IIGH-MALTI, or 
t(11; 18)(q2l; q2l) or without any of these translocations (all p<0.01) (Figure 5.5). There 
was no correlation between MALTI and BCL10 mRNA expression in individual groups 
with different chromosomal translocation status or in all groups combined together. 
5.3.5 MALT1 expression in other NHLs 
We also examined MALT1 expression in follicular lymphoma, mantle cell lymphoma 
and diffuse large B cell lymphoma. Of the 22 cases of follicular lymphoma examined, 
17 cases showed a moderate to strong cytoplasmic MALTI staining, and the remaining 5 
cases displayed a weak MALTI staining. In mantle cell lymphoma, MALTI expression 
was weak in 14 cases and moderate in 4 cases. Among the 27 cases of diffuse large B 
cell lymphoma studied, 20 cases showed moderate to strong MALTI. expression and the 
remaining 7 cases displayed weak MALTI. expression. 
5.4 Discussion 
Mounting evidence indicates that BCL10 and MALTI. specifically transduce antigen 
receptor signaling to activate NFKB and play a critical role in the biology of both B and 
T cells 160. This is best demonstrated by studies of BCL10 and MALTI. deficient mice 
which are characterised by impaired B cell development and function, showing a 
reduced number of marginal zone B cells and poor humoral responses to both T cell 
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dependent and independent stimulations 
124,155,156,164 
. It is believed that in normal B and 
T cells, upon antigen receptor stimulation, Carmal. is activated to recruit BCLIO via 
CARD-CARD interaction and induces BCL10 oligornerisation. BCL10 then binds the 
Ig-like domain of MALTI through a short region downstream of its CARD and induces 
MALTI oligornerisation, subsequently leading to NFKB activation 123,125. The finding of 
identical expression pattern of MALTI and BCLIO in B cell follicle in the present study 
is in line with their roles in B cell activation and maturation. 
One of the remarkable findings of the present study is the observation of characteristic 
expression pattern of MALTI and BCLIO in MALT lymphorna with different 
chromosomal translocations. In those with t(14; 18)(q32; q2l)/IGH-MALTI, the tumour 
cells are characterised by strong cytoplasmic expression of both MALTI. and BCLIO, 
while MALT lymphoma cells with BCLIO break/t(1; 14)(p22; q32) or t(11; 18)(q2l; q2l) 
show strong or moderate BCL10 nuclear expression respectively, but generally a weak 
MALTI cytoplasmic expression. Such differential MALTI and BCLIO expression 
patterns in MALT lymphoma, with various chromosomal translocations may reflect not 
only the consequence of these chromosomal translocations but also the molecular 
mechanisms involved. 
In MALT lymphoma with t(l4; l8)(q32; q2I)/IGH-MALTI, strong cytoplasmic MALTI 
expression is expected given the strong transcriptional activity of the IGH enhancer. 
The strong cytoplasmic BCLIO expression is, to some extent initially, a surprising 
finding, but this could well be explained by the molecular mechanism of MALT1 
mediated NFKB activation. MALTI does not have a structural domain that is capable of 
mediating its self-oligomerisation and over-expression of MALTI alone in fibroblasts in 
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vitro does not activate NFKB 
123,125,127 
. However, MALTI is synergistic with BCLIO in 
NFKB activation and it is believed that the oligornerisation and activation of MALTI 
depend on BCLI 0127 . Thus, it is likely that in MALT lymphorna cells with 
t(14; 18)(q32; q2l)1IGH-MALTI, MALTI interacts with BCL10 and stabilises it in the 
cytoplasm, consequently leading to its accumulation. In line with this notion, there was 
no alteration in BCL10 mRNA expression in MALT lymphoma with 
t(14; 18)(q32; q2l)IIGH-MALTI as compared with other MALT lymphomas lacking the 
BCLIO associated chromosomal translocation. 
Similarly, in view of the direct interaction between BCLIO and MALTI in their 
mediated NFKB activation as demonstrated in in vitro studies, one may expect to see 
NIALTI protein accumulation in MALT lymphoma cells with BCLIO 
break/t(1; 14)(p22; q32). Intriguingly, this is not the case: MALTI is only weakly 
expressed in the cytoplasm of BCLIO break/t(1; 14)(p22; q32) positive cells, in contrast to 
strong BCLIO expression in the nuclei. Such differential expression of the two proteins 
in terms of both level and sub-cellular localisation suggests that MALT1 may not be 
required for BCLIO function. This is supported by knockout mice studies. While 
BCLIO is essential for antigen receptor mediated NFKB activation in both B and T cells, 
deficiency of MALT1 expression does not critically affect BCL10 mediated NFkB 
124,155 
activation in B cells as it does in T cells . It is believed that there is an alternative 
pathway in BCL10 mediated NFKB activation in B cells, which is NIALTI. independent. 
In addition, BCLIO plays an extra role during neurodevelopment, indicating that BCL10 
has additional biological activity compared with MALT1155. 
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Similar to BCLIO break/t(1; 14)(p22; q32) positive MALT lymphoma, tumour cells with 
t(I 1; 1 8)(q2 I; q2 1) generally show a weak/negative MALT I cytoplasmic expression but 
moderate BCLIO nuclear expression. Given that the oligomerisation of the AP12- 
MALTI. fusion product is most likely mediated by the N-terminal BIR domains of the 
API2 molecule, the AP12-MALT1 mediated NFKB activation unlikely requires BCLIO 
or MALT1. In addition, only one allele of the intact MALTI gene remains in MALT 
lymphoma with t(11; 18)(q2l; q2l) and the level of MALT] mRNA is much lower in 
these tumours than those without this translocation. Hence, a weak MALTI cytoplasmic 
expression in MALT lymphoma with t(l 1; 1 8)(q2 I; q2 1) is expected, however, moderate 
nuclear BCLIO expression is a surprising finding. The mechanism underlying BCLlO 
nuclear expression is unclear. Nonetheless this is unlikely related to the level of BCLIO 
mRNA expression since there was no significant difference in its transcript expression 
between cases expressing nuclear BCLIO (excluding those with BCLIO involved 
chromosomal translocation) or those expressing cytoplasmic BCLIO (M-Q Du, 
unpublished data, 2004). 
As shown in Chapter 4, strong nuclear BCLIO staining is highly indicative of presence 
of t(1; 14)(p22; q32) or variants. In the present study, we further showed that high levels 
of cytoplasmic expression of both MALT1 and BCL10 are characteristic of MALT 
lymphoma with t(14; 18)(q32; q2l)1IGH-MALTI. Such characteristic MALTI and 
BCLIO expression pattern was seen in 9/9 MALT lymphomas with 
t(14; 18)(q32; q2l)1IGH-MALTI. The absence of t(14; 18)(q32; q2l)/IGH-MALTI in 
MALT lymphoma. lacking strong MALTI and BCLIO cytoplasmic expression was 
further confirined by interphase FISH analysis of 174 cases of t(11; 18)(q2l; q2l) and 
t(1; 14)(p22; q32) negative cases. Based on MALTI and BCLIO immunohistochernistry 
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followed by interphase FISH analysis, we have shown t(I 4; 1 8)(q32; q2 I)IIGH-MALTI in 
MALT lymphorna of the lung (6%), ocular adnexae (7%) and liver (17%) but not in 
those of the stomach, salivary gland, thyroid and skin. Our current findings on the 
occurrence of t(14; 18)(q32; q2l)1IGH-MALTl in MALT lymphoma of various sites are 
in line with those reported from the previous studies 
161,286-288 
: the translocation is 
mutually exclusive from t(11; 18)(q2l; q2l) and BCLIO break/t(1; 14)(p22; q32), and 
occurs biased to extra-gastrointestinal sites. 
In view of the characteristic pattern of BCL10 and MALT1 expression in MALT 
lymphoma with different chromosomal translocations, BCL10 and MALTI. 
immunohistochemistry may be used as a screening method pointing to the presence of 
these chromosomal translocations. Since both BCL10 and MALTI expression patterns 
in MALT lymphomas with BCL10 break/t(1; 14)(p22; q32) or t(14; 18)(q32; q2l)/IGH- 
MALTI are characteristic, much easy to recognise and the incidence of both 
chromosomal translocations are relatively infrequent in MALT lymphoma, it would be 
rational to screen these translocations first by BCL10 and MALTI 
immunohistochemistry, followed by confirmation with interphase FISH. For MALT 
lymphoma with t(l 1; 1 8)(q2l; q2l), BCL10 and MALT1 immunohistochernistry does not 
provide a strong indication for the presence of the translocation as up to 20% of 
t(11; 18)(q2l; q2l) negative MALT lymphomas also show a moderate BCL10 nuclear 
expression. Detection of this translocation is best carried out by RT-PCR of the API2- 
MALTI fusion transcript or interphase FISH. 
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5.5 Conclusion 
In summary, we have shown that MALTI. expression pattern is identical to that of 
BCLIO in normal lymphoid tissues but varies in MALT lymphomas, with high levels of 
cytoplasmic expression of both MALTI and BCL10 characterising those with 
t(14; I 8)(q32; q2 I)IIGH-MALTI. 
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Chapter 6. General discussion 
The MALT lymphoma concept, proposed by Isaacson and Wright in 1983, was entirely 
based on clinical and histological investigationS289. The concept was reinforced by 
subsequent immunophentypic studies and analysis of the rearranged Ig genes. This is 
now further supported by recent findings of molecular studies that MALT lymphoma, is 
characterised by three unique chromosomal translocations: t(11; 18)(q2l; q2l)/API2- 
MALTI, t(1; 14)(p22; q32)IIGH-BCLIO and t(14; 18)(q32; q2l)1IGH-MALTj49 . These 
chromosomal translocations are specifically associated with MALT lymphoma entity, 
and are not seen in the chronic inflammatory diseases associated with this lymphoma 
such as H. pylori-associated chronic gastritis, Hashimoto's thyroiditis and 
lymphoepithelial sialadenitis nor in other MHLs including nodal and splenic marginal 
104,106,290 
zone B cell lymphomas Interestingly, although these chromosomal 
translocations are specifically associated with MALT lymphoma entity, they occur at 
markedly variable incidences at different sites as shown in this thesis and other 
studies 
106,111,290 
. For example, t(11; 18)(q2l; q2l) occurs most frequently in MALT 
lymphomas of the lung and stomach, but rarely or not in those of the salivary gland, 
thyroid and skin. These findings suggest that the occurrence of the translocation may be 
influenced by different aetiological factors associated with MALT lymphoma of 
different sites. Notably, H. pylori-associated chronic gastritis is strongly related to the 
development of gastric MALT lymphoma. H. pylori infection triggers inflammatory 
responses by attracting and activating neutrophils, which release ROS90. These ROS can 
cause a wide range of genetic damages, particularly double strand break, thus may have 
a role in the acquisition of genetic abnormalities seen in MALT lymphorna. It is 
possible that the occurrence of t(I 1; 1 8)(q2 1; q2 1) is related to oxidative damage induced 
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by H. pylori infection. In line with this hypothesis, the genornic breakpoint of 
t(11; 18)(q2l; q2l) on both derivative chromosomes was random and showed no 
association with sequence motifs known to be associated with chromosomal 
recombination 126 . Furthermore, deletions and duplications ranging from a few to several 
kilobase pair are a common finding at the breakpoint for both API2 and MALT] loci, 
indicating t(I 1; 1 8)(q2 I; q2 1) may result from illegitimate non-homologous end joining 
following double strand breaks 
126 
. 
However, it is surprising to find that the incidence of t(1; 14)(p22; q32) and 
t(14; 18)(q32; q2l) is also dramatically variable in MALT lymphoma of different 
133,161,290,291 
sites . t(1; 14)(p22; q32) occurs frequently in MALT lymphomas of the lung 
and stomach, but not in those of the other mucosal sites, while t(I 4; 1 8)(q32; q2 1) is seen 
frequently in MALT lymphomas of the lung and ocular adenxae, but not in those of the 
stomach. Like most chromosomal translocations associated with lymphoma, 
t(1; 14)(p22; q32) and t(14; 18)(q32; q2l) involve the Ig locus, and their occurrence is 
most likely associated with the VDJ recombination event. It remains to be investigated 
whether their occurrence is also influenced by different aetiological factors associated 
with MALT lyinphoma. 
In view of the specific association of t(11; 18)(q2l; q2l), t(1; 14)(p22; q32) and 
t(14; 18)(q32; q2l) with MALT lymphoma, detection of these chromosomal 
translocations may be valuable in MALT lymphoma diagnosis and differential diagnosis. 
For example, by detecting these chromosomal translocations, we have successfully 
diagnosed MALT IYMPhoma in a case with Waldenstrom's Macroglobulinernia, for 
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which it was impossible to distinguish lymphoplasmacytic lymphorna based on 
histological presentations alone 292 
In addition, detection of these translocations plays a significant role in management of 
gastric MALT lymphoma. Around 75% of patients with gastric MALT lymphoma can 
be cured by H. pylori eradication. To assess the treatment response, a prolong6d follow- 
up with repeated endoscopy and gastric biopsies is essential. Clinically, it would be 
immenselY beneficial if the H. pylori eradication non-responsive cases can be identified 
at diagnosis. In the present studies, we have shown that t(11; 18)(q2l; q2l) and 
t(1; 14)(p22; q32) or variants were nearly exclusively associated with H. pylori 
eradication non-responsive gastric MALT lymphomas and detection of these 
translocations could identify 75% and 5% of such cases, respectively. Detection of these 
chromosomal translocations can be readily carried out on routine diagnostic biopsies. 
Given that BCLIO expression in MALT lymphomas with t(1; 14)(p22; q32) is 
characteristic and the incidence of this translocations is relatively infrequent, it would be 
rational to screen this translocation first by BCLIO immunohistochernistry, followed by 
confirmation with interphase FISH. For MALT lymphoma with t(11; 18)(q2l; q2l), 
BCLIO immunohistochernistry does not provide a strong indication for the presence of 
the translocation as up to 20% of t(I 1; 1 8)(q2 1; q2 1) negative cases also show a moderate 
BCLIO nuclear expression. Detection of this translocation is best carried out by RT- 
PCR or interphase FISH. 
The molecular mechanisms underlying the remaining 20% of H. pylori eradication non- 
responsive gastric MALT lymphomas are not clear. In approximately 5% of gastric 
MALT lymphomas, there is no evidence of H. pylorl infection, and these cases do not 
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238,293 
respond to H. pylori eradication . We have previously studied 17 cases. In each 
case, the lack of H. pylori infection was confirmed by serology, 
histology/immunohistochemistry and none of them responded to antibiotic treatment293. 
Additional chromosomal translocations have been reported in MALT lymphoma and 
they may account for the remaining cases that do not respond to H. pylori eradication. 
The BCL6 proto-oncogene involved chromosomal translocation has been reported in a 
172,173,294 few cases of MALT lymphomas . In a recent study, we have screened 305 cases 
of MALT lymphoma for BCL6 involved translocation by interphase FISH and found the 
translocation in 2/133 cases of gastric MALT lymphom295. Immunohistochemistry also 
revealed aberrant BCL6 expression in these cases. It remains to be examined whether 
BCL6 translocation positive gastric MALT lymphoma responds to H. pylori eradication. 
Another chromosomal translocation recently reported in MALT lymphomas is 
t(3; 14)(pl4; q32)/IGH FoXp, 285,296 . 
Although the study by Streubel et a1285 failed to 
detect t(3; 14)(pl4; q32) in gastric MALT lymphoma, the translocation was seen in a case 
of gastric MALT lymphoma as well as two cases of DLBCL in the report by Wlodarska 
et a1296. t(3; 14)(pl4; q32)-positive MALT lymphomas, like those with t(1; 14)(p22; q32) 
and t(14; 18)(q32; q2l), frequently harbour other chromosomal aberrations such as 
trisomy 3 285 However, the clinical behaviour of t(3; 14)(pl4; q32)-positive gastric 
MALT lymphoma is unknown. By screening 366 cases of MALT lymphoma of 
different sites with interphase FISH using IGH break-apart probes, we have identified 
two cases of gastric MALT lymphoma harbouring a breakpoint in the IGH locus (M. Q. 
Du, unpublished data). One case was confirmed carrying t(3; l4)(pl4; q32)1IGH-F0XP1 
by interphase FISH. Interestingly, this case did not respond to H. pylori eradication 
despite being at stage IE- It remains to be validated in a large cohort whether 
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t(3; 14)(pl4; q32)-positive gastric MALT lymphoma resists to H. pylori eradication. The 
other case, while lacks evidence of common lymphoma associated chromosomal 
translocations, is currently under investigation. 
In addition to gastric MALT lymphoma, detection of chromosomal translocations may 
also help to predict the treatment response of MALT lymphoma of other sites. A recent 
study by Ferreri et al showed that Chlamydia psittaci infection was associated with 
MALT lymphoma of the ocular adnexae and 2 of the 4 patients studied responded to 
antibiotic therapy for Chlamydia psittaci 31 . Given both t(11; 18)(q2l; q2l) and 
t(14; 18)(q32; q2l) frequently occur in ocular MALT lymphoma, it would be pertinent to 
examine the impact of these chromosomal translocations on antibiotic therapy of this 
tumour. Nonetheless, the association between ocular MALT lymphoma Chlamydia 
psittaci infection and the lymphoma respond to antibiotic therapy remain to be validated 
in future investigations. 
In general, different lymphoma subtypes are characterised by distinct chromosomal 
translocations. In a given lymphoma subtype, the same oncogene is frequently 
deregulated by chromosomal translocations involving different partners. For example, 
c-myc is deregulated by chromosomal translocations involving various Ig loci in 
97 Burkitt's lymphoma2 . Similarly, the BCL6 involved translocations, frequently seen in 
DLBCL, may involve several loci including both Ig and non-Ig gene loCi297. In MALT 
lymphoma, notably, different oncogenes are involved by different chromosomal 
translocations, with t(11; 18)(q2l; q2l) generating a chimeric AP12-MALTI fusion 
product. 
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There are no apparent differences in histology and immunophenotype among MALT 
lymphomas with different chromosomal translocation status although t(I 1; 1 8)(q2 I; q2 I)- 
positive cases tend to be more homogeneous, lacking transformed blastS298. Such 
histological homogeneity may be explained by the recent findings that the three major 
MALT lymphoma associated chromosomal translocations essentially target the same 
molecular pathway and they are linked by the physiological role of BCL10 and MALTI 
in antigen receptor mediated NFKB activation. BCLIO specifically transduces antigen 
receptor signalling to activate the NFKB pathway, operating upstream of MALT1. In 
response to the upstream signal, BCLIO binds MALT1 and induces conformational 
changes of MALTI, which allow MALTI. oligomerisation. and trigger the downstream 
events leading to NFKB activation 123,125. In MALT lymphorna with t(1; 14)(p22; q32), 
BCLIO is over-expressed and is thought to form oligomers; through its CARD domain 
without the need of upstream signals, leading to constitutive NFKB activation. In those 
with t(14; 18)(q32; q2l), the oligomerisation of the over-expressed MALT1 is thought to 
be dependent on BCLIO. In MALT lymphorna with t(11; 18)(q2l; q2l), the AP12- 
MALTI fusion product is believed to self-oligomerise through the BIR domain of the 
AP12 molecule, therefore leading to constitutive NRB activation. 
In view of the above findings and hypothesis, it is interesting to investigate whether 
there is any molecular link between the BCLIO/MALT1-NFKB activation pathway and 
BCL6 as well as FOXP I. 
BCL6 is a transcriptional repressor and is believed to exert its oncogenic activity by 
repression of a group of genes involved in B cell activation and terminal differentiation 
(such as B-lymphocyte-induced maturation protein 1 (Blimpl) and cell cycle control 
- 161 - 
(cyclin D2, p27), thus contributing to lymphomagenesiS297 . BCL6 is preferentially 
expressed by B and T cells in germinal centre and is critical for germinal centre 
97 developmene . In view of that BCL10 
is highly expressed in genninal centre B cells 
and is critical for B cell activation and maturation, there might be molecular link 
between the physiological role of BCLIO and BCL6. 
FOXPI is a member of the FOXP subfamily of transcription factors. Although its 
function in B cell development and maturation is unclear, the protein is expressed in 
activated B cells including those in the genninal centre. Interestingly, high FOXPI 
expression is strongly associated with non-genninal centre type of DLBCL, which is 
characterised by high NFKB activitY199. Nonetheless, it remains to be examined whether 
FOXP I is functionally connected to the NFKB activation pathway. 
One of the most intriguing findings in this thesis is the altered subcellular localisation of 
BCL10 protein in MALT lymphoma. In line with the physiologic role of BCL10, 
BCLIO is expressed primarily in the cytoplasm of normal lymphocytes. However, the 
protein is strongly expressed in the nuclei of MALT lymphorna cells with 
t(1; 14)(p22; q32). Moderate levels of nuclear BCLIO expression are also seen in all 
t(11; 18)(q2l; q2l)-positive cases and up to 20% of MALT lymphomas lacking these 
chromosomal translocations. BCLIO nuclear expression is not related to BCLIO 
142,291 
mutation or BCL10 gene amplification . In BCLIO transgeneic mice, in which 
BCL10 gene expression is linked to Ig enhancers, BCL10 is also highly preferentially 
expressed in the nucleus of splenic marginal zone B cells (M. Q. Du and S. Morris, 
unpublished observations). These data strongly indicate that aberrant nuclear BCL10 
-162- 
expression might confer oncogenic activity. It remains a mystery how BCLIO is 
translocated into nuclei, and what is the function of nuclear BCLIO. 
BCLIO does not harbour nuclear localisation signals and its nuclear translocation must 
be mediated by its interacting proteins. Several BCLIO interacting proteins including 
CARMAI, NLALT1 and TRAF6 have been identified 160 . However, none of them 
containing a nuclear localisation signal. It is interesting to note that three NFKB 
interacting molecules including IKBoý NFKB-inducing kinase (NIK) and DcB kinase I 
(IKKI) are capable of shuttling between cytoplasm and nucleus 300 . When these proteins 
together with NFKB are translocated to the nucleus, they continue to modulate NFO 
302 
transcriptional activity'00- . It is possible that BCLIO is a member of such protein 
complex and is translocated to nucleus as a part of the NFKB/regulating partner complex. 
Nonetheless, the hypothesis remains to be tested. 
In summary, the thesis developed the methodology/strategy for screening MALT 
lymphoma associated chromosomal translocations, i. e. t(11; 18)(q2l; q2l), 
t(1; 14)(p22; q32) and t(14; 18)(q32; q2l), and exmnined their frequencies in MALT 
lymphoma of different sites. Detection of these chromosomal translocations plays an 
important role in clinical management of gastric MALT lymphoma although such role in 
extra-gastric MALT lymphomas remains to be investigated. In view the findings of this 
thesis, it is pertinent to suggest the following approach for management of gastric 
MALTlymphoma. t(11; 18)(q2l; q2l) and t(1; 14)(p22; q32) should be routinely screened 
using methods discussed as above. Those positive for the chromosomal translocations 
should be given H. pylori eradication, followed by chemotherapy or radiotherapy, while 
those negative for these chromosomal translocations having clinical or histological 
-163- 
evidence of H. pylori infection, patients should be treated first with H. pylori eradication, 
periodically followed up with endoscopic and histological investigation. Patients, not 
responding to H. pylori eradication by 12 to 18 months, should be treated additionally 
with chemotherapy or radiotherapy. 
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